

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA**

Biogen Idec Inc.
14 Cambridge Center
Cambridge, MA 02142

Plaintiff,

v.

HON. JON W. DUDAS
Under Secretary of Commerce for
Intellectual Property and Director of the
United States Patent and Trademark Office

Office of General Counsel, United States
Patent and Trademark Office, P.O. Box
15667, Arlington, VA 22215
Madison Building East, Rm. 10B20, 600
Dulany Street, Alexandria, VA 22314

Defendant.

Plaintiff Biogen Idec Inc., for its complaint against the Honorable Jon W. Dudas, states as follows:

NATURE OF THE ACTION

1. This is an action by the assignee of United States Patent No. 7,381,560 B2 ("the '560 patent") seeking judgment, pursuant to 35 U.S.C. § 154(b)(4)(A), that the patent term adjustment for the '560 patent be changed from 1,409 days to at least 2,058 days.
2. This action arises under 35 U.S.C. § 154 and the Administrative Procedure Act, 5 U.S.C. §§ 701-706.

THE PARTIES

3. Plaintiff Biogen Idec Inc. is a corporation organized under the laws of Delaware, having a principal place of business at 14 Cambridge Center, Cambridge, Massachusetts 02142.

4. Defendant Jon W. Dudas is the Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (“PTO”), acting in his official capacity. The Director is the head of the agency, charged by statute with providing management supervision for the PTO and for the issuance of patents. The Director is the official responsible for determining the period of patent term adjustment under 35 U.S.C. § 154.

JURISDICTION AND VENUE

5. This Court has jurisdiction to hear this action and is authorized to issue the relief sought pursuant to 28 U.S.C. §§ 1331, 1338(a) and 1361, 35 U.S.C. § 154(b)(4)(A) and 5 U.S.C. §§ 701-706.

6. Venue is proper in this district by virtue of 35 U.S.C. § 154(b)(4)(A).

7. This Complaint is timely filed in accordance with 35 U.S.C. § 154(b)(4)(A) and Fed.R.Civ.P. 6(a)(3).

BACKGROUND

8. Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, and William H. Rastetter are the inventors of U.S. patent application number 09/911,692 (the '692 application), entitled “Expression and Use of Anti-CD20 Antibodies,” which was issued as the '560 patent on 3 June 2008. The '560 patent claims compositions and methods for producing a

class of recombinant antibodies that may be used to treat B-cell disorders, such as non-Hodgkin's lymphoma. The '560 patent is attached as Exhibit A.

9. Plaintiff Biogen Idec Inc. is the assignee of the '560 patent, as evidenced by assignment documents recorded in the PTO, and is the real party in interest in this case.

10. Section 154 of title 35, U.S.C., requires that the Director of the PTO grant a patent term adjustment in accordance with the provisions of section 154(b). Specifically, 35 U.S.C. § 154(b)(3)(D) states that "[t]he Director shall proceed to grant the patent after completion of the Director's determination of a patent term adjustment under the procedures established under this subsection, notwithstanding any appeal taken by the applicant of such determination."

11. In determining the patent term adjustment, the Director is required to extend the term of a patent for a period equal to the total number of days attributable to delay by the PTO under 35 U.S.C. § 154(b)(1), as limited by any overlapping periods of delay by the PTO as specified under 35 U.S.C. § 154(b)(2)(A), any disclaimer of patent term by the applicant under § 154(b)(2)(B), and any delay attributable to the applicant under 35 U.S.C. § 154(b)(2)(C).

12. The Director made a determination of patent term adjustment pursuant to 35 U.S.C. § 154(b)(3) and issued the '560 patent reflecting that determination.

13. Section 154(b)(4)(A) of title 35 provides that "[a]n applicant dissatisfied with a determination made by the Director under paragraph (3) shall have remedy by a civil action against the Director filed in the United States District Court for the District of Columbia within 180 days after the grant of the patent. Chapter 7 of title 5 shall apply to such action."

CLAIM FOR RELIEF

14. The allegations of paragraphs 1-12 are incorporated in this claim for relief as if fully set forth.

15. The patent term adjustment for the '560 patent, as determined by the Director under 35 U.S.C. § 154(b) and indicated on the face of the '560 patent, is 1,409 days. (*See* Ex. A at 1). The determination of the 1,409-day patent term adjustment is in error because the PTO failed to properly account for the period of time between the date that was three years after the actual filing date of the '692 application and the date that the application issued to patent, pursuant to 35 U.S.C. § 154(b)(1)(B). The correct patent term adjustment for the '560 patent is at least 2,058 days.

16. The '692 application was filed on 25 July 2001 and issued as the '560 patent on 3 June 2008.

17. Under 35 U.S.C. § 154(b)(1)(A), the number of days attributable to PTO examination delay ("A Delay") is 1371 days.

18. Under 35 U.S.C. § 154(b)(1)(B), the number of days between the date that was three years after the actual filing date of the '692 application (*i.e.*, 25 July 2004) and the date that the '560 patent was granted (*i.e.*, 3 June 2008) ("B Delay") is 1,389 days.

19. The net patent term adjustment is determined as the sum of the "A Delay" and "B Delay," subject to the limitations specified at 35 U.S.C. § 154(b)(2)(A) - (C).

20. Section 154(b)(2)(A) of title 35, U.S.C., provides that "to the extent that periods of delay attributable to grounds specified in paragraph [(b)](1) overlap, the period of any adjustment ... shall not exceed the actual number of days the issuance of the patent was

delayed.” The overlap between the “A Delay” period and the “B Delay” period in the prosecution of the ’560 patent (*i.e.*, the period of “A Delay” that occurred between 25 July 2004 and 3 June 2008) is 702 days.

21. The ’560 patent is not subject to a disclaimer of term. Thus, the period of patent term adjustment is not limited under 35 U.S.C. § 154(b)(2)(B).

22. The number of days attributable to applicant delay in the prosecution of the ’692 application, as determined by the Director under 35 U.S.C. § 154(b)(2)(C), is 0 days.

23. Accordingly, the correct patent term adjustment under 35 U.S.C. § 154(b)(1) and (2) is the sum of the “A Delay” and “B Delay” ($1,371 + 1,389 = 2,760$ days), reduced by the period of overlap (702 days), for a net adjustment of 2,058 days.

24. The Director erred in the determination of patent term adjustment by treating the entire period of PTO examination delay, and not only the period of PTO examination delay that occurred after the date that was three years after the actual filing date of the ’692 application (*i.e.*, 25 July 2004), as the period of overlap between the “A Delay” and the “B Delay.” Thus, the Director erroneously determined that the net patent term adjustment should be limited under 35 U.S.C. § 154(b)(2)(A) by 1,351 days, rather than the correct interval of 702 days, and arrived at a net patent term adjustment of 1,409 days.

25. In its opinion in *Wyeth v. Dudas*, Civ. Action No. 1:07-cv-01492-JR, this Court explained the proper construction of the provisions of 35 U.S.C. § 154(b) for determining patent term adjustment. *See id.*, Mem. Op. dated 20 September 2008, docket. no. 27, reported at 88 U.S.P.Q.2d 1538. In accord with this Court’s *Wyeth* decision, the patent term adjustment for the ’560 patent is properly determined to be 2,058 days, as set forth above.

26. The Director's determination that the '560 patent is entitled to only 1,409 days of patent term adjustment is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law and in excess of statutory jurisdiction, authority, or limitation.


WHEREFORE, Plaintiff respectfully prays that this Court:

A. Issue an Order changing the period of patent term adjustment for the '560 patent term from 1,409 days to 2,058 days and requiring the Director to extend the term of the '560 patent to reflect the 2,058-day patent term adjustment.

B. Grant such other and further relief as the nature of the case may admit or require and as may be just and equitable.

Respectfully submitted,

SIDLEY AUSTIN LLP



Jeffrey P. Kushan (Bar no. 461155)

Paul J. Zegger (Bar no. 457399)

SIDLEY AUSTIN LLP

1501 K Street, N.W.

Washington, D.C. 20005

Telephone: (202) 736-8914

Facsimile: (202) 736-8711

Dated: 1 December 2008

Attorneys for Plaintiff Biogen Idec Inc.

EXHIBIT A

(12) **United States Patent**
Anderson et al.

(10) **Patent No.:** US 7,381,560 B2
 (45) **Date of Patent:** Jun. 3, 2008

(54) **EXPRESSION AND USE OF ANTI-CD20 ANTIBODIES**

(75) Inventors: **Darrell R. Anderson**, Escondido, CA (US); **Nabil Hanna**, Rancho Santa Fe, CA (US); **Roland A. Newman**, San Diego, CA (US); **Mitchell E. Reff**, San Diego, CA (US); **William H. Rastetter**, Rancho Santa Fe, CA (US)

(73) Assignee: **Biogen Idec Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1409 days.

(21) Appl. No.: **09/911,692**

(22) Filed: **Jul. 25, 2001**

(65) **Prior Publication Data**

US 2003/0095963 A1 May 22, 2003

Related U.S. Application Data

(60) Continuation of application No. 08/475,813, filed on Jun. 7, 1995, now Pat. No. 6,682,734, which is a division of application No. 08/149,099, filed on Nov. 3, 1993, now Pat. No. 5,736,137, which is a continuation-in-part of application No. 07/978,891, filed on Nov. 13, 1992, now abandoned.

(51) **Int. Cl.**
C12N 5/10 (2006.01)
C12N 15/00 (2006.01)
C12P 21/08 (2006.01)

(52) **U.S. Cl.** 435/328; 435/358; 435/361; 435/353; 435/334; 435/343.1; 435/344; 435/326; 435/344.1; 435/69.1; 435/69.6

(58) **Field of Classification Search** 435/326, 435/358, 361, 353, 328, 334, 343.1, 344, 435/344.1, 69.1, 69.6

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,831,175 A	5/1989	Gansow	
4,975,278 A	12/1990	Senter et al.	
5,099,069 A	3/1992	Gansow	
5,124,471 A	6/1992	Gansow	
5,246,692 A	9/1993	Gansow	
5,286,850 A	2/1994	Gansow	
5,439,665 A	8/1995	Hansen	
5,460,785 A	10/1995	Rhodes	
5,500,362 A	3/1996	Robinson et al.	435/7.23
5,595,721 A	1/1997	Kaminski	
5,648,267 A	7/1997	Reff	435/320.1
5,677,180 A	10/1997	Robinson et al.	
5,686,072 A	11/1997	Uhr et al.	
5,693,780 A	12/1997	Newman et al.	
5,721,108 A	2/1998	Robinson et al.	
5,736,137 A	4/1998	Anderson	
5,776,456 A	7/1998	Anderson	
5,843,398 A	12/1998	Kaminski et al.	
5,843,439 A	12/1998	Anderson	

6,015,542 A	1/2000	Kaminski et al.	
6,090,365 A	7/2000	Kaminski et al.	
6,120,767 A	9/2000	Robinson et al.	
6,183,744 B1	2/2001	Goldenberg	
6,287,537 B1	9/2001	Kaminski et al.	
6,306,393 B1	10/2001	Goldenberg	
6,399,061 B1	6/2002	Anderson	
RE38,008 E	2/2003	Abrams	
6,565,827 B1	5/2003	Kaminski et al.	
6,652,852 B1	11/2003	Robinson et al.	
6,682,734 B1	1/2004	Anderson	
6,893,625 B1	5/2005	Robinson et al.	
2002/0009444 A1	1/2002	Grillo-Lopez	
2002/0197255 A1	12/2002	Anderson et al.	
2003/0021781 A1	1/2003	Anderson et al.	
2003/0026804 A1	2/2003	Grillo-Lopez	
2003/0082172 A1	5/2003	Anderson et al.	
2003/0095963 A1	5/2003	Anderson	
2003/0147885 A1	8/2003	Anderson et al.	
2003/0206903 A1	11/2003	Grillo-Lopez	
2004/0167319 A1	8/2004	Teeling	
2004/0213784 A1	10/2004	Grillo-Lopez et al.	
2005/0163708 A1	7/2005	Robinson et al.	

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0 125 023 A1 11/1984

(Continued)

OTHER PUBLICATIONS

Lowman, H.B. Slides presented at IBC Antibody Engineering Conference, Dec. 2, 2003. Differential Activities in a Series of Humanized Anti-CD20 Antibodies.

Polyak, M.J., et al. (2002) *Blood* 99: 3256-62. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.

Chinn, et al. "Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma." Proceedings of the American Medical Association for Cancer Research, vol. 33, Abstract 2012, p. 337, 1992.

Classon, et al. "The Primary Structure of the Human Leukocyte Antigen CD37, A Species Homologue of the Rat MRC OC-44 Antigen." *The Journal of Experimental Medicine*, vol. 169, No. 4, pp. 1497-1502, 1989.

(Continued)

Primary Examiner—Ronald Schwadron
 (74) *Attorney, Agent, or Firm*—Sidley Austin LLP

(57) **ABSTRACT**

Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.

10 Claims, 21 Drawing Sheets

US 7,381,560 B2

Page 2

U.S. PATENT DOCUMENTS

2005/0186205 A1 8/2005 Anderson et al.
2006/0034835 A1 2/2006 Adams

FOREIGN PATENT DOCUMENTS

EP 0 125 023 B1 11/1984
EP 0 173 494 A2 3/1986
EP 0 274 394 A2 7/1988
EP 0 274 394 A3 7/1988
EP 0 682 040 A1 11/1995
EP 0 682 040 B1 11/1995
EP 0 451 216 B1 1/1996
EP 0 669 836 B1 3/1996
EP 0 752 248 A1 1/1997
EP 0 125 023 B2 3/2002
WO 87/02671 A1 5/1987
WO WO 88/04936 7/1988
WO 89/00999 A1 2/1989
WO WO 91/04320 4/1991
WO WO 92/07466 5/1992
WO 93/02108 A1 2/1993
WO WO 93/02180 2/1993
WO WO 94/11026 5/1994
WO 00/27428 A1 5/2000
WO 00/27433 A1 5/2000
WO 01/10460 A1 2/2001
WO 2004/056312 7/2004

OTHER PUBLICATIONS

DeNardo, et al. "Requirements for a Treatment Plan in System for Radioimmunotherapy." *International Journal of Radiation Oncology Biology Physics*, vol. 11, No. 2, pp. 335-348, 1985.
Kaminski, et al. "Radioimmunotherapy (RIT) of Refractory B-Cell Lymphoma with 131-I-Anti-B1 (Anti-CD20) Antibody: Promising Early Results Using Non-Marrow Ablative Radiation Doses." *Blood*, Abstract 161, p. 162.
Langmuir, "Radioimmunotherapy: Clinical Results and Dosimetric Considerations." *Nuclear Medicine and Biology*, Vol. 19, No. 2, pp. 213-225, 1992.
Larson, et al. "Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose ¹³¹I-labeled Monoclonal Antibodies Administered to Man." *Nuclear Medicine and Biology*, vol. 16, No. 2, pp. 153-158, 1989.
Leichner, et al. "Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particles." *Medical Physics*, vol. 20, No. 2, Pt.2, pp. 529-534, 1993.
Leichner, et al. "Dosimetry and Treatment Planning in Radioimmunotherapy." *Frontiers of Radiation Therapy and Oncology*, vol. 24, pp. 109-120, 1990.
Link, et al. "A Unique Antigen on Mature B-Cells Defined by a Monoclonal Antibody." *The Journal of Immunology*, vol. 137, No. 9, pp. 3013-3018, 1986.
Macey, et al. "A Treatment Planning Program for Radioimmunotherapy" *Frontiers of Radiation Therapy and Oncology*, vol. 24, pp. 123-131, 1990.
Meredith, et al. "Dose Fractionation of Radiolabeled Antibodies in Patients with Metastatic Colon Cancer." *Journal of Nuclear Medicine*, vol. 33, No. 9, pp. 1648-1653, 1992.
Parker, et al. "Radioimmunotherapy of Human B-Cell Lymphoma with ⁹⁰Y-conjugated Antiidiotype Monoclonal Antibody." *Cancer Research*, vol. 50, No. 3, pp. 1022s-1028s, 1990.
Pearson, et al. "Enhanced Therapeutic Efficacy of an Immunotoxin in combination with Chemotherapy against an Intraperitoneal Human Tumor Xenograft in Athymic Mice." *Cancer Research* vol. 49, No. 18, pp. 4990-4995, 1989.
Press, et al. "Endocytosis and Degradation of Monoclonal of Antibodies Targeting Human B-Cell Malignancies" *Cancer Research*, vol. 49, No. 17, pp. 4906-4912, 1989.
Press, et al. "Radiolabeled Antibody Therapy of Human B Cell Lymphomas." *Immunobiology of Proteins and Peptides VI*, vol. 303, pp. 91-96, 1991.

Securities and Exchange Commission, Form S-1 Registration Statement, Filed 1991, IDEC Pharmaceuticals.

Senter, Peter D. "Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy." *The FASEB Journal*, vol. 4, pp. 188-193, 1990.

Senter, et al. "Activation of Prodrugs by Antibody-Enzyme Conjugates" *Immunobiology of Proteins and Peptides VI*, vol. 303, pp. 97-105, 1991.

Schwartz-Albiez, et al. "The B Cell-Associated CD37 Antigen (gp40-52) Structure and Subcellular Expression of an Extensively Glycosylated Glycoprotein." *The Journal of Immunology*, vol. 140, No. 3, pp. 905-914, 1988.

Sharkey, et al. "Biological Considerations for Radioimmunotherapy." *Cancer Research*, vol. 50, No. 3, pp. 964s-969s, pp. 1990.

Stewart, et al. "Intraperitoneal ¹³¹I- And ⁹⁰Y-Labelled Monoclonal Antibodies for Ovarian Cancer: Pharmacokinetics and Normal Tissue Dosimetry." *International Journal of Cancer, Supplement 3*, pp. 71-76, 1988.

Uckun, et al. "Combined Ex Vivo Treatment with Immunotoxins and Mafosfamid: A Novel Immunochemotherapeutic Approach for Elimination of Neoplastic T Cells from Autologous Marrow Grafts." *The Journal of Immunology*, vol. 134, No. 5, pp. 3504-3515, 1985.

Uckun, et al. "Increased Efficiency in Selective Elimination of Leukemia Cells by a Combination of a Stable Derivative of Cyclophosphamide and a Human B-Cell-specific Immunotoxin Containing Pokeweed Antiviral Protein." *Cancer Research*, vol. 45, No. 1, pp. 69-75, 1985.

Yokota, et al. "Synergistic Potentiation of in Vivo Antitumor Activity of Anti-Human T-Leukemia Immunotoxins by Recombinant α -Interferon and Daunorubicin." *Cancer Research*, vol. 50, No. 1, pp. 32-37, 1990.

Badger, et al. "Experimental Radioimmunotherapy of Murine Lymphoma with 131 I-labeled Anti-T-Cell Antibodies." *Cancer Research*, 46, pp. 6223-6228, 1986.

Buchsbaum, et al. "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody." *Cancer Research*; 52, pp. 637-642, 1992.

Chen, et al. "Tumor Idiotype Vaccines. VI. Synergistic Anti-Tumor Effects with Combined "Internal Image" Anti-Idiotypes and Chemotherapy." *Journal of Immunology*, 143, pp. 1053-1057, No. 3, 1989.

Clark et al. "Role of the Bp35 cell surface polypeptide in human B-cell activation" vol. 82; pp. 1776-1770, 1985.

Clark, et al. "Phase I Evaluation of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy." *Journal Cellular Biochemistry Supp.* 9A, p. 63, 1985.

DeNardo, et al. "Fractionated Radioimmunotherapy of B-Cell Malignancies with 131I-Lym-1." *Cancer Research (Suppl.)* 50, pp. 1014s-1016s, 1990.

Kaminski, et al. "Initial Clinical Radioimmunotherapy Result with ¹³¹I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma." *Antibody Immunoconjugates, and Radiopharmaceuticals* vol. 5, No. 3 p. 345, 1992.

Kaminski, et al. "131-I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma." *Third Conference on Rit and Rit of Cancer, Abstract. No. 144, 1990.*

Langmuir, "Radioimmunotherapy: Clinical Results and Dosimetric Considerations." *Nuclear Medicine Biology* vol. 19, No. 2, pp. 213-225, 1992.

Levy, et al. "Tumor Therapy with Monoclonal Antibodies." *Federation Proceedings* 42:9 pp. 2650-2656, 1983.

Macklis, et al. "Radiobiologic Studies of Low-Dose-Rate ⁹⁰Y-Lymphoma Therapy." *Cancer Supplement*, vol. 73, No. 3, pp. 966-973, 1994.

Maloney, et al. "The Anti-Tumor effect of Monoclonal Anti-CD20 Antibody (mAb) Therapy Includes Direct Anti-Proliferative Activity and Production of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines." *Interferon and Chronic*

US 7,381,560 B2

Page 3

- Myleogenous Leukemia. Fred Hutchinson Cancer Research & University of Washington, 637a, p. 2535.
- Maloney, et al. "Monoclonal Anti-Idiotypic Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells." *Blood*, vol. 80, No. 6, pp. 1502-1510, 1992.
- Masucci, et al. "Chemotherapy and Immunotherapy of Colorectal Cancer." *Medical Oncology Tumor Pharmacother* vol. 8, No. 3, pp. 207-220, 1991.
- Nadler, et al. "A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin." *Journal of Clinical Investigative*, vol. 67, pp. 134-140, 1981.
- Reilly, "Radioimmunotherapy of malignancies." *Clinical Pharmacy*, vol. 10, pp. 359-375, 1991.
- Press, et al. Scientific Proceedings, ASCO, Abstract No. 864, 1986.
- See-Lasley, et al. "Hodgkin's Disease and Non-Hodgkin's Lymphoma Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP)." *Manual of Oncology Therapeutics*, C.V. Mosby Company, pp. 44-71, 1981.
- Senter, et al. "Enhancement of the in vitro and in vivo Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates." *Cancer Research* 49, pp. 5789-5792, 1989.
- Stashenko, et al. "Characterization of Human B Lymphocyte-Specific Antigen." *The Journal of Immunology* vol. 125, No. 4, pp. 1678-1685, 1960.
- Idec Pharmaceuticals v. Corixa Corp.*, Case No. 01-1637-IEG (S.D. Cal. Oct. 14, 2003).
- Biogen Idec v. Corixa Corp.*, Case No. 01-1637-IEG (S.D. Cal. Jan. 22, 2004).
- Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma." *Blood*, 1992, 80:863-878.
- Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes." *Eur J Immunol*, 1986, 16(8):881-87.
- Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19." *J Immunol*, 1988, 141(12):4388-94.
- Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, *Antibody Immunoconjugates, and Radiopharmaceuticals*, vol. 3, No. 1, Abstract No. 83.
- Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, *Proceedings of ASCO*, vol. 9, Abstract No. 1051.
- Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," *The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting*, p. 852, Abstract No. 622.
- Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, *Antibody Immunoconjugates, and Radiopharmaceuticals*, vol. 4, No. 1, p. 36, Abstract No. 66.
- Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, *Blood*, vol. 76, No. 10, p. 355a, Abstract No. 1409.
- Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, *Journal of Clinical Oncology*, vol. 10, No. 11, pp. 1696-1711.
- Adams, R.A. et al., Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2, *Can Res* 28:1121-1125 (1968).
- Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, *Can. Res.* 27:2479-2482 (1967).
- Anderson, K.C., et al., Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow, *Blood* 69(2):597-604 (1987).
- Anderson, D.R., et al., Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody, The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.
- Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation, *Blood* 63(6):1424-1433 (1984).
- Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. *Hem. Onc. Clinics of N.A.* 5(5):1013-1025 (1991).
- Armitage, J.O. et al., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristin and prednisone (CHOP), *Cancer* 50:1695 (1982).
- Bhan, A.K., et al., Stages of B cell differentiation in human lymphoid tissue, *J. Exp. Med.*, 154:737-749 (1981).
- Boulianne, G.L. et al., Production of functional chimaeric mouse/human antibody, *Nature* 312:643 (Dec. 1984).
- Brunner, K.T. et al., Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹Cr-labeled allogeneic target cells in vitro; inhibition by isoantibody and drugs, *Immunology* 14:181-189 (1968).
- Buchsbaum, D.J., et al., A comparison of ¹³¹I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts, *Int. J. Radiation Oncology Biol. Phys.*, 18:1033-1041 (1990).
- Buchsbaum, D.J., et al., Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies, *Cancer Research (Suppl.)* 50:993s-999s (1990).
- Buchsbaum, D.J., et al., Comparison of ¹³¹I- and ⁹⁰Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts, *Int. J. Radiation Oncology Biol. Phys.* 25:629-638 (1993).
- Calvert, J.E., et al., Cellular events in the differentiation of antibody-secreting cells, *Seminars in Hematology*, 21(4):226-243 (1984).
- Chomczynski, P. et al., Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, *Anal. Biochem.* 162:156-159 (1987).
- Clark, E.A., et al., Role of the Bp35 cell surface polypeptide in human B-cell activation, *Proc. Natl. Acad. Sci. USA*, 82:1766-1770 (1985).
- Cope, Antibody shows promise in treating B-cell lymphoma, *Oncology*, 8(4):100 (1994).
- DeNardo, S.J., et al., Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, *Antibody, Immunoconjugates, and Radiopharmaceuticals*, 1(1):17-33 (1988).
- DeNardo, S.J., et al., The biologic window for chimeric L6 radioimmunotherapy, *Cancer* 73(3):1023-32 (1994).
- Dickson, Scientists produce chimeric monoclonal abs, *Genetic Engineering News* 5/3 (Mar. 1985).
- Eary, J.F. et al, Imaging and Treatment of B-Cell Lymphoma, *J. Nuc. Med.* 31/8:1257-1268 (1990).
- Einfeld, D.A. et al., Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, *EMBO* 7:711 (1988).
- Golay, J.T., et al., The CD20 (Bp35) antigen is involved in activation of B cells from the G₀ to the G₁ phase of the cell cycle, *J. Immunology* 135(6):3795-3801 (1985).
- Goldenberg, D.M. et al., Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, *J. Clin. Onc.* 9/4:548-564 (1991).
- Greenberger, J.S., et al., Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture, *Cancer Research* 45:758-767 (1985).
- Hekman, A., et al., Immunotherapy, The Netherlands Cancer Institute Amsterdam Annual Report, pp. 47-48 (1993).
- Lipton, J.M., et al., Distribution of B1, calla, β2 microglobulin and Ia on hematopoietic progenitors and hematopoiesis supporting cells (HSC) in short and long-term cultures, *Blood*, 60(5)(Suppl. 1):170a (Abstract 609) (1982).

US 7,381,560 B2

Page 4

- Kaminski, M.G. et al., Radioimmunotherapy of B-cell lymphoma with [¹³¹I] anti-B1 (anti-CD20) antibody, *NEJM* 329/7 (1993).
- Liu, A.Y. et al., Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity. *J. Immunol.* 139/10:3521-3526 (1987).
- Marx, Antibodies made to order, *Science* 229 455 (Aug. 1985).
- Morrison, S.L. et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, *PNAS* 81:6851-6854 (Nov. 1984).
- Morrison, Transfectomas provide novel chimeric antibodies, *Science* 229:1202-1207 (Sep. 1985).
- Munro, Uses of chimaeric antibodies, *Nature* 312:597 (Dec. 1984).
- Nadler, L.M., et al., B cell origin of non-T cell acute lymphoblastic leukemia a model for discrete stages of neoplastic and normal pre-B cell differentiation, *J. Clin. Invest.* 74:332-340 (1984).
- Nadler, L.M., et al., Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma, *The Lancet*, vol. II, pp. 427-431 (1984).
- Nadler, L.M., et al., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, *Cancer Research*, 40:3147-3154 (1980).
- Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with human physiological effector function, *Nature* 314:268 (Mar. 1985).
- Oettgen, H.C., et al., Further biochemical studies of the human B-cell differentiation antigens B1 and B2, *Hybridoma*, 2(1):17-28 (1983).
- Ozato, K., et al., Monoclonal antibodies to mouse MHC antigens III. Hybridoma antibodies reacting to antigens to the H-2^b haplotype reveal genetic control of isotype expression, *J. Immunology*, 126(1):317-321 (1981).
- Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, *Blood* 69(2):584-591 (1987).
- Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." *New England Journal of Medicine* 329/17: 1219-12223 (1993).
- Press, O.W. et al., Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, *J. Clin. Onc.* 7/8:1027-1038 (1989).
- Reff, M., et al., Depletion of a B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, *J. Cellular Biochem., Suppl.* 17E:260 (Abstract T103) (1993).
- Reff, M., et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, *Blood*, 83(2):435-445 (1994).
- Robertson, M.J., et al., Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia, *Blood*, 79(9):2229-2236 (1992).
- Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," *Hum. Antibod. Hybridomas* 2:84-93 (1991).
- Sahagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, *J. Immunol.* 137:1066-1074 (1986).
- Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, *Harvey Lectures* 69:125-143 (1974).
- Schlom J., et al., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, *J. Natl. Cancer Inst.*, 82(9):763-771 (1990).
- Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, *Nature* 276:269 (1978).
- Smeland, E.B., et al., Activation of human B cells: Alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells, *J. Immunology*, 138(10):3179-3184 (1987).
- Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, *Nucl. Med. Bio.* 18(6): 589-603 (1991).
- Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, *Hybridoma* 5/1:517 (1986).
- Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, *J. Immunol.* 135:8564 (Nov. 1985).
- Tedder, T.F., et al., The B cell surface molecule B1 is functionally linked with B cell activation and differentiation, *J. Immunology*, 135(2):973-979 (1985).
- Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. *Som. Cell & Mol. Gen.* 12/6:555-566 (1986).
- Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, *J. Biol. Chem.* 264(19):11282-11287 (1989).
- Wessels, B.W., et al., Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies, *Med. Phys.*, 11(5):638-645 (1984).
- Anderson D.R. et al. *Biochem. Soc. Trans.* 25(2): 705-08, 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
- Armitage J.O. et al. *J. Clin. Oncol.* 16(8): 2780-95, 1998. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
- Berinstein N.L. et al. *Ann. Oncol.* 9:995-1001, 1998. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
- Beychok S. (in) *Cells of Immunoglobulin Synthesis*, B. Pernis et al., eds. New York: Academic Press, 1979, 69-88. Comparative aspects of in vitro and cellular assembly of immunoglobulins.
- Buchsbaum D.J. et al. *Cancer Res.* 52: 637-642, 1992. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by pre-dosing with unlabeled anti-B1 monoclonal antibody.
- Carrasquillo J.A. et al. *J. Nucl. Med.* 26: 67, abst. No. 276, 1985. Improved imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody.
- Chinn P.C. et al. *Int. J. Oncol.* 15(5): 1017-25, Nov. 1999. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
- Chinn P.C. et al. *Proc. Ann. Mtg. Am. Assn. Cancer Res.* 40: 574, abst. No. 3786, 1999. A 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium.
- Cogliatti S.B. et al. *Sw. Med. Weekly* 192: 607-17, 2002. Who is WHO and what was Real?
- Davis T.A. et al. *Clin. Cancer Res.* 5(3): 611-15, 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
- Davis T.A. et al. *Proc. Ann. Mtg. Amer. Assn. Cancer Res.* 39: 435, abst. No. 2964, 1998. Therapy of B cell lymphoma with anti-CD20 can result in relapse with loss of CD20 expression.
- Dillman R.O. *J. Clin. Oncol.* 12(7): 1497-1515, 1994. Antibodies as cytotoxic therapy.
- Grillo-López A.J. IBC Int'l. Conference on Antibody Engineering, La Jolla, Dec. 1994. IDEC-C2B8 chimeric antibody and IDEC-Y2B8 radiolabeled antibody phase I and II studies in patients with non-Hodgkin's lymphoma (abstract of presentation).
- Grillo-López A.J. et al. *Ann. Oncol.* 7(3 Suppl.): 57, abst. No. 195, 1996. Treatment (rx) of relapsed non-Hodgkin's lymphoma (NHL) using the 90-yttrium (90-Y) labeled anti-CD20 monoclonal antibody (MAB) IDEC-Y2B8: a phase I clinical trial (PI CT).
- Grillo-López A.J. et al. *Antibody Immunocconj. Radiopharm.* 8: 60, abst. No. 10, 1995. Treatment options for patients with relapsed low-grade or follicular lymphoma: the role of IDEC-C2B8.
- Grillo-López A.J. et al. *Blood* (86(10 Suppl. 1): 55a, abst. No. 207, 1995. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma.
- Grillo-López A.J. et al. *Br. J. Haematol.* 93(Suppl. 2): 283, abst. No. 1072, 1996. IDEC-C2B8 chimeric anti-CD20 antibody (MAB):

US 7,381,560 B2

Page 5

- safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL).
- Horning S.J. et al. *Blood* 100(11 part 1): 357a, abst. No. 1385, 2002. Rituximab treatment failures: tositumomab and Iodine I 131 tositumomab (Bexxar®) can produce meaningful durable responses.
- IDEC Pharmaceuticals Corp. and Genentech, Inc., Product insert for Rituxan® approved by U.S. Food and Drug Administration on Nov. 26, 1997.
- Janakirman N. et al. *Blood* 92(10 Suppl. 1): 337a, abst. No. 1384, Nov. 1998. Rituximab: correlation between effector cells and clinical activity in NHL.
- Kinoshita T. et al. *J. Clin. Oncol.* 16(12): 3916, Dec. 1998. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
- Maloney D.C. et al. *Blood* 90(6): 2188-2195, 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
- Maloney D.G. et al. *Blood* 88(10: Suppl. 1): 637a, abst. No. 2635, 1996. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines.
- Maloney D.G. et al. *J. Clin. Oncol.* 15(10): 3266-3274, Oct. 1997. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's Lymphoma.
- Maloney D.M. et al. *Blood* 84(8): 2457-66, 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
- McLaughlin P. et al. *Blood* 92(10 Suppl. 1): 414a-415a, abst. No. 1712, Nov. 1998. Efficacy controls and long-term follow-up for relapsed or refractory, low-grade or follicular (R-LG/F) NHL.
- McLaughlin P. et al. *J. Clin. Oncol.* 16(8): 2825-2833, Aug. 1998. Rituximab chimeric-anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
- McLaughlin P. et al. *Oncology* 12(12): 1763-81, 1998. Clinical status and optimal use of rituximab for B-cell lymphomas.
- Non-Hodgkin's Lymphoma Pathologic Classification Project. *Cancer* 49(10): 2112-35, 1982. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas.
- Pietersz G.A. et al. *Immunol. Cell. Biol.* 65(2): 111-25, 1987. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer.
- Piro L.D. et al. *Ann. Oncol.* 10: 655-61, 1999. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
- Press O.W. *Cancer J. Sci. Amer.* 4(Suppl 2): S19-S26, Jul. 1998. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
- Teeling J.L. et al. *Blood* 104:1793-1800, 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
- Teeling J.L. et al. *J. Immunol.* 277: 362-71, 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
- White C.A. et al. *Ann. Oncol.* 10(3 Suppl): 64, abst. No. 215, 1999. Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDEC-Y2B8 phase I/II ⁹⁰yttrium trial.
- White C.A. et al. *Ann. Rev. Med.* 52: 125-45, 2001. Antibody-targeted immunotherapy for treatment of malignancy.
- White C.A. et al. *Blood* 87(9): 3640-49, 1996. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-idiotype monoclonal antibodies.
- White C.A. et al. *Eur. J. Cancer* 35: S57, abst. No. 107, 1999. Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma.
- Witzig T. et al. *Blood* 90(10 Suppl. 1): 586a, abst. No. 2606, 1997. IDEC-Y2B8 ⁹⁰yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a phase I/II trial.
- Witzig T.E. et al. *J. Clin. Oncol.* 17(12): 3793-3803, 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
- Witzig T.E. et al. *J. Clin. Oncol.* 20: 2453-63, 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
- Witzig T.E. et al. *Blood* 94(10 Suppl. 1): 631a, abst. No. 2805, 1999. Prospective randomized controlled study of Zevalin™ (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results.




FIG. 1

U.S. Patent

Jun. 3, 2008

Sheet 2 of 21

US 7,381,560 B2

```

LINKER #1 15bp | SV40 ORIGIN=332bp
GACGTCGCGG CCGCTCTAGG CCTCCAAAAA AGCCTCCTCA CTA1CTTCTGG AATAGCTCAG 60
AGGCCGAGGC GGCCTCGGCC TCTGCATAAA TAAAAAAAT TAGTCAGCCA TGCATGGGGC 120
GGAGAATGGG CGGAAC1TGGG CGGAGTTAGG GCGGGGATGG GCGGAGTTAG GGGCGGGACT 180
ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCATACTTC TGCCTGCTGG GGAGCCTGGG 240
GAC1TTCCAC ACCTGGTTGC T1GACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT 300
GGGGAGCCTG GGGACTTTCC ACACCCTAAC TGACACACAT TCCACAG1AAT TAATTCCCCT 360
AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCCGC 420
GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCAT1TG 480
ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA 540
TGGGTGGACT ATTTACGGTA AACTGCCAC TGGCAGTAC ATCAAGTGTA TCATATGCCA 600
AGTACGCCCC CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATT1A TGCCAGTAC 660
ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC 720
ATGGTGATGC GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA 780
TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGACCA1A AAATCAACGG 840
GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA 900
CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACG1TGAACC GTCAGATCGC CTGGAGACGC 960
CATCACAGAT CTCTCACCAT GAGGGTCCCC GCTCAGCTCC TGGGGCTCCT GCTGCTCTGG 1020
CTCCAGGTG CACGATGTGA TGGTACCAAG GTGGAATCA AAC1GTACGGT GGCTGCACCA 1080
TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGA1ACTGC CTCTGTTGTG 1140
TGCCTGCTGA ATA1ACTTCTA TCCAGAGAG GCCAAAGTAC AGTGGAAAGG1T GGATAACGCC 1200
HUMAN KAPPA CONSTANT 324bp 107 AMINO ACID & STOP CODON
CTCCAATCGG GTA1ACTCCCA GGAGAGTGTC ACAGAGCAGG ACAGCAAGGA CAGCACCTAC 1260
AGCCTCAGCA GCACCCTGAC GCTGAGCAAA GCAGACTACG AGAAACACAA AGTCTACGCC 1320
TGCGAAGTCA CCCATCAGGG CCTGAGCTCG CCCGTCACAA AGAGCTTCAA CAGGGGAGAG 1380
STOP
LIGHT
CHAIN | Eco RI LINKER #4=85bp
TGT1TGATT1C AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATT1CGT GACAACATGC 1440
GGCCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT 1500

```

FIG. 2A

U.S. Patent

Jun. 3, 2008

Sheet 3 of 21

US 7,381,560 B2

```

GTTTGCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC TGTCCTTTCC 1560
                                BGH poly A=231bp
TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT 1620
GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT 1680
GCGGTGGGCT CTATGGAACC AGCTGGGGCT CGACAGCTAT GCCAAGTACG CCCCTATTG 1740
                                | LINKER #5=15bp |
                                1702 3          1717 8
ACGTCAATGA CGGTAAATGG CCCGCCTGGC ATTATGCCCA GTACATGACC TTATGGGACT 1800
TTCCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT 1860
                                CMV PROMOTER-ENHANCER=334bp
GGCAGTACAT CAATGGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC 1920
CCATTGACGT CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CAAAATGTC 1980
GTAACAACCTC CGCCCCATTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA 2040
                                LINKER #6=7bp
TAAGCAGAGC TGGGTACGTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCGTCCGAC 2100
                                2051 2 2058 9
                                LEADER=51bp
ATGGGTTGGA GCCTCATCTT GCTCTTCCTT GTCGCTGTTG CTACGCGTGT CGCTAGCACC 2160
                                START HEAVY CHAIN
                                Mlu I 2151 | 2 Nhe I
                                -5 -4 -3 114 115
AAGGGCCCAT CGGTCTTCCC CCTGGCACCC TCCTCCAAGA GCACCTCTGG GGGCACAGCG 2220
GCCCTGGGCT GCCTGGTCAA GGACTACTTC CCCGAACCGG TGACGGTGTC GTGGAACTCA 2280
GGCGCCCTGA CCAGCGGCGT GCACACCTTC CCGGCTGTCC TACAGTCCTC AGGACTCTAC 2340
                                HUMAN GAMMA 1 CONSTANT
TCCCTCAGCA GCGTGGTGAC CGTGCCCTCC AGCAGCTTGG GCACCCAGAC CTACATCTGC 2400
                                993bp=330 AMINO ACID & STOP CODON
AACGTGAATC ACAAGCCCAG CAACACCAAG GTGGACAAGA AAGCAGAGCC CAAATCTTGT 2460
GACAAAACCTC ACACATGCCC ACCGTGCCCA GCACCTGAAC TCCTGGGGGG ACCGTCAAGTC 2520
TTCCTCTTCC CCCCCAAAACC CAAGGACACC CTCATGATCT CCCGGACCCC TGAGGTCAACA 2580
TGCCTGGTGG TGGACGTGAG CCACGAAGAC CCTGAGGTCA AGTTCAACTG GTACGTGGAC 2640
GGCGTGGAGG TGCATAATGC CAAGACAAAG CCGCGGGAGG AGCAGTACAA CAGCACGTAC 2700
CGTGTGGTCA GCGTCCTCAC CGTCCTGCAC CAGGACTGGC TGAATGGCAA GGACTIONAAG 2760
TGCAAGGTCT CCAACAAAGC CCTCCCAGCC CCCATCGAGA AAACCATCTC CAAAGCCAAA 2820
GGGCAGCCCC GAGAACCACA GGTGTACACC CTGCCCCCAT CCCGGGATGA GGTGACCAGG 2880
AACCAGGTCA GCCTGACCTG CCTGGTCAAA GGCTTCTATC CCAGCGACAT CGCCGTGGAG 2940
TGGGAGAGCA ATGGGCAGCC GGAGAACAAC TACAAGACCA CGCCTCCCGT GCTGGACTCC 3000

```

FIG. 2B

U.S. Patent

Jun. 3, 2008

Sheet 4 of 21

US 7,381,560 B2

GACGGCTCCT TCTTCCTCTA CAGCAAGCTC ACCGTGGACA AGAGCAGGTG GCAGCAGGGG 3060
 AACGTCTTCT CATGCTCCGT GATGCATGAG GCTCTGCACA ACCACTACAC GCAGAAGAGC 3120
 STOP HEAVY CHAIN | Bam HI LINKER #7=81bp
 CTCTCCCTGT CTCCGGGTAA ATGAGGATCC GTTAACGGTT ACCAACTACC TAGACTGGAT 3180
 3144 5
 TCGTGACAAC ATGCGGCCGT GATATCTACG TATGATCAGC CTGGACTGTG CTTTCTAGTT 3240
 3225 6
 GCCAGCCATC TGTTGTTTGC CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC 3300
 BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp
 CCACTGTCTT TCCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCAAT 3360
 CTATTCTGGG GGGTGGGGTG GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA 3420
 GGCATGCTGG GGATGCGGTG GGCTCTATGG AACCACTGG GGCTCGACAG CGCTGGATCT 3480
 3456 7 LINKER #8=34bp
 CCCGATCCCC AGCTTTGCTT CTCAATTTCT TATTTGCATA ATGAGAAAAA AAGGAAAATT 3540
 3490 1
 AATTTTAAACA CCAATTCAGT AGTTGATTGA GCAAATGCGT TGCCAAAAAG GATGCTTTAG 3600
 MOUSE BETA GLOBIN MAJOR PROMOTER=366bp
 AGACAGTGTT CTCTGCACAG ATAAGGACAA ACATTATTCA GAGGGAGTAC CCAGAGCTGA 3660
 GACTCCTAAG CCAGTGAGTG GCACAGCATT CTAGGGAGAA ATATGCTTGT CATCACCGAA 3720
 GCCTGATTCC GTAGAGCCAC ACCTTGGTAA GGGCCAATCT GCTCACACAG GATAGAGAGG 3780
 GCAGGAGCCA GGGCAGAGCA TATAAGGTGA GGTAGGATCA GTTGCTCCTC ACATTTGCTT 3840
 CTGACATAGT TGTGTTGGGA GCTTGGATAG CTTGGACAGC TCAGGGCTGC GATTTGCGGC 3900
 3856 7 LINKER #9=19bp 5' UNTRANSLATED DHFR=82bp
 CAAACTTGAC GGCAATCCTA GCGTGAAGGC TGGTAGGATT TTATCCCCGC TGCCATCATG 3960
 3957 8 START DHFR
 GTTCGACCAT TGAAGTGCAT CGTCGCCGTG TCCCAAAATA TGGGGATTGG CAAGAACGGA 4020
 GACCTACCCT GGCCTCCGT CAGGAACGAG TTCAAGTACT TCCAAAGAAT GACCACAACC 4080
 TCTTCAGTGG AAGGTAAACA GAATCTGGTG ATTATGGGTA GGAAAACCTG GTTCTCCATT 4140
 MOUSE DHFR=564bp=187 AMINO ACID & STOP CODON
 CCTGAGAAGA ATCGACCTTT AAAGGACAGA ATTAATATAG TTCTCAGTAG AGAACTCAA 4200
 GAACCACCAC GAGGAGCTCA TTTTCTTGCC AAAAGTTTGG ATGATGCCTT AAGACTTATT 4260
 GAACAACCGG AATTGGCAAG TAAAGTAGAC ATGGTTTGG TAGTCGGAGG CAGTTCTGTT 4320
 TACCAGGAAG CCATGAATCA ACCAGGCCAC CTTAGACTCT TTGTGACAAG GATCATGCAG 4380
 GAATTTGAAA GTGACACGTT TTTCCAGAA ATTGATTTGG GCAAATATAA ACTTCTCCCA 4440
 GAATACCCAG GCGTCCTCTC TGAGGTCCAG GAGGAAAAAG GCATCAAGTA TAAGTTTGAA 4500

FIG. 2C

U.S. Patent

Jun. 3, 2008

Sheet 5 of 21

US 7,381,560 B2

STOP DHFR
 GTCTACGAGA AGAAAGAC TA ACAGGAAGAT GCTTTCAAGT TCTCTGCTCC CCTCCTAAAG 4560
 4521 2

3' UNTRANSLATED DHFR=82bp LINKER #10=10bp
 TCATGCATTT TTATAAGACC ATGGGACTTT TGCTGGCTTT AGATCAGCCT CGACTGTGCC 4620
 4603 4 4613 4

TTCTAGTTGC CAGCCATCTG TTGTTTGCCC CTCCTCCGTG CCTTCCCTTGA CCCTGGAAGG 4680

BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp
 TGCCACTCCC ACTGTCCCTT CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG 4740

GTGTCAATTCT ATTCTGGGGG GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA 4800

CAATAGCAGG CATGCTGGGG ATGCGGTGGG CTCTATGGAA CCAGCTGGGG CTCGAGCTAC 4860
 4844 5 LINKER #11=17bp

TAGCTTTGCT TCTCAATTC TTATTTGCAT AATGAGAAAA AAAGGAAAAT TAATTTTAAC 4920

ACCAATTCAG TAGTTGATTG AGCAAATGCG TTGCCAAAAA GGATGCTTTA GAGACAGTGT 4980

MOUSE BETA GLOBIN MAJOR PROMOTER=366bp
 TCTCTGCACA GATAAGGACA AACATTATTC AGAGGGAGTA CCCAGAGCTG AGACTCCTAA 5040

GCCAGTGAGT GGCACAGCAT TCTAGGGAGA AATATGCTTG TCATCACCGA AGCCTGATTC 5100

CGTAGAGCCA CACCTTGGTA AGGGCCAATC TGCTCACACA GGATAGAGAG GGCAGGAGCC 5160

AGGGCAGAGC ATATAAGGTG AGGTAGGATC AGTTGCTCCT CACATTTGCT TCTGACATAG 5220

LINKER #12=21bp START NEO
 TTGTGTTGGG AGCTTGGATC GATCCTCTAT GGTGGAACAA GATGGATTGC ACGCAGGTTT 5280
 5227 8 5248 9

TCCGGCCGCT TGGGTGGAGA GGCTATTCGG CTATGACTGG GCACAACAGA CAATCGGCTG 5340

CTCTGATGCC GCCGTGTTCC GGCTGTCAGC GCAGGGGGCC CCGGTTCTTT TTGTCAAGAC 5400

NEOMYCIN PHOSPHOTRANSFERASE
 CGACCTGTCC GGTGCCCTGA ATGAACTGCA GGACGAGGCA GCGGGGCTAT CGTGGCTGGC 5460

795bp=264 AMINO ACIDS & STOP CODON
 CACGACGGGG GTTCCTTGGC CAGCTGTGCT CGACGTTGTC ACTGAAGCGG GAAGGGACTG 5520

GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA TCTCACCTTG CTCCTGCCG 5580

GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT ACGCTTGATC CGGCTACCTG 5640

CCCATTGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA CGTACTCGGA TGAAGCCGG 5700

TCTTGTCGAT CAGGATGATC TGGACGAAGA GCATCAGGGG CTCGCGCCAG CCGAACTGTT 5760

CGCCAGGCTC AAGGCGCGCA TGCCCGACGG CGAGGATCTC GTCGTGACCC ATGGCGATGC 5820

CTGCTTGCCG AATATCATGG TGGAAAATGG CCGCTTTTCT GGATTCATCG ACTGTGGCCG 5880

GCTGGGTGTG GCGGACCGCT ATCAGGACAT AGCGTTGGCT ACCCGTGATA TTGCTGAAGA 5940

GCTTGGCGGC GAATGGGCTG ACCGCTTCCT CGTGCTTTAC GGTATCGCCG CTCCCGATTG 6000

FIG. 2D

U.S. Patent

Jun. 3, 2008

Sheet 7 of 21

US 7,381,560 B2

```

GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT TACCAATGCT 7560
                                         |
                                         |7550
TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTTCG TTCATCCATA GTTGCCCTGAC 7620
TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA 7680
TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC CAGCCAGCCG 7740
                                         BETA LACTAMASE=861bp
GAAGGGCCGA GCGCAGAAGT GGTCCCTGCAA CTTTATCCCG CTCCATCCAG TCTATTAATT 7800
                                         286 AMINO ACID & STOP CODON
GTTGCCGGGA AGCTAGAGTA AGTAGTTTCGC CAGTTAATAG TTTGCGCAAC GTTGTTGCCA 7860
TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC AGCTCCGGTT 7920
CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG GTTAGCTCCT 7980
TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC ATGGTTATGG 8040
CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTTCT GTGACTGGTG 8100
AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCCG 8160
CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGAA 8220
AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTTGATGT 8280
AACCACCTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC GTTTCTGGGT 8340
GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT 8400
START BETA LACTAMASE
GAATACTCAT ACTCTTCCTT TTTCAATATT ATTGAAECAT TTATCAGGGT TATTGTCTCA 8460
|
|8410
TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT 8520
TTCCCCGAAA AGTGCCACCT

```

FIG. 2F

U.S. Patent

Jun. 3, 2008

Sheet 8 of 21

US 7,381,560 B2

LINKER #1=15bp
 GACGTCGCGG CCGCTCTAGG CCTCCAAAA AGCCTCCTCA CTACTTCTGG AATAGCTCAG 60
 15 6
 AGGCCGAGGC GGCCTCGGCC TCTGCATAAA TAAAAAAAT TAGTCAGCCA TGCATGGGGC 120
 SV40 ORIGIN=332bp
 GGAGAATGGG CGGAAGTGGG CGGAGTTAGG GCGGGGATGG GCGGAGTTAG GGGCGGGACT 180
 ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCATACTTC TGCCTGCTGG GGAGCCTGGG 240
 GACTTTCCAC ACCTGGTTGC TGACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT 300
 GGGGAGCCTG GGGACTTTCC ACACCCTAAC TGACACACAT TCCACAGAAAT TAATTCCCCT 360
 347 8
 AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCGCG 420
 GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTTG 480
 ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA 540
 CVM PROMOTER-ENHANCER=567bp
 TGGGTGGACT ATTTACGGTA AACTGCCCCAC TTGGCAGTAC ATCAAGTGTG TCATATGCCA 600
 AGTACGCCCC CTATTGACGT CAATGACGGT AAATGGCCCCG CCTGGCATTG TGCCAGTAC 660
 ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC 720
 ATGGTGATGC GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGG 780
 TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACC AATCAACGG 840
 GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA 900
 LINKER #3=7bp
 CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACGTGAACC GTCAGATCGC CTGGAGACGC 960
 927 8 934 5
 Bgl 2 | START LIGHT CHAIN NATURAL LEADER=66bp
 CATCACAGAT CTCTCACTAT GGATTTTCAG GTGCAGATTA TCAGCTTCTT GCTAATCAGT 1020
 978 9
 GCTTCAGTCA TAATGTCCAG AGGACAAATT GTTCTCTCCC AGTCTCCAGC AATCCTGTCT 1080
 1044 5+1
 GCATCTCCAG GGGAGAAGGT CACAATGACT TGCAGGGCCA GCTGAAGTGT AAGTTACATC 1140
 CACTGGTTCC AGCAGAAGCC AGGATCCTCC CCCAAACCCT GGATTTATGC CACATCCAAC 1200
 LIGHT CHAIN VARIABLE REGION 318bp 106 AMINO ACID
 CTGGCTTCTG GAGTCCCTGT TCGCTTCAGT GGCAGTGGGT CTGGGACTTC TTA CTCTCTC 1260
 ACCATCAGCA GAGTGGAGGC TGAAGATGCT GCCACTTATT ACTGCCAGCA GTGGACTAGT 1320
 AACCACCCA CGTTCGGAGG GGGGACCAAG CTGGAAATCA AACGTACGGT GGCTGCACCA 1380
 1362 3
 TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAACTGC CTCTGTTGTG 1440
 TGCCTGCTGA ATAACCTCTA TCCAGAGAG GCCAAAGTAC AGTGGAAAGT GGATAACGCC 1500

FIG. 3A

U.S. Patent

Jun. 3, 2008

Sheet 9 of 21

US 7,381,560 B2

HUMAN KAPPA CONSTANT=324bp=107 AMINO ACID & STOP CODON
 CTCCAATCGG GTAAC TCCCA GGAGAGTGTC ACAGAGCAGG ACAGCAAGGA CAGCACCTAC 1560
 AGCCTCAGCA GCACCCTGAC GCTGAGCAAA GCAGACTACG AGAAACACAA AGTCTACGCC 1620
 TGCGAAGTCA CCCATCAGGG CCTGAGCTCG CCCGTCACAA AGAGCTTCAA CAGGGGAGAG 1680
 STOP
 LIGHT
 CHAIN|Eco RI LINKER #4=81bp
 TGT|TGA|ATTC AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATTCTG GACAACA TGC 1740
 1646 17
 GGCCGTGATA TCTACSTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT 1800
 1771 2
 GTTTGCCCTT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCAC TGTCCTTTCC 1860
 TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT 1920
 BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp
 GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT 1980
 GCGGTGGGCT CTATGGAACC AGCTGGGGCT CGACAGC|AT GCCAAGTACG CCCCCTATTG 2040
 2002 3 2017 8
 ACGTCAATGA CGGTAAATGG CCCGCCTGGC ATTATGCCA GTACATGACC TTATGGGACT 2100
 TTCCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT 2160
 CMV PROMOTER-ENHANCER=334bp
 GGCAGTACAT CAATGGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC 2220
 CCATTGACGT CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAAATGTC 2280
 GTAACAACCTC CGCCCCATTG ACGCAAATGG GCGGTAGCGG TGTACGGTGG GAGGTCTATA 2340
 LINKER #6=7bp Sal I
 TAAGCAGAGC TGGGTACGTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCCGTCCGAC 2400
 2351 2 2358 9
 START
 HEAVY CHAIN SYNTHETIC & NATURAL LEADER Mlu I 2457 8
 ATCGGTTGGA GCCTCATCTT GCTCTTCCTT GTCGCTGTTG CTACCGGTGT CCTGTCCGAG 2460
 2401 -5 -4 -3 -2 -1 +1
 GTACAACCTG AGCAGCCTGG GGCTGAGCTG GTGAAGCCTG GGGCCTCAGT GAAGATGTCC 2520
 TGCAAGGCTT CTGGCTACAC ATTTACCACT TACAATATGC ACTGGGTAAA ACAGACACCT 2580
 HEAVY CHAIN VARIABLE=363bp=121 AMINO ACID
 GGTCCGGGGC TGGAAATGGAT TGGAGCTATT TATCCGGAA ATGGTGATAC TTCCTACAAT 2640
 CAGAAGTTCA AAGGCAAGGC CACATTGACT GCAGACAAAT CCTCCAGCAC AGCCTACATG 2700
 CAGCTCAGCA GCCTGACATC TGAGGACTCT GCGGTCTATT ACTGTGCAAG ATCGACTTAC 2760
 TACGGCGGTG ACTGGTACTT CAATGTCTGG GGCGCAGGGA CCACGGTCAC CGTCTCTGCA 2820
 Nhe I
 GCTAGCACCA AGGGCCCATC GGTCTTCCCC CTGGCACCTT CCTCCAAGAG CACCTCTGGG 2880
 GGCACAGCGG CCCTGGGCTG CCTGGTCAAG GACTACTTCC CCGAACCAGT GACGGTGTCC 2940
 HUMAN GAMMA 1 CONSTANT=993bp
 TGGAACTCAG GCGCCCTGAC CAGCGGCGTG CACACCTTCC CGGCTGTCTT ACAGTCTCTCA 3000

FIG. 3B

U.S. Patent

Jun. 3, 2008

Sheet 10 of 21

US 7,381,560 B2

330 AMINO ACID & STOP CODON

GGACTCTACT CCCTCAGCAG CGTGGTGACC GTGCCCTCCA GCAGCTTGGG CACCCAGACC 3060
TACATCTGCA ACGTGAATCA CAAGCCCAGC AACACCAAGG TGGACAAGAA AGCAGAGCCC 3120
AAATCTTG TG ACAA AACTCA CACATGCCCA CCGTGCCCCAG CACCTGAACT CCTGGGGGGGA 3180
CCGTCACTCT TCCTCTTCCC CCCAAAACCC AAGGACACCC TCATGATCTC CCGGACCCCT 3240
GAGGTCACAT GCGTGGTGGT GGACGTGAGC CACGAAGACC CTGAGGTCAA GTTCAACTGG 3300
TACGTGGACG GCGTGGAGGT GCATAATGCC AAGACAAAGC CGCGGGGAGGA GCAGTACAAC 3360
AGCACGTACC GTGTGGTCAG CGTCCTCACC GTCCTGCACC AGGACTGGCT GAATGGCAAG 3420
GAGTACAAGT GCAAGGTCTC CAACAAAGCC CTCCCAGCCC CCATCGAGAA AACCATCTCC 3480
AAAGCCAAAG GGCAGCCCCG AGAACCACAG GTGTACACCC TGCCCCCCTC CCGGGATGAG 3540
CTGACCAAGA ACCAGGTGAG CCTGACCTGC CTGGTCAAAG GCTTCTATCC CAGCGACATC 3600
GCCGTGGAGT GGGAGAGCAA TGGGCAGCCG GAGAACAAC ACAAGACCAC GCCTCCCGTG 3560
CTGGACTCCG ACGGCTCCTT CTTCCTCTAC AGCAAGCTCA CCGTGGACAA GAGCAGGTGG 3720
CAGCAGGGGA ACGTCTTCTC ATGCTCCGTG ATGCATGAGG CTCTGCACAA CCACTACACG 3780
CAGAAGAGCC TCTCCCTGTC TCCGGGTAAA TGAGGATCCG TTAACGGTTA CCAACTACCT 3840
STOP HEAVY CHAIN | Bam HI LINKER #7=81bp
3813 4

AGACTGGATT CGTGACAACA TGCGGCCGTG ATATCTACGT ATGATCAGCC TCGACTGTGC 3900
3894 5

CTTCTAGTTG CCAGCCATCT GTTGTTTGCC CCTCCCCCGT GCCTTCCTTG ACCCTGGAAE 3960
GTGCCACTCC CACTGTCCTT TCCTAATAAA ATGAGGAAAT TGCATCGCAT TGTCTGAGTA 4020

BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp

GGTGTCAATC TATTCTGGGG GGTGGGGTGG GGCAGGACAG CAAGGGGGAG GATTGGGAAG 4080

ACAATAGCAG GCATGCTGGG GATGCGGTGG GCTCTATGGA ACCAGCTGGG GCTCGACAGC 4140
LINKER #8=34bp
4125 6

GCTGGATCTC CCGATCCCCA GCTTTGCTTC TCAATTTCTT ATTTGCATAA TGAGAAAAAA 4200
AGGAAAATTA ATTTAACAC CAATTCAGTA GTTGATTGAG CAAATGCGTT GCCAAAAAGG 4260

MOUSE BETA GLOBIN MAJOR PROMOTER=386bp

ATGCTTTAGA GACAGTGGTC TCTGCACAGA TAAGGACAAA CATTATTCAG AGGGAGTACC 4320
CAGAGCTGAG ACTCCTAAGC CAGTGAGTGG CACAGCATTG TAGGGAGAAA TATGCTTGTC 4380
ATCACCGAAG CCTGATTCCG TAGAGCCACA CCTTGGTAAG GGCCAATCTG CTCACACAGG 4440
ATAGAGAGGG CAGGAGCCAG GGCAGAGCAT ATAAGGTGAG GTAGGATCAG TTGCTCCTCA 4500

FIG. 3C

U.S. Patent

Jun. 3, 2008

Sheet 11 of 21

US 7,381,560 B2

CATTGCTTC TGACATAGTT **LINKER #9=19bp** **5' UNTRANSLATED DHFR=82bp**
 GTGTTGGGAG CTTGGATAGC TTGGACAGCT CAGGGCTGGC 4560
 4525 8 4544 5
 ATTCGCGCC AAACCTGACG GCAATCCTAG CGTGAAGGCT GGTAGGATTT TATCCCCGCT 4620
START DHFR
 GCCATCATGG TTTCGACCATT GAACTGCATC GTCGCCGTGT CCCAAAATAT GGGGATTGGC 4680
 4626 7
 AAGAACGGAG ACCTACCCTG GCCTCCGCTC AGGAACGAGT TCAAGTACTT CCAAAGAATG 4740
 ACCACAACCT CTTCAGTGGG AGGTAAACAG AATCTGGTGA TTATGGGTAG GAAAACCTGG 4800
DHFR=564bp=187 AMINO ACID & STOP CODON
 TTCTCCATTC CTGAGAAGAA TCGACCTTTA AAGGACAGAA TTAATATAGT TCTCAGTAGA 4860
 GAACTCAAAG AACCACCACG AGGAGCTCAT TTTCTTGCCA AAAGTTTGGG TGATGCCTTA 4920
 AGACTTATTG AACAAACCGG ATTGGCAAGT AAAGTAGACA TGGTTTGGAT AGTCGGAGGC 4980
 AGTTCTGTTT ACCAGGAAGC CATGAATCAA CCAGGCCACC TTAGACTCTT TGTGACAAGG 5040
 ATCATGCAGG AATTTGAAAG TGACACGTTT TTCCAGAAA TTGATTTGEG GAAATATAAA 5100
 CTTCTCCAG AATACCCAGG CGTCCTCTCT GAGGTCCAGG AGGAAAAAGG CATCAAGTAT 5160
STOP DHFR **3' UNTRANSLATED DHFR=82bp**
 AAGTTTGAAG TCTACGAGAA GAAAGACTAA CAGGAAGATG CTTTCAAGTT CTCTGCTCCC 5220
 5140 1
 CTCTAAAGC TATGCATTTT TATAAGACCA TGGGACTTTT GCTGGCTTTA **LINKER #10**
 =10bp GATCAGCCTC 5280
 5272 3
 GACTGTGCCT TCTAGTTGCC AGCCATCTGT TGTTTGCCCC TCCCCCGTGC CTTCTTTGAC 5340
BOVINE GROWTH HORMONE POLYADENYLATION=231bp
 CCTGGAAGGT GCCACTCCCA CTGTCCTTTC CTAATAAAAT GAGGAAATTG CATCGCATTG 5400
 TCTGAGTAGG TGTCATTCTA TTCTGGGGGG TGGGGTGGGG CAGGACAGCA AGGGGGAGGA 5460
LINKER #11
 TTGGAAGAC AATAGCAGGC ATGCTGGGGA TGCGGTGGGC TCTATGGAAC CAGCTGGGGC 5520
 =17bp 5513 4
 TCGAGCTACT AGCTTTGCTT CTCAATTTCT TATTTGCATA ATGAGAAAAA AAGGAAAATT 5580
 5530 1
 AATTTTAAAC CCAATTCAGT AGTTGATTGA GCAAATGCGT TGCCAAAAG GATGCTTTAG 5640
MOUSE BETA GLOBIN MAJOR PROMOTER=366bp
 AGACAGTGTT CTCTGCACAG ATAAGGACAA CTAGGGAGAA ATATGCTTGT CATCACCGAA 5700
 GACTCCTAAG CCAGTGAGTG GCACAGCATT CTAGGGAGAA ATATGCTTGT CATCACCGAA 5760
 GCCTGATTCC GTAGAGCCAC ACCTTGGTAA GGGCCAATCT GCTCACACAG GATAGAGAGG 5820
 GCAGGAGCCA GGGCAGAGCA TATAAGGTGA GGTAGGATCA GTTGCTCCTC ACATTTGCTT 5880
LINKER #12=21bp **START NEO**
 CTGACATAGT TGTGTTGGGA GCTTGGATCG ATCCTCTATG GTTGAACAAG ATGGATTGCA 5940
 5896 7 5917 8
 CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC 6000

FIG. 3D

U.S. Patent

Jun. 3, 2008

Sheet 12 of 21

US 7,381,560 B2

AATCGGCTGC TCTGATGCCG CCGTGTTCGG GCTGTACGCG CAGGGGGCGC CGGTTCTTTT 6060
 NEOMYCIN PHOSPHOTRANSFERASE=795bp=264 AMINO ACID & STOP CODON
 TGTCAAGACC GACCTGTCCG GTGCCCTGAA TGAAGTGCAG GACGAGGCAG CGCGGCTATC 6120
 GTGGGCTGGC ACGACGGGGC TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG 6180
 AAGGGACTGG CTGCTATTGG GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC 6240
 TCCTGCCGAG AAAGTATCCA TCATGGCTGA TGCAATGCGG CCGCTGCATA CGCTTGATCC 6300
 GGCTACCTGC CCATTCGACC ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT 6360
 GGAAGCCGGT CTTGTGATC AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC 6420
 CGAACTGTTT GCCAGGCTCA AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA 6480
 TGGCGATGCC TGCTTGCCGA ATATCATGGT GGAAAATGGC CGCTTTTCTG GATTCATCGA 6540
 CTGTGGCCGG CTGGGTGTGG CCGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATTA 6600
 TGCTGAAGAG CTTGGCGGGC AATGGGCTGA CCGCTTCCTC GTGCTTTAAG GTATCGCCGC 6660
 TCCCGATTCC CAGCGCATCC CCTTCTATCG CTTCTTGAC GAGTTCTTCT GAGCGGGACT 6720
 STOP NEO
 6712'3
 CTGGGGTTCC AAATGACCGA CCAAGCGAGC CCCAACCTGC CATCACGAGA TTTCCGATTCC 6780
 3' UNTRANSLATED NEO=173bp
 ACCGCCGCCT TCTATGAAAG GTTGGGCTTC GGAATCGTTT TCCGGGACGC CCGCTGGATG 6840
 ATCCTCCAGC GCGGGGATCT CATGCTGGAG TTCTTCGCCC ACCCCAACTT GTTTATTGCA 6900
 6885'6
 GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT TCACAAATA AGCATTTTTT 6960
 SV40 EARLY POLYADENYLATION REGION=133bp
 TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATC TATCTTATCA TGTCTGGATC 7020
 7018'9
 LINKER #13=19bp
 GCGGCCGCGA TCCCGTCCAG AGCTTGGCGT AATCATGGTC ATAGCTGTTT CCTGTGTGAA 7080
 7037'8
 PUC 19
 ATTGTTATCC GCTCACAATT CCACACAACA TACGAGCCGG AAGCATAAAG TGTAAGCCT 7140
 GGGGTGCCTA ATGAGTGAGC TAACTCACAT TAATTGCGTT GCGCTCACTG CCCGCTTTCC 7200
 AGTCGGGAAA CCTGTCTGTC CAGCTGCATT AATGAATCCG CCAACGCGCG GGGAGAGGCG 7260
 GTTTGCGTAT TGGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC TCGGTCGTTT 7320
 GGCTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC ACAGAATCAG 7380
 GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCALG AACCGTAAAA 7440
 7461=BACTERIAL ORIGIN OF REPLICATION
 AGGCCGCGTT GCTGGCGTTT TTCCATAGGC TCCGCCCCCC TGACGAGCAT CACAAAAATC 7500

FIG. 3E

U.S. Patent

Jun. 3, 2008

Sheet 13 of 21

US 7,381,560 B2

GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG GCGTTTCCCC 7560
 CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA TACCTGTCCG 7620
 CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCAATGCTC ACGCTGTAGG TATCTCAGTT 7680
 CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT CAGCCCCGACC 7740
 GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC GACTTATCGC 7800
 CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG GTATGTAGGC GGTGCTACAG 7860
 AGTTCCTTGA GTGGTGGCCT AACTACGGCT AACTAGAAAG GACAGTATT GGTATCTGCG 7920
 CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC GGCAAAACAAA 7980
 CCACCGCTGG TAGCGGTGGT TTTTTTGTTC GCAAGCAGCA GATTACGCGC AGAAAAAAG 8040
 GATCTCAAGA AGATCCTTTG ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAAACT 8100
 CACGTTAAGG GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTACCTAG ATCCTTTTAA 8160
 ATAAAAATG AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG TCTGACAGTT STOP 8220
BETA LACTAMASE
ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTTTCG TCATCCATAG 8280
 TTGCCTGACT CCCCCTCGTG TAGATAACTA CGATACGGGA GGGCTTACCA TCTGGCCCCA 8340
 GTGCTGCAAT GATACCGCGA GACCCACGCT CACCGGCTCC AGATTTATCA GCAATAAACCC 8400
BETA LACTAMASE=861bp=286 AMINO ACID & STOP CODON
 AGCCAGCCGG AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT 8460
 CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCCGC AGTTAATAGT TTGCCCAACG 8520
 TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG GCTTCATTCA 8580
 GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC AAAAAAGCGG 8540
 TTAGCTCCTT CGGTCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG TTATCACTCA 8700
 TGGTTATGGC AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTTCTG 8760
 TGACTGGTGA GACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA CCGAGTTGCT 8820
 CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA AAAGTGCTCA 8880
 TCATTGGAAA ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG TTGAGATCCA 8940
 GGTGATGTA ACCCACTCGT GCACCCAACT GATCTTCAGC ATCTTTTACT TTCACCAGCG 9000
 TTTCTGGGTG AGCAAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA AGGGCGACAC 9060
 GGAAATGTTG AATACTCATA START BETA LACTAMASE CTCTTCCTTT TTCAATATTA TTGAAGCATT TATCAGGGTT 9120
 ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAAACAA ATAGGGGTTT 9180
 CGCGCACATT TCCCCGAAAA GTGCCACCT

FIG. 3F




FIG. 4

U.S. Patent

Jun. 3, 2008

Sheet 15 of 21

US 7,381,560 B2

LEADER

	-19		-15		-10		-5				
FRAME 1	Met Gly Trp Ser	Leu Ile Leu Leu Phe Leu Val Ala Val Ala Thr Arg Val									
	ATG GGT TGG AGC	CTC ATC TTG CTC TTC CTT GTC GCT GTT GCT ACG CGT GTC									
	2409	2418	2427	2436	2445						
	-1	+1	FR1	10	15						
Leu Ser	Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser										
CTG TCC	CAG GTA CAA CTG CAG CAG CCT GGG GCT GAG CTG GTG AAG CCT GGG GCG TCA										
	2460	2469	2478	2487	2496	2505					
	20	25	30	31	CDR1	35	36				
Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His Trp											
GTG AAG ATG TCC TGC AAG GCT TCT GGC TAC ACA TTT ACC AGT TAC AAT ATG CAC TGG											
	2517	2526	2535	2544	2553	2562					
	40	FR2	45	49	50	52	52A	53	54		
Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn											
GTA AAA CAG ACA CCT GGT CGG GGC CTG GAA TGG ATT GGA GCT ATT TAT CCC GGA AAT											
	2574	2583	2592	2601	2610	2619					
55	CDR2	60	65	66	FR3	70					
Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys											
GGT CAT ACT TCC TAC AAT CAG AAG TTC AAA GGC AAG GCC ACA TTG ACT GCA GAC AAA											
	2631	2640	2649	2658	2667	2676					
75	80	82	82A	82B	82C	83	85				
Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val											
TCC TCC AGC ACA GCC TAC ATG CAG CTC ACC ACC CTG ACA TCT GAG GAC TCT GCG GTC											
	2688	2697	2706	2715	2724	2733					
90	94	95	CDR3	100	100A	100B	100C	100D	101	102	103
Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly											
TAT TAC TGT GCA AGA TCG ACT TAC TAC GGC GGT GAC TGG TAC TTC AAT GTC TGG GGC											
	2745	2754	2763	2772	2781	2790					
105	FR4	110	113								
Ala Gly Thr Thr Val Thr Val Ser Ala											
GCA GGG ACC ACG GTC ACC GTC CTC GCA											
	2802	2811	2820								

FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B

US 7,381,560 B2

1

EXPRESSION AND USE OF ANTI-CD20 ANTIBODIES

RELATED APPLICATIONS

This is a continuation of U.S. application Ser. No. 08/475, 813, filed Jun. 7, 1995, now U.S. Pat. No. 6,682,734; which is a divisional of U.S. application Ser. No. 08/149,099, filed Nov. 3, 1993, now U.S. Pat. No. 5,736,137; which is a continuation-in-part of U.S. application Ser. No. 07/978, 891, filed Nov. 13, 1992, now abandoned. This patent document is related to U.S. application Ser. No. 07/977,691, filed Nov. 13, 1992, now abandoned; and U.S. application Ser. No. 08/147,696, filed Nov. 3, 1993, now U.S. Pat. No. 5,648,267, both entitled "IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME." Related patent applications Ser. Nos. 07/978,891, 07/977,691, and 08/147,696 are incorporated herein by reference.

37 C.F.R. §1.74(d)/(e) COPYRIGHT NOTICE

A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner does not object to the reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.

A. FIELD OF THE INVENTION

The references to be discussed throughout this document are set forth merely for the information described therein prior to the filing dates of this document, and nothing herein is to be construed as an admission, either express or implied, that the references are "prior art" or that the inventors are not entitled to antedate such descriptions by virtue of prior inventions or priority based on earlier filed applications.

The present invention is directed to the treatment of B cell lymphoma using chimeric and radiolabeled antibodies to the B cell surface antigen Bp35 ("CD20").

B. BACKGROUND OF THE INVENTION

The immune system of vertebrates (for example, primates, which include humans, apes, monkeys, etc.) consists of a number of organs and cell types which have evolved to accurately and specifically recognize foreign microorganisms ("antigen") which invade the vertebrate-host; specifically bind to such foreign microorganisms; and, eliminate/destroy such foreign microorganisms. Lymphocytes, amongst others, are critical to the immune system. Lymphocytes are produced in the thymus, spleen and bone marrow (adult) and represent about 30% of the total white blood cells present in the circulatory system of humans (adult). There are two major sub-populations of lymphocytes: T cells and B cells. T cells are responsible for cell mediated immunity, while B cells are responsible for antibody production (humoral immunity). However, T cells and B cells can be considered as interdependent—in a typical immune response, T cells are activated when the T cell receptor binds to fragments of an antigen that are bound to major histocompatibility complex ("MHC") glycoproteins on the surface of an antigen presenting cell; such activation causes

2

release of biological mediators ("interleukins") which, in essence, stimulate B cells to differentiate and produce antibody ("immunoglobulins") against the antigen.

Each B cell within the host expresses a different antibody on its surface thus, one B cell will express antibody specific for one antigen, while another B cell will express antibody specific for a different antigen. Accordingly, B cells are quite diverse, and this diversity is critical to the immune system. In humans, each B cell can produce an enormous number of antibody molecules (ie about 10^7 to 10^8). Such antibody production most typically ceases (or substantially decreases) when the foreign antigen has been neutralized. Occasionally, however, proliferation of a particular B cell will continue unabated; such proliferation can result in a cancer referred to as "B cell lymphoma."

T cells and B cells both comprise cell surface proteins which can be utilized as "markers" for differentiation and identification. One such human B cell marker is the human B lymphocyte-restricted differentiation antigen Bp35, referred to as "CD20." CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation. Specifically, the CD20 molecule may regulate a step in the activation process which is required for cell cycle initiation and differentiation and is usually expressed at very high levels on neoplastic ("tumor") B cells. CD20, by definition, is present on both "normal" B cells as well as "malignant" B cells, ie those B cells whose unabated proliferation can lead to B cell lymphoma. Thus, the CD20 surface antigen has the potential of serving as a candidate for "targeting" of B cell lymphomas.

In essence, such targeting can be generalized as follows: antibodies specific to the CD20 surface antigen of B cells are, eg injected into a patient. These anti-CD20 antibodies specifically bind to the CD20 cell surface antigen of (ostensibly) both normal and malignant B cells; the anti-CD20 antibody bound to the CD20 surface antigen may lead to the destruction and depletion of neoplastic B cells. Additionally, chemical agents or radioactive labels having the potential to destroy the tumor can be conjugated to the anti-CD20 antibody such that the agent is specifically "delivered" to, eg, the neoplastic B cells. Irrespective of the approach, a primary goal is to destroy the tumor: the specific approach can be determined by the particular anti-CD20 antibody which is utilized and, thus, the available approaches to targeting the CD20 antigen can vary considerably.

For example, attempts at such targeting of CD20 surface antigen have been reported. Murine (mouse) monoclonal antibody 1F5 (an anti-CD20 antibody) was reportedly administered by continuous intravenous infusion to B cell lymphoma patients. Extremely high levels (>2 grams) of 1F5-were reportedly required to deplete circulating tumor cells, and the results were described as being "transient." Press et al., "Monoclonal Antibody 1F5 (Anti-CD20) Sero-therapy of Human B-Cell Lymphomas." *Blood* 69/2:584-591 (1987). A potential problem with this approach is that non-human monoclonal antibodies (eg, murine monoclonal antibodies) typically lack human effector functionality, ie they are unable to, inter alia, mediate complement dependent lysis or lyse human target cells through antibody dependent cellular toxicity or Fc-receptor mediated phagocytosis. Furthermore, non-human monoclonal antibodies can be recognized by the human host as a foreign protein; therefore, repeated injections of such foreign antibodies can lead to the induction of immune responses leading to harmful hypersensitivity reactions. For murine-based monoclonal antibodies, this is often referred to as a Human Anti-Mouse Antibody response, or "HAMA" response. Additionally, these

US 7,381,560 B2

3

“foreign” antibodies can be attacked by the immune system of the host such that they are, in effect, neutralized before they reach their target site.

Lymphocytes and lymphoma cells are inherently sensitive to radiotherapy for several reasons: the local emission of ionizing radiation of radiolabeled antibodies may kill cells with or without the target antigen (eg, CD20) in close proximity to antibody bound to the antigen; penetrating radiation may obviate the problem of limited access to the antibody in bulky or poorly vascularized tumors; and, the total amount of antibody required may be reduced. The radionuclide emits radioactive particles which can damage cellular DNA to the point where the cellular repair mechanisms are unable to allow the cell to continue living; therefore, if the target cells are tumors, the radioactive label beneficially kills the tumor cells. Radiolabeled antibodies, by definition, include the use of a radioactive substance which may require the need for precautions for both the patient (ie possible bone marrow transplantation) as well as the health care provider (ie the need to exercise a high degree of caution when working with the radioactivity).

Therefore, an approach at improving the ability of murine monoclonal antibodies to be effective in the treatment of B-cell disorders has been to conjugate a radioactive label or toxin to the antibody such that the label or toxin is localized at the tumor site. For example, the above-referenced IF5 antibody has been “labeled” with iodine-131 (“¹³¹I”) and was reportedly evaluated for biodistribution in two patients. See Eary, J. F. et al., “Imaging and Treatment of B-Cell Lymphoma” *J. Nuc. Med.* 31/8:1257-1268 (1990); see also, Press, O. W. et al., “Treatment of Refractory Non-Hodgkin’s Lymphoma with Radiolabeled MB-1 (Anti-CD37) Antibody” *J. Clin. Onc.* 7/8:1027-1038 (1989) (indication that one patient treated with ¹³¹I-labeled IF-5 achieved a “partial response”); Goldenberg, D. M. et al., “Targeting, Dosimetry and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody” *J. Clin. Onc.* 9/4:548-564 (1991) (three of eight patients receiving multiple injections reported to have developed a HAMA response); Appelbaum, F. R. “Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma” *Hem./Onc. Clinics of N.A.* 5/5:1013-1025 (1991) (review article); Press, O. W. et al “Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support.” *New England Journal of Medicine* 329/17: 1219-1223 (1993) (iodine-131 labeled anti-CD20 antibody IF5 and B1); and Kaminski, M. G. et al “Radioimmunotherapy of B-Cell Lymphoma with [¹³¹I] Anti-B1 (Anti-CD20) Antibody”. *NEJM* 329/7(1993) (iodine-131 labeled anti-CD20 antibody B1; hereinafter “Kaminski”).

Toxins (ie chemotherapeutic agents such as doxorubicin or mitomycin C) have also been conjugated to antibodies. See, for example, PCT published application WO 92/07466 (published May 14, 1992).

“Chimeric” antibodies, ie antibodies which comprise portions from two or more different species (eg, mouse and human) have been developed as an alternative to “conjugated” antibodies. For example, Liu, A. Y. et al., “Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity” *J. Immun.* 139/10:3521-3526 (1987), describes a mouse/human chimeric antibody directed against the CD20 antigen. See also, PCT Publication No. WO 88/04936. However, no information is provided as to the ability, efficacy or practicality of using such chimeric antibodies for the treatment of B cell disorders in the reference. It is noted that *in vitro* functional assays (eg complement dependent lysis (“CDC”);

4

antibody dependent cellular cytotoxicity (“ADCC”), etc.) cannot inherently predict the *in vivo* capability of a chimeric antibody to destroy or deplete target cells expressing the specific antigen. See, for example, Robinson, R. D. et al., “Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities,” *Hum. Antibod. Hybridomas* 2:84-93 (1991) (chimeric mouse-human antibody having undetectable ADCC activity). Therefore, the potential therapeutic efficacy of chimeric antibody can only truly be assessed by *in vivo* experimentation.

What is needed, and what would be a great advance in the art, are therapeutic approaches targeting the CD20 antigen for the treatment of B cell lymphomas in primates, including, but not limited to, humans.

C. SUMMARY OF THE INVENTION

Disclosed herein are therapeutic methods designed for the treatment of B cell disorders, and in particular, B cell lymphomas. These protocols are based upon the administration of immunologically active chimeric anti-CD20 antibodies for the depletion of peripheral blood B cells, including B cells associated with lymphoma; administration of radiolabeled anti-CD20 antibodies for targeting localized and peripheral B cell associated tumors; and administration of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies in a cooperative therapeutic strategy.

D. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagrammatic representation of a tandem chimeric antibody expression vector useful in the production of immunologically active chimeric anti-CD20 antibodies (“TCAE 8”);

FIGS. 2A through 2F are the nucleic acid sequence of the vector of FIG. 1 (also set forth as SEQ ID NO:1);

FIGS. 3A through 3F are the nucleic acid sequence of the vector of FIG. 1 further comprising murine light and heavy chain variable regions (“anti-CD20 in TCAE8”) (also set forth as SEQ ID NO:2);

FIG. 4 shows the nucleic acid (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequences (including CDR and framework regions) of murine variable region light chain derived from murine anti-CD20 monoclonal antibody 2B8;

FIG. 5 shows the nucleic acid (SEQ ID NO:5) and amino acid (SEQ ID NO:6) sequences (including CDR and framework regions) of murine variable region heavy chain derived from murine anti-CD20 monoclonal antibody 2B8;

FIG. 6 are flow cytometry results evidencing binding of fluorescent-labeled human C1q to chimeric anti-CD20 antibody, including, as controls labeled C1q; labeled C1q and murine anti-CD20 monoclonal antibody 2B8; and labeled C1q and human IgG1,k;

FIG. 7 represents the results of complement related lysis comparing chimeric anti-CD20 antibody and murine anti-CD20 monoclonal antibody 2B8;

FIG. 8 represents the results of antibody mediated cellular cytotoxicity with *in vivo* human effector cells comparing chimeric anti-CD20 antibody and 2B8;

FIG. 9A, 9B and 9C provide the results of non-human primate peripheral blood B lymphocyte depletion after infusion of 0.4 mg/kg (A); 1.6 mg/kg (B); and 6.4 mg/kg (C) of immunologically active chimeric anti-CD20 antibody;

FIG. 10 provides the results of, *inter alia*, non-human primate peripheral blood B lymphocyte depletion after infusion of 0.01 mg/kg of immunologically active chimeric anti-CD20 antibody;

US 7,381,560 B2

5

FIG. 11 provides results of the tumoricidal impact of Y2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor;

FIG. 12 provides results of the tumoricidal impact of C2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor;

FIG. 13 provides results of the tumoricidal impact of a combination of Y2B8 and C2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor; and

FIGS. 14A and 14B provide results from a Phase I/II clinical analysis of C2B8 evidencing B-cell population depletion over time for patients evidencing a partial remission of the disease (14A) and a minor remission of the disease (14B).

E. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Generally, antibodies are composed of two light chains and two heavy chain molecules; these chains form a general "Y" shape, with both light and heavy chains forming the arms of the Y and the heavy chains forming the base of the Y. Light and heavy chains are divided into domains of structural and functional homology. The variable domains of both the light ("V_L") and the heavy ("V_H") chains determine recognition and specificity. The constant region domains of light ("C_L") and heavy ("C_H") chains confer important biological properties, eg antibody chain association, secretion, transplacental mobility, Fc receptor binding complement binding, etc. The series of events leading to immunoglobulin gene expression in the antibody producing cells are complex. The variable domain region gene sequences are located in separate germ line gene segments referred to as "V_H," "D," and "J_H," or "V_L" and "J_L." These gene segments are joined by DNA rearrangements to form the complete V regions expressed in heavy and light chains, respectively. The rearranged, joined V segments (V_L-J_L and V_H-D-J_H) then encode the complete variable regions or antigen binding domains of light and heavy chains, respectively.

Serotherapy of human B cell lymphomas using an anti-CD20 murine monoclonal antibody (1F5) has been described by Press et al., (69 *Blood* 584, 1987, supra); the reported therapeutic responses, unfortunately, were transient. Additionally, 25% of the tested patients reportedly developed a human anti-mouse antibody (HAMA) response to the serotherapy. Press et al., suggest that these antibodies, conjugated to toxins or radioisotopes, might afford a more lasting clinical benefit than the unconjugated antibody.

Owing to the debilitating effects of B cell lymphoma and the very real need to provide viable treatment approaches to this disease, we have embarked upon different approaches having a particular antibody, 2B8, as the common link between the approaches. One such approach advantageously exploits the ability of mammalian systems to readily and efficiently recover peripheral blood B cells; using this approach, we seek to, in essence, purge or deplete B cells in peripheral blood and lymphatic tissue as a means of also removing B cell lymphomas. We accomplish this by utilization of, inter alia, immunologically active, chimeric anti-CD20 antibodies. In another approach, we seek to target tumor cells for destruction with radioactive labels.

As used herein, the term "anti-CD20 antibody" is an antibody which specifically recognizes a cell surface nonglycosylated phosphoprotein of 35,000 Daltons, typically designated as the human B lymphocyte restricted differentiation antigen Bp35, commonly referred to as CD20. As

6

used herein, the term "chimeric" when used in reference to anti-CD20 antibodies, encompasses antibodies which are most preferably derived using recombinant deoxyribonucleic acid techniques and which comprise both human (including immunologically "related" species, eg, chimpanzee) and non-human components: the constant region of the chimeric antibody is most preferably substantially identical to the constant region of a natural human antibody; the variable region of the chimeric antibody is most preferably derived from a non-human source and has the desired antigenic and specificity to the CD20 cell surface antigen. The non-human source can be any vertebrate source which can be used to generate antibodies to a human CD20 cell surface antigen or material comprising a human CD20 cell surface antigen. Such non-human source includes, but is not limited to, rodents (eg, rabbit, rat, mouse, etc.) and non-human primates (eg, Old World Monkey, Ape, etc.). Most preferably, the non-human component (variable region) is derived from a murine source. As used herein, the phrase "immunologically active" when used in reference to chimeric anti-CD20 antibodies, means a chimeric antibody which binds human C1q, mediates complement dependent lysis ("CDC") of human B lymphoid cell lines, and lyses human target cells through antibody dependent cellular cytotoxicity ("ADCC"). As used herein, the phrases "indirect labeling" and "indirect labeling approach" both mean that a chelating agent is covalently attached to an antibody and at least one radionuclide is inserted into the chelating agent. Preferred chelating agents and radionuclides are set forth in Srivagtava, S. C. and Mease, R. C., "Progress in Research on Ligands, Nuclides and Techniques for Labeling Monoclonal Antibodies," *Nucl. Med. Bio.* 18/6: 589-603 (1991) ("Srivagtava") which is incorporated herein by reference. A particularly preferred chelating agent is 1-isothiocyanatobenzyl-3-methyldiothelene triaminepent acetic acid ("MX-DTPA"); particularly preferred radionuclides for indirect labeling include indium [111] and yttrium [90]. As used herein, the phrases "direct labeling" and "direct labeling approach" both mean that a radionuclide is covalently attached directly to an antibody (typically via an amino acid residue). Preferred radionuclides are provided in Srivagtava; a particularly preferred radionuclide for direct labeling is iodine [131] covalently attached via tyrosine residues. The indirect labeling approach is particularly preferred.

The therapeutic approaches disclosed herein are based upon the ability of the immune system of primates to rapidly recover, or rejuvenate, peripheral blood B cells. Additionally, because the principal immune response of primates is occasioned by T cells, when the immune system has a peripheral blood B cell deficiency, the need for "extraordinary" precautions (ie patient isolation, etc.) is not necessary. As a result of these and other nuances of the immune systems of primates, our therapeutic approach to B cell disorders allows for the purging of peripheral blood B cells using immunologically active chimeric anti-CD20 antibodies.

Because peripheral blood B cell disorders, by definition, can indicate a necessity for access to the blood for treatment, the route of administration of the immunologically active chimeric anti-CD20 antibodies and radioalabeled anti-CD20 antibodies is preferably parenteral; as used herein, the term "parenteral" includes intravenous, intramuscular, subcutaneous, rectal, vaginal or intraperitoneal administration. Of these, intravenous administration is most preferred.

The immunologically active chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies will typically be provided by standard technique within a pharmaceutically

US 7,381,560 B2

7

acceptable buffer, for example, sterile saline, sterile buffered water, propylene glycol, combinations of the foregoing, etc. Methods for preparing parenterally administrable agents are described in *Pharmaceutical Carriers & Formulations*, Martin, Remington's Pharmaceutical Sciences, 15th Ed. (Mack Pub. Co., Easton, Pa. 1975), which is incorporated herein by reference.

The specific, therapeutically effective amount of immunologically active chimeric anti-CD20 antibodies useful to produce a unique therapeutic effect in any given patient can be determined by standard techniques well known to those of ordinary skill in the art.

Effective dosages (ie therapeutically effective amounts) of the immunologically active chimeric anti-CD20 antibodies range from about 0.001 to about 30 mg/kg body weight, more preferably from about 0.01 to about 25 mg/kg body weight, and most preferably from about 0.4 to about 20.0 mg/kg body weight. Other dosages are viable; factors influencing dosage include, but are not limited to, the severity of the disease; previous treatment approaches; overall health of the patient; other diseases present, etc. The skilled artisan is readily credited with assessing a particular patient and determining a suitable dosage that falls within the ranges, or if necessary, outside of the ranges.

Introduction of the immunologically active chimeric anti-CD20 antibodies in these dose ranges can be carried out as a single treatment or over a series of treatments. With respect to chimeric antibodies, it is preferred that such introduction be carried out over a series of treatments; this preferred approach is predicated upon the treatment methodology associated with this disease. While not wishing to be bound by any particular theory, because the immunologically active chimeric anti-CD20 antibodies are both immunologically active and bind to CD20, upon initial introduction of the immunologically active chimeric anti-CD20 antibodies to the individual, peripheral blood B cell depletion will begin; we have observed a nearly complete depletion within about 24 hours post treatment infusion. Because of this, subsequent introduction(s) of the immunologically active chimeric anti-CD20 antibodies (or radiolabeled anti-CD20 antibodies) to the patient is presumed to: a) clear remaining peripheral blood B cells; b) begin B cell depletion from lymph nodes; c) begin B cell depletion from other tissue sources, eg, bone marrow, tumor, etc. Stated again, by using repeated introductions of the immunologically active chimeric anti-CD20 antibodies, a series of events take place, each event being viewed by us as important to effective treatment of the disease. The first "event" then, can be viewed as principally directed to substantially depleting the patient's peripheral blood B cells; the subsequent "events" can be viewed as either principally directed to simultaneously or serially clearing remaining B cells from the system clearing lymph node B cells, or clearing other tissue B cells.

In effect, while a single dosage provides benefits and can be effectively utilized for disease treatment/management, a preferred treatment course can occur over several stages; most preferably, between about 0.4 and about 20 mg/kg body weight of the immunologically active chimeric anti-CD20 antibodies is introduced to the patient once a week for between about 2 to 10 weeks, most preferably for about 4 weeks.

With reference to the use of radiolabeled anti-CD20 antibodies, a preference is that the antibody is non-chimeric; this preference is predicated upon the significantly longer circulating half-life of chimeric antibodies vis-a-vis murine antibodies (ie, with a longer circulating half-life, the radio-

8

nuclide is present in the patient for extended periods). However, radiolabeled chimeric antibodies can be beneficially utilized with lower millicurie ("mCi") dosages used in conjunction with the chimeric antibody relative to the murine antibody. This scenario allows for a decrease in bone marrow toxicity to an acceptable level, while maintaining therapeutic utility.

A variety of radionuclides are applicable to the present invention and those skilled in the art are credited with the ability to readily determine which radionuclide is most appropriate under a variety of circumstances. For example, iodine [131] is a well known radionuclide used for targeted immunotherapy. However, the clinical usefulness of iodine [131] can be limited by several factors including: eight-day physical half-life; dehalogenation of iodinated antibody both in the blood and at tumor sites; and emission characteristics (eg large gamma component) which can be suboptimal for localized dose deposition in tumor. With the advent of superior chelating agents, the opportunity for attaching metal chelating groups to proteins has increased the opportunities to utilize other radionuclides such as indium [131] and yttrium [90]. Yttrium [90] provides several benefits for utilization in radioimmunotherapeutic applications: the 64 hour half-life of yttrium [90] is long enough to allow antibody accumulation by tumor and, unlike eg iodine [131], yttrium [90] is a pure beta emitter of high energy with no accompanying gamma irradiation in its decay, with a range in tissue of 100 to 1000 cell diameters. Furthermore, the minimal amount of penetrating radiation allows for outpatient administration of yttrium [90]-labeled antibodies. Furthermore, internalization of labeled antibody is not required for cell killing, and the local emission of ionizing radiation should be lethal for adjacent tumor cells lacking the target antigen.

One non-therapeutic limitation to yttrium [90] is based upon the absence of significant gamma radiation making imaging therewith difficult. To avoid this problem, a diagnostic "imaging" radionuclide, such as indium [111], can be utilized for determining the location and relative size of a tumor prior to the administration of therapeutic doses of yttrium [90]-labeled anti-CD20. Indium [111] is particularly preferred as the diagnostic radionuclide because: between about 1 to about 10 mCi can be safely administered without detectable toxicity; and the imaging data is generally predictive of subsequent yttrium [90]-labeled antibody distribution. Most imaging studies utilize 5 mCi indium [111]-labeled antibody because this dose is both safe and has increased imaging efficiency compared with lower doses, with optimal imaging occurring at three to six days after antibody administration. See, for example, Murray J. L., 26 *J. Nuc. Med.* 3328 (1985) and Carraguillo, J. A. et al, 26 *J. Nuc. Med.* 67 (1985).

Effective single treatment dosages (ie therapeutically effective amounts) of yttrium [90] labeled anti-CD20 antibodies range from between about 5 and about 75 mCi, more preferably between about 10 and about 40 mCi. Effective single treatment non-marrow ablative dosages of iodine [131] labeled anti-CD20 antibodies range from between about 5 and about 70 mCi, more preferably between about 5 and about 40 mCi. Effective single treatment ablative dosages (ie may require autologous bone marrow transplantation) of iodine [131] labeled anti-CD20 antibodies range from between about 30 and about 600 mCi, more preferably between about 50 and less than about 500 mCi. In conjunction with a chimeric anti-CD20 antibody, owing to the longer circulating half life vis-a-vis murine antibodies, an effective single treatment non-marrow ablative dosages of

US 7,381,560 B2

9

iodine [131] labeled chimeric anti-CD20 antibodies range from between about 5 and about 40 mCi, more preferably less than about 30 mCi. Imaging criteria for, eg the indium [111] label, are typically less than about 5 mCi.

With respect to radiolabeled anti-CD20 antibodies, therapy therewith can also occur using a single therapy treatment or using multiple treatments. Because of the radionuclide component, it is preferred that prior to treatment, peripheral stem cells ("PSC") or bone marrow ("BM") be "harvested" for patients experiencing potentially fatal bone marrow toxicity resulting from radiation. BM and/or PSC are harvested using standard techniques, and then purged and frozen for possible reinfusion. Additionally, it is most preferred that prior to treatment a diagnostic dosimetry study using a diagnostic labeled antibody (eg using indium [111]) be conducted on the patient, a purpose of which is to ensure that the therapeutically labeled antibody (eg using yttrium [90]) will not become unnecessarily "concentrated" in any normal organ or tissue.

Chimeric mouse/human antibodies have been described. See, for example, Morrison, S. L. et al., *PNAS* 11:6851-6854 (November 1984); European Patent Publication No. 173494; Boulianne, G. L., et al., *Nature* 312:643 (December 1984); Neubeiger, M. S. et al., *Nature* 314:268 (March 1985); European Patent Publication No. 125023; Tan et al., *J. Immunol.* 135:8564 (November 1985); Sun, L. K et al., *Hybridoma* 5/1:517 (1986); Sahagan et al., *J. Immunol.* 137:1066-1074 (1986). See generally, Muron, *Nature* 312:597 (December 1984); Dickson, *Genetic Engineering News* 5/3 (March 1985); Marx, *Science* 229 455 (August 1985); and Morrison *Science* 229:1202-1207 (September 1985). Robinson et al., in PCT Publication Number WO 88/04936 describe a chimeric antibody with human constant region and murine variable region, having specificity to an epitope of CD20; the murine portion of the chimeric antibody of the Robinson references is derived from the 2H7 mouse monoclonal antibody (gamma 2b, kappa). While the reference notes that the described chimeric antibody is a "prime candidate" for the treatment of B cell disorders, this statement can be viewed as no more than a suggestion to those in the art to determine whether or not this suggestion is accurate for this particular antibody, particularly because the reference lacks any data to support an assertion of therapeutic effectiveness, and importantly, data using higher order mammals such as primates or humans.

Methodologies for generating chimeric antibodies are available to those in the art. For example, the light and heavy chains can be expressed separately, using, for example, immunoglobulin light chain and immunoglobulin heavy chains in separate plasmids. These can then be purified and assembled in vitro into complete antibodies; methodologies for accomplishing such assembly have been described. See, for example, Scharff, M., *Harvey Lectures* 69:125 (1974). In vitro reaction parameters for the formation of IgG antibodies from reduced isolated light and heavy chains have also been described. See, for example, Beychok, S., *Cells of Immunoglobulin Synthesis*, Academic Press, New York, p. 69, 1979. Co-expression of light and heavy chains in the same cells to achieve intracellular association and linkage of heavy and light chains into complete H₂L₂ IgG antibodies is also possible. Such co-expression can be accomplished using either the same or different plasmids in the same host cell.

Another approach, and one which is our most preferred approach for developing a chimeric non-human/human anti-CD20 antibody, is based upon utilization of an expression vector which includes, ab initio, DNA encoding heavy and

10

light chain constant regions from a human source. Such a vector allows for inserting DNA encoding non-human variable regions such that a variety of non-human anti-CD20 antibodies can be generated, screened and analyzed for various characteristics (eg type of binding specificity, epitope binding regions, etc.); thereafter, cDNA encoding the light and heavy chain variable regions from a preferred or desired anti-CD20 antibody can be incorporated into the vector. We refer to these types of vectors as Tandem Chimeric Antibody Expression ("TCAE") vectors. A most preferred TCAE vector which was used to generate immunologically active chimeric anti-CD20 antibodies for therapeutic treatment of lymphomas is TCAE 8. TCAE 8 is a derivative of a vector owned by the assignee of this patent document, referred to as TCAE 5.2, the difference being that in TCAE 5.2, the translation initiation start site of the dominant selectable marker (neomycin phosphotransferase, "NEO") is a consensus Kozak sequence, while for TCAE 8, this region is a partially impaired consensus Kozak sequence. Details regarding the impact of the initiation start site of the dominant selectable marker of the TCAE vectors (also referred to as "ANEX vector") vis-a-vis protein expression are disclosed in detail in application Ser. No. 08/147,696, now U.S. Pat. No. 5,648,267, filed herewith.

TCAE 8 comprises four (4) transcriptional cassettes, and these are in tandem order, ie a human immunoglobulin light chain absent a variable region; a human immunoglobulin heavy chain absent a variable region; DHFR; and NEO. Each transcriptional cassette contains its own eukaryotic promoter and polyadenylation region (reference is made to FIG. 1 which is a diagrammatic representation of the TCAE 8 vector). Specifically:

- 1) the CMV promoter/enhancer in front of the immunoglobulin heavy chain is a truncated version of the promoter/enhancer in front of the light chain, from the Nhe I site at -350 to the Sst I site at -16 (see, 41 *Cell* 521, 1985).
- 2) a human immunoglobulin light chain constant region was derived via amplification of cDNA by a PCR reaction. In TCAE 8, this was the human immunoglobulin light chain kappa constant region (Kabat numbering, amino acids 108-214, allotype Km 3, (see, Kabat, E. A. "Sequences of proteins of immunological interest," NIH Publication, Fifth Ed. No. 91-3242, 1991)), and the human immunoglobulin heavy chain gamma 1 constant region (Kabat numbering amino acids 114-478, allotype Gmla, Gmlz). The light chain was isolated from normal human blood (IDEC Pharmaceuticals Corporation, La Jolla, Calif.); RNA therefrom was used to synthesize cDNA which was then amplified using PCR techniques (primers were derived vis-a-vis the consensus from Kabat). The heavy chain was isolated (using PCR techniques) from cDNA prepared from RNA which was in turn derived from cells transfected with a human IgG1 vector (see, 3 *Prot. Eng.* 531, 1990; vector pN₁,62). Two amino acids were changed in the isolated human IgG1 to match the consensus amino acid sequence from Kabat, to wit: amino acid 225 was changed from valine to alanine (GTT to GCA), and amino acid 287 was changed from methionine to lysine (ATG to AAG);
- 3) The human immunoglobulin light and heavy chain cassettes contain synthetic signal sequences for secretion of the immunoglobulin chains;
- 4) The human immunoglobulin light and heavy chain cassettes contain specific DNA restriction sites which allow for insertion of light and heavy immunoglobulin variable

US 7,381,560 B2

11

regions which maintain the transitional reading frame and do not alter the amino acids normally found in immunoglobulin chains;

- 5) The DHFR cassette contained its own eukaryotic promoter (mouse beta globin major promoter, "BETA") and polyadenylation region (bovine growth hormone polyadenylation, "BGH"); and
- 6) The NEO cassette contained its own eukaryotic promoter (BETA) and polyadenylation region (SV40 early polyadenylation, "SV").

With respect to the TCAE 8 vector and the NEO cassette, the Kozak region was a partially impaired consensus Kozak sequence (which included an upstream Cla I site):

```
(SEQ ID NO: 7)
                ClaI   -3       +1
GGGAGCTTGG ATCGAT ccTct ATG Gtt
```

(In the TCAE 5.2 vector, the change is between the ClaI and ATG regions, to wit: ccAcc.)

The complete sequence listing of TCAE 8 (including the specific components of the four transcriptional cassettes) is set forth in FIG. 2 (SEQ. ID. NO. 1).

As will be appreciated by those in the art, the TCAE vectors beneficially allow for substantially reducing the time in generating the immunologically active chimeric anti-CD20 antibodies. Generation and isolation of non-human light and heavy chain variable regions, followed by incorporation thereof within the human light chain constant transcriptional cassette and human heavy chain constant transcriptional cassette, allows for production of immunologically active chimeric anti-CD20 antibodies.

We have derived a most preferred non-human variable region with specificity to the CD20 antigen using a murine source and hybridoma technology. Using polymerase chain reaction ("PCR") techniques, the murine light and heavy variable regions were cloned directly into the TCAE 8 vector—this is the most preferred route for incorporation of the non-human variable region into the TCAE vector. This preference is principally predicated upon the efficiency of the PCR reaction and the accuracy of insertion. However, other equivalent procedures for accomplishing this task are available. For example, using TCAE 8 (or an equivalent vector), the sequence of the variable region of a non-human anti-CD20 antibody can be obtained, followed by oligonucleotide synthesis of portions of the sequence or, if appropriate, the entire sequence; thereafter, the portions or the entire synthetic sequence can be inserted into the appropriate locations within the vector. Those skilled in the art are credited with the ability to accomplish this task.

Our most preferred immunologically active chimeric anti-CD20 antibodies were derived from utilization of TCAE 8 vector which included murine variable regions derived from monoclonal antibody to CD20; this antibody (to be discussed in detail, infra), is referred to as "2B8." The complete sequence of the variable regions obtained from 2B8 in TCAE 8 ("anti-CD20 in TCAE 8") is set forth in FIG. 3 (SEQ. ID. NO. 2).

The host cell line utilized for protein expression is most preferably of mammalian origin; those skilled in the art are credited with ability to preferentially determine particular host cell lines which are best suited for the desired gene product to be expressed therein. Exemplary host cell lines include, but are not limited to, DG44 and DUXB11 (Chinese Hamster Ovary lines, DHFR minus), HELA (human cervical carcinoma), CVI (monkey kidney line), COS (a derivative of

12

CVI with SV40 T antigen), R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HAK (hamster kidney line), SP2/O (mouse myeloma), P3x63-Ag3.653 (mouse myeloma), BFA-lclBPT (bovine endothelial cells), RAJI (human lymphocyte) and 293 (human kidney). Host cell lines are typically available from commercial services, the American Tissue Culture Collection or from published literature.

- Preferably the host cell line is either DG44 ("CHO") or SP2/O. See Umland, G. et al., "Effect of gamma rays and the dihydrofolate reductase locus: deletions and inversions." *Som. Cell & Mol. Gen.* 12/6:555-566 (1986), and Shulman, M. et al., "A better cell line for making hybridomas secreting specific antibodies." *Nature* 276:269 (1978), respectively.
- Most preferably, the host cell line is DG44. Transfection of the plasmid into the host cell can be accomplished by any technique available to those in the art. These include, but are not limited to, transfection (including electrophoresis and electroporation), cell fusion with enveloped DNA, microinjection, and infection with intact virus. See, Ridgway, A. A. G. "Mammalian Expression Vectors." Chapter 24.2, pp. 470-472 *Vectors*, Rodriguez and Denhardt, Eds. (Butterworths, Boston, Mass. 1988). Most preferably, plasmid introduction into the host is via electroporation.

F. EXAMPLES

The following examples are not intended, nor are they to be construed, as limiting the invention. The examples are intended to evidence: dose-imaging using a radiolabeled anti-CD20 antibody ("12B8"); radiolabeled anti-CD20 antibody ("Y2B8"); and immunologically active, chimeric anti-CD20 antibody ("C2B8") derived utilizing a specific vector ("TCAE 8") and variable regions derived from murine anti-CD20 monoclonal antibody ("2B8").

I. Radiolabeled Anti-CD20 Antibody 2B8

A. Anti-CD20 Monoclonal Antibody (Murine) Production ("2B8")

BALB/C mice were repeatedly immunized with the human lymphoblastoid cell line SB (see, Adams, R. A. et al., "Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2." *Can Res* 28:1121-1125 (1968); this cell line is available from the American Tissue Culture Collection, Rockville, Md., under ATCC accession number ATCC CCL 120), with weekly injections over a period of 3-4 months. Mice evidencing high serum titers of anti-CD20 antibodies, as determined by inhibition of known CD20-specific antibodies (anti-CD20 antibodies utilized were Leu 16, Beckton Dickinson, San Jose, Calif., Cat. No. 7670; and B1, Coulter Corp., Hialeah, Fla., Cat. No. 6602201) were identified; the spleens of such mice were then removed. Spleen cells were fused with the mouse myeloma SP2/O in accordance with the protocol described in Einfeld, D. A. et al., (1988) *EMBO* 7:711 (SP2/O has ATCC accession no. ATCC CRL 8006).

Assays for CD20 specificity were accomplished by radioimmunoassay. Briefly, purified anti-CD20 B1 was radiolabeled with I^{125} by the iodobead method as described in Valentine, M. A. et al., (1989) *J. Biol. Chem.* 264:11282. (I^{125} Sodium Iodide, ICN, Irvine, Calif., Cat. No. 28665H). Hybridomas were screened by co-incubation of 0.05 ml of media from each of the fusion wells together with 0.05 ml of I^{125} labeled anti-CD20 B1 (10 ng) in 1% BSA, PBS (pH 7.4), and 0.5 ml of the same buffer containing 100,000 SB cells. After incubation for 1 hr at room temperature, the cells were harvested by transferring to 96 well titer plates (V&P

US 7,381,560 B2

13

Scientific, San Diego, Calif.), and washed thoroughly. Duplicate wells containing unlabeled anti-CD20 B1 and wells containing no inhibiting antibody were used as positive and negative controls, respectively. Wells containing greater than 50% inhibition were expanded and cloned. The antibody demonstrating the highest inhibition was derived from the cloned cell line designated herein as "2B8."

B. Preparation of 2B8-MX-DTPA Conjugate

i. MX-DTPA

Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyl-diethylene triamminepentaacetic acid ("carbon-14 labeled MX-DTPA") was used as a chelating agent for conjugation of radiolabel to 2B8. Manipulations of MX-DTPA were conducted to maintain metal-free conditions, ie metal-free reagents were utilized and, when possible, polypropylene plastic containers (flasks, beakers, graduated cylinders, pipette tips) washed with ALCONOX detergent (Alconox, Inc.) and rinsed with MILLI-Q purified water (Millipore, Inc.), were similarly utilized. MX-DTPA was obtained as a dry solid from Dr. Otto Gansow (National Institute of Health, Bethesda, Md.) and stored desiccated at 4° C. (protected from light), with stock solutions being prepared in MILLI-Q water at a concentration of 2-5 mM, with storage at -70° C. MX-DTPA was also obtained from Coulter Immunology (Hiialeah, Fla.) as the disodium salt in water and stored at -70° C.

ii. Preparation of 2B8

Purified 2B8 was prepared for conjugation with MX-DTPA by transferring the antibody into metal-free 50 mM bicine-NaOH, pH 8.6, containing 150 mM NaCl, using repetitive buffer exchange with CENTRICON 30™ spin filters (30,000 D, MWCO; Amicon). Generally, 50-200 µL of protein (10 mg/ml) was added to the filter unit, followed by 2 mL of bicine buffer. The filter was centrifuged at 4° C. in a Sorval SS-34 rotor (6,000 rpm, 45 min.). Retentate volume was approximately 50-100 µL; this process was repeated twice using the same filter. Retentate was transferred to a polypropylene 1.5 mL screw cap tube, assayed for protein, diluted to 10.0 mg/mL and stored at 4° C. until utilized; protein was similarly transferred into 50 mM sodium citrate, pH 5.5, containing 150 mM NaCl and 0.05% sodium azide, using the foregoing protocol.

iii. Conjugation of 2B8 with MX-DTPA

Conjugation of 2B8 with MX-DTPA was performed in polypropylene tubes at ambient temperature. Frozen MX-DTPA stock solutions were thawed immediately prior to use. 50-200 µL of protein at 10 mg/mL were reacted with MX-DTPA at a molar ratio of MX-DTPA-to-2B8 of 4:1. Reactions were initiated by adding the MX-DTPA stock solution and gently mixing; the conjugation was allowed to proceed overnight (14 to 20 hr), at ambient temperature. Unreacted MX-DTPA was removed from the conjugate by dialysis or repetitive ultrafiltration, as described above in Example I.B.ii, into metal-free normal saline (0.9% w/v) containing 0.05% sodium azide. The protein concentration was adjusted to 10 mg/mL and stored at 4° C. in a polypropylene tube until radiolabeled.

iv. Determination of Mx-DTPA Incorporation

MX-DTPA incorporation was determined by scintillation counting and comparing the value obtained with the purified conjugate to the specific activity of the carbon-[14]-labeled MX-DTPA. For certain studies, in which non-radioactive MX-DTPA (Coulter Immunology) was utilized, MX-DTPA incorporation was assessed by incubating the conjugate with an excess of a radioactive carrier solution of yttrium-[90] of known concentration and specific activity.

14

A stock solution of yttrium chloride of known concentration was prepared in metal-free 0.05 N HCl to which carrier-free yttrium-[90] (chloride salt) was added. An aliquot of this solution was analyzed by liquid scintillation counting to determine an accurate specific activity for this reagent. A volume of the yttrium chloride reagent equal to 3-times the number of mols of chelate expected to be attached to the antibody, (typically 2 mol/mol antibody), was added to a polypropylene tube, and the pH adjusted to 4.0-4.5 with 2 M sodium acetate. Conjugated antibody was subsequently added and the mixture incubated 15-30 min. at ambient temperature. The reaction was quenched by adding 20 mM EDTA to a final concentration of 1 mM and the pH of the solution adjusted to approximately pH 6 with 2M sodium acetate.

After a 5 min. incubation, the entire volume was purified by high-performance, size-exclusion chromatography (described infra). The eluted protein-containing fractions were combined, the protein concentration determined, and an aliquot assayed for radioactivity. The chelate incorporation was calculated using the specific activity of the yttrium-[90] chloride preparation and the protein concentration.

v. Immunoreactivity of 2B8-MX-DTPA

The immunoreactivity of conjugated 2B8 was assessed using whole-cell ELISA. Mid-log phase SB cells were harvested from culture by centrifugation and washed two times with 1× HBSS. Cells were diluted to 1-2×10⁶ cells/mL in HBSS and aliquoted into 96-well polystyrene microtiter plates at 50,000-100,000 cells/well. The plates were dried under vacuum for 2 h. at 40-45° C. to fix the cells to the plastic; plates were stored dry at -20° C. until utilized. For assay, the plates were warmed to ambient temperature immediately before use, then blocked with 1× PBS, pH 7.2-7.4 containing 1% BSA (2 h). Samples for assay were diluted in 1× PBS/1% BSA, applied to plates and serially diluted (1:2) into the same buffer. After incubating plates for 1 h. at ambient temperature, the plates were washed three times with 1× PBS. Secondary antibody (goat anti-mouse IgG1-specific HRP conjugate 50 µL) was added to wells (1:1500 dilution in 1× PBS/1% BSA) and incubated 1 h. at ambient temperature. Plates were washed four times with 1× PBS followed by the addition of ABTS substrate solution (50 mM sodium citrate, pH 4.5 containing 0.01% ATBS and 0.001% H₂O₂). Plates were read at 405 nm after 15-30 min. incubation. Antigen-negative HSB cells were included in assays to monitor non-specific binding. Immunoreactivity of the conjugate was calculated by plotting the absorbance values vs. the respective dilution factor and comparing these to values obtained using native antibody (representing 100% immunoreactivity) tested on the same plate; several values on the linear portion of the titration profile were compared and a mean value determined (data not shown).

vi. Preparation of Indium-[111]-Labeled 2B8-MX-DTPA ("I2B8")

Conjugates were radiolabeled with carrier-free indium-[111]. An aliquot of isotope (0.1-2 mCi/mg antibody) in 0.05 M HCL was transferred to a polypropylene tube and approximately one-tenth volume of metal-free 2 M HCL added. After incubation for 5 min., metal-free 2 M sodium acetate was added to adjust the solution to pH 4.0-4.4. Approximately 0.5 mg of 2B8-MX-DTPA was added from a stock solution of 10.0 mg/mL DTPA in normal saline, or 50 mM sodium citrate/150 mM NaCl containing 0.05% sodium azide, and the solution gently mixed immediately. The pH solution was checked with pH paper to verify a value of 4.0-4.5 and the mixture incubated at ambient temperature for 15-30 min. Subsequently, the reaction was

US 7,381,560 B2

15

quenched by adding 20 mM EDTA to a final concentration of 1 mM and the reaction mixture was adjusted to approximately pH 6.0 using 2 M sodium acetate.

After a 5-10 min. incubation, uncomplexed radioisotope was removed by size-exclusion chromatography. The HPLC unit consisted of Waters Model 6000 or TosoHaas Model TSK-6110 solvent delivery system fitted, respectively, with a Waters U6K or Rheodyne 700 injection valve. Chromatographic separations were performed using a gel permeation column (BioRad SEC-250; 7.5x300 mm or comparable TosoHaas column) and a SEC-250 guard column (7.5x100 mm). The system was equipped with a fraction collector (Pharmacia Frac200) and a UV monitor fitted with a 280 nm filter (Pharmacia model UV-1). Samples were applied and eluted isocratically using 1x PBS, pH 7.4, at 1.0 mL/min flow rate. One-half milliliter fractions were collected in glass tubes and aliquots of these counted in a gamma counter. The lower and upper windows were set to 100 and 500 KeV respectively.

The radioincorporation was calculated by summing the radioactivity associated with the eluted protein peak and dividing this number by the total radioactivity eluted from the column; this value was then expressed as a percentage (data not shown). In some cases, the radioincorporation was determined using instant thin-layer chromatography ("ITLC"). Radiolabeled conjugate was diluted 1:10 or 1:20 in 1x PBS containing or 1x PBS/1 mM DTPA, then 1 µL was spotted 1.5 cm from one end of a 1x5 cm strip of ITLC SG paper. The paper was developed by ascending chromatography using 10% ammonium acetate in methanol:water (1:1;v/v). The strip was dried, cut in half crosswise, and the radioactivity associated with each section determined by gamma counting. The radioactivity associated with the bottom half of the strip (protein-associated radioactivity) was expressed as a percentage of the total radioactivity, determined by summing the values for both top and bottom halves (data not shown).

Specific activities were determined by measuring the radioactivity of an appropriate aliquot of the radiolabeled conjugate. This value was corrected for the counter efficiency (typically 75%) and related to the protein concentration of the conjugate, previously determined by absorbance at 280 nm, and the resulting value expressed as mCi/mg protein.

For some experiments, 2B8-MX-DTPA was radiolabeled with indium [111] following a protocol similar to the one described above but without purification by HPLC; this was referred to as the "mix-and-shoot" protocol.

vii. Preparation of Yttrium-[90]-Labeled 2B8-MX-DTPA ("Y2B8")

The same protocol described for the preparation of I2B8 was followed for the preparation of the yttrium-[90]-labeled 2B8-MX-DTPA ("Y2B8") conjugate except that 2 ng HCl was not utilized; all preparations of yttrium-labeled conjugates were purified by size-exclusion chromatography as described above.

C. Non-Human Animal Studies.

i. Biodistribution of Radiolabeled 2B8-MX-DTPA

I2B8 was evaluated for tissue biodistribution in six-to-eight week old BALB/c mice. The radiolabeled conjugate was prepared using clinical-grade 2B8-MX-DTPA following the "mix and shoot" protocol described above. The specific activity of the conjugate was 2.3 mCi/mg and the conjugate was formulated in PBS, pH 7.4 containing 50 mg/mL HSA. Mice were injected intravenously with 100 µL of I2B8 (approximately 21 µCi) and groups of three mice

16

were sacrificed by cervical dislocation at 0, 24, 48, and 72 hours. After sacrifice, the tail, heart, lungs, liver, kidney, spleen, muscle, and femur were removed, washed and weighed; a sample of blood was also removed for analysis. Radioactivity associated with each specimen was determined by gamma counting and the percent injected dose per gram tissue subsequently determined. No attempt was made to discount the activity contribution represented by the blood associated with individual organs.

In a separate protocol, aliquots of 2B8-MX-DTPA incubated at 4° C. and 30° C. for 10 weeks were radiolabeled with indium-[111] to a specific activity of 2.1 mCi/mg for both preparations. These conjugates were then used in biodistribution studies in mice as described above.

For dosimetry determinations, 2B8-MX-DTPA was radiolabeled with indium-[111] to a specific activity of 2.3 mCi/mg and approximately 1.1 µCi was injected into each of 20 BALB/c mice. Subsequently, groups of five mice each were sacrificed at 1, 24, 48 and 72 hours and their organs removed and prepared for analysis. In addition, portions of the skin, muscle and bone were removed and processed for analysis; the urine and feces were also collected and analyzed for the 24-72 hour time points.

Using a similar approach, 2B8-MX-DTPA was also radiolabeled with yttrium-[90] and its biological distribution evaluated in BALB/c mice over a 72-hour time period. Following purification by HPLC size exclusion chromatography, four groups of five mice each were injected intravenously with approximately 1 µCi of clinically-formulated conjugate (specific activity: 12.2 mCi/mg); groups were subsequently sacrificed at 1, 24, 48 and 72 hours and their organs and tissues analyzed as described above. Radioactivity associated with each tissue specimen was determined by measuring bremsstrahlung energy with a gamma scintillation counter. Activity values were subsequently expressed as percent injected dose per gram tissue or percent injected dose per organ. While organs and other tissues were rinsed repeatedly to remove superficial blood, the organs were not perfused. Thus, organ activity values were not discounted for the activity contribution represented by internally associated blood.

ii. Tumor Localization of I2B8

The localization of radiolabeled 2B8-MX-DTPA was determined in athymic mice bearing Ramos B cell tumors. Six-to-eight week old athymic mice were injected subcutaneously (left-rear flank) with 0.1 mL of RPMI-1640 containing 1.2×10^7 Ramos tumor cells which had been previously adapted for growth in athymic mice. Tumors arose within two weeks and ranged in weight from 0.07 to 1.1 grams. Mice were injected intravenously with 100 µL of indium-[111]-labeled 2B8-MX-DTPA (16.7 µCi) and groups of three mice were sacrificed by cervical dislocation at 0, 24, 48, and 72 hours. After sacrifice the tail, heart, lungs, liver, kidney, spleen, muscle, femur, and tumor were removed, washed, weighed; a sample of blood was also removed for analysis. Radioactivity associated with each specimen was determined by gamma counting and the percent injected dose per gram tissue determined.

iii. Biodistribution and Tumor Localization Studies with Radiolabeled 2B8-MX-DTPA

Following the preliminary biodistribution experiment described above (Example I.B.viii.a.), conjugated 2B8 was radiolabeled with indium-[111] to a specific activity of 2.3 mCi/mg and roughly 1.1 µCi was injected into each of twenty BALB/c mice to determine biodistribution of the radiolabeled material. Subsequently, groups of five mice each were sacrificed at 1, 24, 48 and 72 hours and their

US 7,381,560 B2

17

organs and a portion of the skin, muscle and bone were removed and processed for analysis. In addition, the urine and feces were collected and analyzed for the 24-72 hour time-points. The level of radioactivity in the blood dropped from 40.3% of the injected dose per gram at 1 hour to 18.9% at 72 hours (data not shown). Values for the heart, kidney, muscle and spleen remained in the range of 0.7-9.8% throughout the experiment. Levels of radioactivity found in the lungs decreased from 14.2% at 1 hour to 7.6% at 72 hours; similarly the respective liver injected-dose per gram values were 10.3% and 9.9%. These data were used in determining radiation absorbed dose estimates I2B8 described below.

The biodistribution of yttrium-[90]-labeled conjugate, having a specific activity of 12.2 mCi/mg antibody, was evaluated in BALB/c mice. Radioincorporations of >90% were obtained and the radiolabeled antibody was purified by HPLC. Tissue deposition of radioactivity was evaluated in the major organs, and the skin, muscle, bone, and urine and feces over 72 hours and expressed as percent injected dose/g tissue. Results (not shown) evidenced that while the levels of radioactivity associated with the blood dropped from approximately 39.2% injected dose per gram at 1 hour to roughly 15.4% after 72 hours the levels of radioactivity associated with tail, heart, kidney, muscle and spleen remained fairly constant at 10.2% or less throughout the course of the experiment. Importantly, the radioactivity associated with the bone ranged from 4.4% of the injected dose per gram bone at 1 hour to 3.2% at 72 hours. Taken together, these results suggest that little free yttrium was associated with the conjugate and that little free radiometal was released during the course of the study. These data were used in determining radiation absorbed dose estimates for Y2B8 described below.

For tumor localization studies, 2B8-MX-DTPA was prepared and radiolabeled with ¹¹¹Indium to a specific activity of 2.7 mCi/mg. One hundred microliters of labeled conjugate (approximately 24 μ Ci) were subsequently injected into each of 12 athymic mice bearing Ramos B cell tumors. Tumors ranged in weight from 0.1 to 1.0 grams. At time points of 0, 24, 48, and 72 hours following injection, 50 μ L of blood was removed by retro-orbital puncture, the mice sacrificed by cervical dislocation, and the tail, heart, lungs, liver, kidney, spleen, muscle, femur, and tumor removed. After processing and weighing the tissues, the radioactivity associated with each tissue specimen was determined using a gamma counter and the values expressed as percent injected dose per gram.

The results (not shown) evidenced that the tumor concentrations of the ¹¹¹In-2B8-MX-DTPA increased steadily throughout the course of the experiment. Thirteen percent of the injected dose was accumulated in the tumor after 72 hours. The blood levels, by contrast, dropped during the experiment from over 30% at time zero to 13% at 72 hours. All other tissues (except muscle) contained between 1.3 and 6.0% of the injected dose per gram tissue by the end of the experiment; muscle tissue contained approximately 13% of the injected dose per gram.

D. Human Studies

i. 2B8 and 2B8-MX-DTPA: Immunohistology Studies with Human Tissues

The tissue reactivity of murine monoclonal antibody 2B8 was evaluated using a panel of 32 different human tissues fixed with acetone. Antibody 2B8 reacts with the anti-CD20 antigen which had a very restricted pattern of tissue distri-

18

bution, being observed only in a subset of cells in lymphoid tissues including those of hematopoietic origin.

In the lymph node, immunoreactivity was observed in a population of mature cortical B-lymphocytes as well as proliferating cells in the germinal centers. Positive reactivity was also observed in the peripheral blood, B-cell areas of the tonsils, white pulp of the spleen, and with 40-70% of the medullary lymphocytes found in the thymus. Positive reactivity was also seen in the follicles of the lamina propria (Peyer's Patches) of the large intestines. Finally, aggregates or scattered lymphoid cells in the stroma of various organs, including the bladder, breast, cervix, esophagus, lung, parotid, prostate, small intestine, and stomach, were also positive with antibody 2B8 (data not shown).

All simple epithelial cells, as well as the stratified epithelia and epithelia of different organs, were found to be unreactive. Similarly, no reactivity was seen with neuroectodermal cells, including those in the brain, spinal cord and peripheral nerves. Mesenchymal elements, such as skeletal and smooth muscle cells, fibroblasts, endothelial cells, and polymorphonuclear inflammatory cells were also found to be negative (data not shown).

The tissue reactivity of the 2B8-MX-DTPA conjugate was evaluated using a panel of sixteen human tissues which had been fixed with acetone. As previously demonstrated with the native antibody (data not shown), the 2B8-MX-DTPA conjugate recognized the CD20 antigen which exhibited a highly restricted pattern of distribution, being found only on a subset of cells of lymphoid origin. In the lymph node, immunoreactivity was observed in the B cell population. Strong reactivity was seen in the white pulp of the spleen and in the medullary lymphocytes of the thymus. Immunoreactivity was also observed in scattered lymphocytes in the bladder, heart, large intestines, liver, lung, and uterus, and was attributed to the presence of inflammatory cells present in these tissues. As with the native antibody, no reactivity was observed with neuroectodermal cells or with mesenchymal elements (data not shown).

ii. Clinical Analysis of I2B8 (Imaging) and Y2B8 (Therapy)

a. Phase I/II Clinical Trial Single Dose Therapy Study

A Phase I/II clinical analysis of I2B8 (imaging) followed by treatment with a single therapeutic dose of Y2B8 is currently being conducted. For the single-dose study, the following schema is being followed:

1. Peripheral Stem Cell (PSC) or Bone Marrow (BM) Harvest with Purging;
2. I2B8 Imaging;
3. Y2B8 Therapy (three Dose Levels); and
4. PSC or Autologous BM Transplantation (if necessary based upon absolute neutrophil count below 500/mm³ for three consecutive days or platelets below 20,000/mm³ with no evidence of marrow recovery on bone marrow examination).

The Dose Levels of Y2B8 are as follows:

Dose Level	Dose (mCi)
1.	20
2.	30
3.	40

Three patients are to be treated at each of the dose levels for determination of a Maximum Tolerated Dose ("MTD").

US 7,381,560 B2

19

Imaging (Dosimetry) Studies are conducted as follows: each patient is involved in two in vivo biodistribution studies using I2B8. In the first study, 2 mg of I2B8 (5 mCi), is administered as an intravenous (i.v.) infusion over one hour; one week later 2B8 (ie unconjugated antibody) is administered by i.v. at a rate not to exceed 250 mg/hr followed immediately by 2 mg of I2B8 (5 mCi) administered by i.v. over one hour. In both studies, immediately following the I2B8 infusion, each patient is imaged and imaging is repeated at time t=14-18 hr (if indicated), t=24 hr; t=72 hr; and t=96 hr (if indicated). Whole body average retention times for the indium [111] label are determined; such determinations are also made for recognizable organs or tumor lesions ("regions of interest").

The regions of interest are compared to the whole body concentrations of the label; based upon this comparison, an estimate of the localization and concentration of Y2B8 can be determined using standard protocols. If the estimated cumulative dose of Y2B8 is greater than eight (8) times the estimated whole body dose, or if the estimated cumulative dose for the liver exceeds 1500 cGy, no treatment with Y2B8 should occur.

If the imaging studies are acceptable, either 0.0 or 1.0 mg/kg patient body weight of 2B8 is administered by i.v. infusion at a rate not to exceed 250 mg/h. This is followed by administration of Y2B8 (10,20 or 40 mCi) at an i.v. infusion rate of 20 mCi/hr.

b. Phase I/II Clinical Trial: Multiple Dose Therapy Study

A Phase I/II clinical analysis of Y2B8 is currently being conducted. For the multiple-dose study, the following schema is being followed:

1. PSC or BM Harvest;
2. I2B8 Imaging;
3. Y2B8 Therapy (three Dose Levels) for four doses or a total cumulative dose of 80 mCi; and
4. PSC or Autologous BM Transplantation (based upon decision of medical practitioner).

The Dose Levels of Y2B8 are as follows:

Dose Level	Dose (mCi)
1.	10
2.	15
3.	20

Three patients are to be treated at each of the dose levels for determination of an MTD.

Imaging (Dosimetry) Studies are conducted as follows: A preferred imaging dose for the unlabeled antibody (ie 2B8) will be determined with the first two patients. The first two patients will receive 100 mg of unlabeled 2B8 in 250 cc of normal saline over 4 hrs followed by 0.5 mCi of I2B8—blood will be sampled for biodistribution data at times t=0, t=10 min., t=120 min., t=24 hr, and t=48 hr. Patients will be scanned with multiple regional gamma camera images at times t=2 hr, t=24 hr and t=48 hr. After scanning at t=48 hr, the patients will receive 250 mg of 2B8 as described, followed by 4.5 mCi of I2B8—blood and scanning will then follow as described. If 100 mg of 2B8 produces superior imaging, then the next two patients will receive 50 mg of 2B8 as described, followed by 0.5 mCi of I2B8 followed 48 hrs later by 100 mg 2B8 and then with 4.5 mCi of I2B8. If 250 mg of 2B8 produces superior imaging, then the next two patients will receive 250 mg of 2B8 as described, followed by 0.5 mCi of I2B8 followed 48 hrs later with 500 mg 2B8

20

and then with 4.5 mCi of I2B8. Subsequent patients will be treated with the lowest amount of 2B8 that provides optimal imaging. Optimal imaging will be defined by: (1) best effective imaging with the slowest disappearance of antibody; (2) best distribution minimizing compartmentalization in a single organ; and (3) best subjective resolution of the lesion (tumor/background comparison).

For the first four patients, the first therapeutic dose of Y2B8 will begin 14 days after the last dose of I2B8; for subsequent patients, the first therapeutic dose of Y2B8 will begin between two to seven days after the I2B8.

Prior to treatment with Y2B8, for the patients other than the first four, 2B8 will be administered as described, followed by i.v. infusion of Y2B8 over 5-10 min. Blood will be sampled for biodistribution at times t=0, t=10 min., t=120 min., t=24 hr and t=48 hr. Patients will receive repetitive doses of Y2B8 (the same dose administered as with the first dose) approximately every six to eight weeks for a maximum of four doses, or total cumulative dose of 80 mCi. It is most preferred that patients not receive a subsequent dose of Y2B8 until the patients' WBC is greater than/equal to 3,000 and AGC is greater than/equal to 100,000.

Following completion of the three-dose level study, an MTD will be defined. Additional patients will then be enrolled in the study and these will receive the MTD.

II. Chimeric Anti-CD20 Antibody Production ("C2B8")

A. Construction of Chimeric Anti-CD20 Immunoglobulin DNA Expression Vector

RNA was isolated from the 2B8 mouse hybridoma cell (as described in Chomczynski, P. et al., "Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction." *Anal. Biochem.* 162:156-159 (1987)). and cDNA was prepared therefrom. The mouse immunoglobulin light chain variable region DNA was isolated from the cDNA by polymerase chain reaction using a set of DNA primers with homology to mouse light chain signal sequences at the 5' end and mouse light chain J region at the 3' end. Primer sequences were as follows:

1. V_L Sense (SEQ ID NO:8)
 5' ATC AC AGATCT CTC ACC ATG GAT TTT CAG GTG CAG
 ATT ATC AGC TTC 3'

(The underlined portion is a Bgl II site; the above-lined portion is the start codon.)

2. V_L Antisense (SEQ ID NO:9)
 5' TGC AGC ATC CGTACG TTT GAT TTC CAG CTT 3'

(The underlined portion is a Bsi WI site.)

See, FIGS. 1 and 2 for the corresponding Bgl II and Bsi WI sites in TCAE 8, and FIG. 3 for the corresponding sites in anti-CD20 in TCAE 8.

These resulting DNA fragments were cloned directly into the TCAE 8 vector in from of the human kappa light chain constant domain and sequenced. The determined DNA sequence for the murine variable region light chain is set forth in FIG. 4 (SEQ ID NO:3); see also FIG. 3, nucleotides 978 through 1362. FIG. 4 further provides the amino acid sequence from this murine variable region, and the CDR and framework regions (SEQ ID NO:4). The mouse light chain variable region from 2B is in the mouse kappa VI family. See Kabat, supra.

US 7,381,560 B2

21

The mouse heavy chain variable region was similarly isolated and cloned in front of the human IgG1 constant domains. Primers were as follows:

1. V_H Sense (SEQ ID NO:10)
5' GCG GCT CCC ACGCGT GTC CTG TCC CAG 3'

(The underlined portion is an Mlu I site.)

2. V_H Antisense (SEQ ID NO:11)
5' GG(G/C) TGT TGT GCTAGC TG(A/C) (A/G)GA GAC
(G/A)GT GA 3'

(The underlined portion is an Nhe I site.)

See, FIGS. 1 and 2 for corresponding Mlu I and Nhe I sites in TCAE 8, and FIG. 3 for corresponding sites in anti-CD20 in TCAE 8.

The sequence for this mouse heavy chain is set forth in FIG. 5 (SEQ ID NO:5); see also FIG. 3, nucleotide 2401 through 2820. FIG. 5 also provides the amino acid sequence from this murine variable region, and the CDR and framework regions (SEQ ID NO:6). The mouse heavy chain variable region from 2B8 is in the mouse VH 2B family. See Kabat, supra.

B. Creation of Chimeric Anti-CD20 Producing CHO and SP2/0 Transfectomas

Chinese hamster ovary ("CHO") cells DG44 were grown in SSFM II minus hypoxanthine and thymidine media (Gibco, Grand Island, N.Y., Form No. 91-0456PK); SP2/0 mouse myeloma cells were grown in Dulbecco's Modified Eagles Medium media ("DMEM") (Irvine Scientific, Santa Ana, Calif., Cat. No. 9024) with 5% fetal bovine serum and 20 ml/L glutamine added. Four million cells were electroporated with either 25 µg CHO or 50 µg SP2/0 plasmid DNA that had been restricted with Not I using a BTX 600 electroporation system (BTX, San Diego, Calif.) in 0.4 ml disposable cuvettes. Conditions were either 210 volts for CHO or 180 volts for SP2/0, 400 microfaradays, 13 ohms. Each electroporation was plated into six 96 well dishes (about 7,000 cells/well). Dishes were fed with media containing G418 (GENETICIN, Gibco, Cat. No. 860-1811) at 400 µg/ml active compound for CHO (media further included 50 µM hypoxanthine and 8 µM thymidine) or 800 µg/ml for SP2/0, two days following electroporation and thereafter 2 or 3 days until colonies arose. Supernatant from colonies was assayed for the presence of chimeric immunoglobulin via an ELISA specific for human antibody. Colonies producing the highest amount of immunoglobulin were expanded and plated into 96 well plates containing media plus methotrexate (25 nM for SP2/0 and 5nM for CHO) and fed every two or three days. Supernatants were assayed as above and colonies producing the highest amount of immunoglobulin were examined. Chimeric anti-CD20 antibody was purified from supernatant using protein A affinity chromatography.

Purified chimeric anti-CD20 was analyzed by electrophoresis in polyacrylamide gels and estimated to be greater than about 95% pure. Affinity and specificity of the chimeric antibody was determined based upon 2B8. Chimeric anti-CD20 antibody tested in direct and competitive binding assays, when compared to murine anti-CD20 monoclonal antibody 2B8, evidenced comparable affinity and specificity on a number of CD20 positive B cells lines (data not presented). The apparent affinity constant ("Kap") of the chimeric antibody was determined by direct binding of I¹²⁵

22

radiolabeled chimeric anti-CD20 and compared to radiolabeled 2B8 by Scatchard plot; estimated Kap for CHO produced chimeric anti-CD20 was 5.2×10^{-9} M and for SP2/0 produced antibody, 7.4×10^{-9} M. The estimated Kap for 2B8 was 3.5×10^{-9} M. Direct competition by radioimmunoassay was utilized to confirm both the specificity and retention of immunoreactivity of the chimeric antibody by comparing its ability to effectively compete with 2B8. Substantially equivalent amounts of chimeric anti-CD20 and 2B8 antibodies were required to produce 50% inhibition of binding to CD20 antigens on B cells (data not presented), ie there was a minimal loss of inhibiting activity of the anti-CD20 antibodies, presumably due to chimerization.

The results of Example II.B indicate, inter alia, that chimeric anti-CD20 antibodies were generated from CHO and SP2/0 transfectomas using the TCAE 8 vectors, and these chimeric antibodies had substantially the same specificity and binding capability as murine anti-CD20 monoclonal antibody 2B8.

C. Determination of Immunological Activity of Chimeric Anti-CD20 Antibodies

i. Human C1q Analysis

Chimeric anti-CD20 antibodies produced by both CHO and SP2/0 cell lines were evaluated for human C1q binding in a flow cytometry assay using fluorescein labeled C1q (C1q was obtained from Quidel, Mira Mesa, Calif., Prod. No. A400 and FITC label from Sigma, St. Louis Mo., Prod. No. F-7250; FITC. Labeling of C1q was accomplished in accordance with the protocol described in *Selected Methods In Cellular Immunology*, Michell & Shiigi, Ed. (W. H. Freeman & Co., San Francisco, Calif., 1980, p. 292). Analytical results were derived using a Becton Dickinson FACScan™ flow cytometer (fluorescein measured over a range of 515-545 nm). Equivalent amounts of chimeric anti-CD20 antibody, human IgG1,K myeloma protein (Binding Site, San Diego, Calif., Prod. No. BP078), and 2B8 were incubated with an equivalent number of CD20-positive SB cells, followed by a wash step with FACS buffer (0.2% BSA in PBS, pH 7.4, .02% sodium azide) to remove unattached antibody, followed by incubation with FITC labeled C1q. Following a 30-60 min. incubation, cells were again washed. The three conditions, including FITC-labeled C1q as a control, were analyzed on the FACScan™ following manufacturing instructions. Results are presented in FIG. 6.

As the results of FIG. 6 evidence, a significant increase in fluorescence was observed only for the chimeric anti-CD20 antibody condition; ie only SB cells with adherent chimeric anti-CD20 antibody were C1q positive, while the other conditions produced the same pattern as the control.

ii. Complement Dependent Cell Lyses

Chimeric anti-CD20 antibodies were analyzed for their ability to lyse lymphoma cell lines in the presence of human serum (complement source). CD20 positive SB cells were labeled with ⁵¹Cr by admixing 100 µCi of ⁵¹Cr with 1×10^6 SB cells for 1 hr at 37° C.; labeled SB cells were then incubated in the presence of equivalent amounts of human complement and equivalent amounts (0-50 µg/ml) of either chimeric anti-CD20 antibodies or 2B8 for 4 hrs at 37° C. (see, Brunner, K. T. at al., "Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹Cr-labeled allogeneic target cells in vitro." *Immunology* 14:181-189 (1968). Results are presented in FIG. 7.

The results of FIG. 7 indicate, inter alia, that chimeric anti-CD20 antibodies produced significant lysis (49%) under these conditions.

US 7,381,560 B2

23

iii. Antibody Dependent Cellular Cytotoxicity Effector Assay

For this study, CD20 positive cells (SB) and CD20 negative cells (T cell leukemia line HSB; see, Adams, Richard, "Formal Discussion," *Can. Res.* 27:2479-2482 (1967); ATCC deposit no. ATCC CCL 120.1) were utilized; both were labeled with ⁵¹Cr. Analysis was conducted following the protocol described in Brunner, K. T. et al., "Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹Cr-labeled allogeneic target cells in vitro; inhibition by isoantibody and drugs." *Immunology* 14:181-189 (1968); a substantial chimeric anti-CD20 antibody dependent cell mediated lysis of CD20 positive SB target cells (⁵¹Cr-labeled) at the end of a 4 hr, 37° C. incubation, was observed and this effect was observed for both CHO and SP2/0 produced antibody (effector cells were human peripheral lymphocytes; ratio of effector cells:target was 100:1). Efficient lysis of target cells was obtained at 3.9 µg/ml. In contrast, under the same conditions, the murine anti-CD20 monoclonal antibody 2B8 had a statistically insignificant effect, and CD20 negative HSB cells were not lysed. Results are presented in FIG. 8.

The results of Example II indicate, inter alia, that the chimeric anti-CD20 antibodies of Example I were immunologically active.

III. Depletion of B Cells In Vivo using Chimeric Anti-CD20 A Non-Human Primate Study

Three separate non-human primate studies were conducted. For convenience, these are referred to herein as "Chimeric Anti-CD20: CHO & SP2/0;" "Chimeric Anti-CD20: CHO;" and "High Dosage Chimeric Anti-CD20." Conditions were as follows:

Chimeric Anti-CD20: CHO & SP2/0

Six cynomolgus monkeys ranging in weight from 4.5 to 7 kilograms (White Sands Research Center, Alamogordo, N. Mex.) were divided into three groups of two monkeys each. Both animals of each group received the same dose of immunologically active chimeric anti-CD20 antibody. One animal in each group received purified antibody produced by the CHO transfectoma; the other received antibody produced by the SP2/0 transfectoma. The three groups received antibody dosages corresponding to 0.1 mg/kg, 0.4 mg/kg, and 1.6 mg/kg each day for four (4) consecutive days. The chimeric immunologically active anti-CD20 antibody, which was admixed with sterile saline, was administered by intravenous infusion; blood samples were drawn prior to each infusion. Additional blood samples were drawn beginning 24 hrs after the last injection (T=0) and thereafter on days 1, 3, 7, 14 and 28; blood samples were also taken thereafter at biweekly intervals until completion of the study at day 90.

Approximately 5 ml of whole blood from each animal was centrifuged at 2000 RPM for 5 min. Plasma was removed for assay of soluble chimeric anti-CD20 antibody levels. The pellet (containing peripheral blood leukocytes and red blood cells) was resuspended in fetal calf serum for fluorescent-labeled antibody analysis (see, "Fluorescent Antibody Labeling of Lymphoid Cell Population," *infra.*).

Chimeric Anti-CD20: CHO

Six cynomolgus monkeys ranging in weight from 4 to 6 kilograms (White Sands) were divided into three groups of two monkeys each. All animals were injected with immunologically active chimeric anti-CD20 antibodies produced from the CHO transfectoma (in sterile saline). The three groups were separated as follows: subgroup 1 received daily

24

intravenous injections of 0.01 mg/kg of the antibody over a four (4) day period; subgroup 2 received daily intravenous injections of 0.4 mg/kg of the antibody over a four (4) day period; subgroup 3 received a single intravenous injection of 6.4 mg/kg of the antibody. For all three subgroups, a blood sample was obtained prior to initiation of treatment; additionally, blood samples were also drawn at T=0, 1, 3, 7, 14 and 28 days following the last injection, as described above, and these samples were processed for fluorescent labeled antibody analysis (see, "Fluorescent Antibody Labeling," *infra.*). In addition to peripheral blood B cell quantitation, lymph node biopsies were taken at days 7, 14 and 28 following the last injection, and a single cell preparation stained for quantitation of lymphocyte populations by flow cytometry.

High Dosage Chimeric Anti-CD20

Two cynomolgus monkeys (White Sands) were infused with 16.8 mg/kg of the immunologically active chimeric anti-CD20 antibodies from the CHO transfectomas (in sterile saline) weekly over a period of four consecutive weeks. At the conclusion of the treatment, both animals were anesthetized for removal of bone marrow; lymph node biopsies were also taken. Both sets of tissue were stained for the presence of B lymphocytes using Leu 16 by flow cytometry following the protocol described in Ling, N. R. et al., "B-cell and plasma cell antigens." *Leucocyte Typing III White Cell Differentiations Antigens*, A. J. McMichael, Ed. (Oxford University Press, Oxford UK, 1987), p. 302.

Fluorescent Antibody Labeling of Lymphoid Cell Population

After removal of plasma, leukocytes were washed twice with Hanks Balanced Salt Solution ("HBSS") and resuspended in a plasma equivalent volume of fetal bovine serum (heat inactivated at 56° C. for 30 min.). A 0.1 ml volume of the cell preparation was distributed to each of six (6), 15 ml conical centrifuge tubes Fluorescein labeled monoclonal antibodies with specificity for the human lymphocyte surface markers CD2 (AMAC, Westbrook, Me.), CD20 (Becton Dickinson) and human IgM (Binding Site, San Diego, Calif.) were added to 3 of the tubes for identifying T and B lymphocyte populations. All reagents had previously tested positive to the corresponding monkey lymphocyte antigens. Chimeric anti-CD20 antibody bound to monkey B cell surface CD20 was measured in the fourth tube using polyclonal goat anti-human IgG coupled with phycoerythrin (AMAC). This reagent was pre-adsorbed on a monkey Ig-sepharose column to prevent cross-reactivity to monkey Ig, thus allowing specific detection and quantitation of chimeric anti-CD20 antibody bound to cells. A fifth tube included both anti-IgM and anti-human IgG reagents for double stained B cell population. A sixth sample was included with no reagents for determination of autofluorescence. Cells were incubated with fluorescent antibodies for 30 min., washed and fixed with 0.5 ml of fixation buffer (0.15 M NaCl, 1% paraformaldehyde, pH7.4) and analyzed on a Becton Dickinson FACScan™ instrument. Lymphocyte populations were initially identified by forward versus right angle light scatter in a dot-plot bitmap with unlabeled leucocytes. The total lymphocyte population was then isolated by gating out all other events. Subsequent fluorescence measurements reflected only gated lymphocyte specific events.

Depletion of Peripheral Blood B Lymphocytes

No observable difference could be ascertained between the efficacy of CHO and SP2/0 produced antibodies in

US 7,381,560 B2

25

depleting B cells in vivo, although a slight increase in B cell recovery beginning after day 7 for monkeys injected with chimeric anti-CD20 antibodies derived from CHO transfectomas at dosage levels 1.6 mg/kg and 6.4 mg/kg was observed and for the monkey injected with SP2/0 producing antibody at the 0.4 mg/kg dose level. FIGS. 9A, B and C provide the results derived from the chimeric anti-CD20: CHO & SP2/0 study, with FIG. 9A directed to the 0.4 mg/kg dose level; FIG. 9B directed to the 1.6 mg/kg dose level; and FIG. 9C directed to the 6.4 mg/kg dose level.

As is evident from FIG. 9, there was a dramatic decrease (>95%) in peripheral B cell levels after the therapeutic treatment across all tested dose ranges, and these levels were maintained up to seven (7) days post infusion; after this period, B cell recovery began, and, the time of recovery initiation was independent of dosage levels.

In the Chimeric Anti-CD20:CHO study, a 10-fold lower antibody dosage concentration (0.01 mg/kg) over a period of four daily injections (0.04 mg/kg total) was utilized. FIG. 10 provides the results of this study. This dosage depleted the peripheral blood B cell population to approximately 50% of normal levels estimated with either the anti-surface IgM or the Leu 16 antibody. The results also indicate that saturation of the CD20 antigen on the B lymphocyte population was not achieved with immunologically active chimeric anti-CD20 antibody at this dose concentration over this period of time for non-human primates; B lymphocytes coated with the antibody were detected in the blood samples during the initial three days following therapeutic treatment. However, by day 7, antibody coated cells were undetectable.

Table I summarizes the results of single and multiple doses of immunologically active chimeric anti-CD20 antibody on the peripheral blood populations; single dose condition was 6.4 mg/kg; multiple dose condition was 0.4 mg/kg over four (4) consecutive days (these results were derived from the monkeys described above).

TABLE I

PERIPHERAL BLOOD POPULATION FROM C2B8 PRIMATE STUDY

Monkey	Dose	Day	CD2	Anti-Hu IgG
A	0.4 mg/kg (4 doses)	Prebleed	81.5	—
		0	86.5	0.2
		7	85.5	0.0
		21	93.3	—
		28	85.5	—
B	0.4 mg/kg (4 doses)	Prebleed	81.7	—
		0	94.6	0.1
		7	92.2	0.1
		21	84.9	—
		28	84.1	—
C	6.4 mg/kg (1 dose)	Prebleed	77.7	0.0
		7	85.7	0.1
		21	86.7	—
		28	76.7	—
		28	85.7	0.1
D	6.4 mg/kg (1 dose)	Prebleed	85.7	0.1
		7	94.7	0.1
		21	85.2	—
		28	85.9	—
		28	85.9	—

Monkey	Anti-Hu IgG + Anti-Hu IgM*	Leu-16	% B Cell Depletion
A	—	9.4	0
	0.3	0.0	97
	0.1	1.2	99
	—	2.1	78
	—	4.1	66
B	—	14.8	0
	0.2	0.1	99
	0.1	0.1	99

26

TABLE I-continued

PERIPHERAL BLOOD POPULATION FROM C2B8 PRIMATE STUDY			
C	—	6.9	53
	—	8.7	41
	0.2	17.0	0
	0.1	0.0	99
	—	14.7	15
D	—	8.1	62
	0.1	14.4	0
	0.2	0.0	99
	—	9.2	46
	—	6.7	53

*Double staining population which indicates extent of chimeric anti-CD20 coated B cells.

The data summarized in Table I indicates that depletion of B cells in peripheral blood under conditions of antibody excess occurred rapidly and effectively, regardless of single or multiple dosage levels. Additionally, repletion was observed for at least seven (7) days following the last injection, with partial B cell recovery observed by day 21.

Table II summarizes the effect of immunologically active, chimeric anti-CD20 antibodies on cell populations of lymph nodes using the treatment regimen of Table I (4 daily doses of 0.4 mg/kg; 1 dose of 6.4 mg/kg); comparative values for normal lymph nodes (control monkey, axillary and inguinal) and normal bone marrow (two monkeys) are also provided.

TABLE II

CELL POPULATIONS OF LYMPH NODES

Monkey	Dose	Day	CD2	Anti-Hu IgM
A	0.4 mg/kg (4 doses)	7	66.9	—
		14	76.9	19.6
		28	61.6	19.7
B	0.4 mg/kg (4 doses)	7	59.4	—
		14	83.2	9.9
		28	84.1	15.7
C	6.4 mg/kg (1 dose)	7	75.5	—
		14	74.1	17.9
		28	66.9	23.1
D	6.4 mg/kg (1 dose)	7	83.8	—
		14	74.1	17.9
		28	84.1	12.8

Monkey	Anti-Hu IgG + Anti-Hu IgM	Leu-16	% B Lymphocyte Depletion
A	7.4	40.1	1
	0.8	22.6	44
	—	26.0	36
B	29.9	52.2	0
	0.7	14.5	64
	—	14.6	64
C	22.3	35.2	13
	1.1	23.9	41
	—	21.4	47
D	12.5	19.7	51
	0.2	8.7	78
	—	12.9	68

	Anti-Hu IgG + CD2	Anti-Hu IgM	Leu-16	% B Lymphocyte Depletion
Normal Lymph Nodes				
Control 1				
Axillary	55.4	25.0	—	41.4 NA
Inguinal	52.1	31.2	—	39.5 NA

US 7,381,560 B2

27

TABLE II-continued

CELL POPULATIONS OF LYMPH NODES					
Normal Bone Marrow					
Control 2	65.3	19.0	—	11.4	NA
Control 3	29.8	28.0	—	16.6	NA

The results of Table II evidence effective depletion of B lymphocytes for both treatment regimens. Table II further indicates that for the non-human primates, complete saturation of the B cells in the lymphatic tissue with immunologically active, chimeric anti-CD20 antibody was not achieved; additionally, antibody coated cells were observed seven (7) days after treatment, followed by a marked depletion of lymph node B cells, observed on day 14.

Based upon this data, the single High Dosage Chimeric Anti-CD20 study referenced above was conducted, principally with an eye toward pharmacology/toxicology determination. In this study was conducted to evaluate any toxicity associated with the administration of the chimeric antibody, as well as the efficacy of B cell depletion from peripheral blood lymph nodes and bone marrow. Additionally, because the data of Table II indicates that for that study, the majority of lymph node B cells were depleted between 7 and 14 days following treatment, a weekly dosing regimen might evidence more efficacious results. Table III summarizes the results of the High Dosage Chimeric Anti-CD20 study.

TABLE III

CELL POPULATIONS OF LYMPH NODES AND BONE MARROW					
Lymphocyte Populations (%)					
Monkey	CD2	CD20 ^a	mIgM + anti-C2B8 ^b	C2B8 ^c	Day ^d
Inguinal Lymph Node					
E	90.0	5.3	4.8	6.5	22
F	91.0	6.3	5.6	6.3	22
G	89.9	5.0	3.7	5.8	36
H	85.4	12.3	1.7	1.8	36
Bone Marrow					
E	46.7	4.3	2.6	2.8	22
F	41.8	3.0	2.1	2.2	22
G	35.3	0.8	1.4	1.4	36
H	25.6	4.4	4.3	4.4	36

^aIndicates population stained with Leu 16.

^bIndicates double staining population, positive for surface IgM cells and chimeric antibody coated cells.

^cIndicates total population staining for chimeric antibody including double staining surface IgM positive cells and single staining (surface IgM negative) cells.

^dDays after injection of final 16.8 mg/kg dose.

Both animals evaluated at 22 days post treatment cessation contained less than 5% B cells, as compared to 40% in control lymph nodes (see, Table II, supra). Similarly, in the bone marrow of animals treated with chimeric anti-CD20 antibody, the levels of CD20 positive cells were less than 3% as compared to 11-15% in the normal animals (see, Table II, supra). In the animals evaluated at 36 days post treatment cessation, one of the animals (H) had approximately 12% B cells in the lymph node and 4.4% B cells in bone marrow, while the other (G) had approximately 5% B cells in the lymph node and 0.8% in the bone marrow—the data is indicative of significant B cell depletion.

28

The results of Example III.A indicate, *inter alia*, that low doses of immunologically active, chimeric anti-CD20 leads to long-term peripheral blood B cell depletion in primates. The data also indicates that significant depletion of B cell populations was achieved in peripheral lymph nodes and bone marrow when repetitive high doses of the antibody were administered. Continued follow-up on the test animals has indicated that even with such severe depletion of peripheral B lymphocytes during the first week of treatment, no adverse health effects have been observed. Furthermore, as recovery of B cell population was observed, a conclusion to be drawn is that the pluripotent stem cells of these primates were not adversely affected by the treatment.

B. Clinical Analysis of C2B8

i. Phase I/II Clinical Trial of C2B8: Single Dose Therapy Study

Fifteen patients having histologically documented relapsed B cell lymphoma have been treated with C2B8 in a Phase I/II Clinical Trial. Each patient received a single dose of C2B8 in a dose-escalating study; there were three patients per dose: 10 mg/m²; 50 mg/m²; 100 mg/m²; 250 mg/m² and 500 mg/m². Treatment was by i.v. infusion through an 0.22 micron in-line filter with C2B8 being diluted in a final volume of 250 cc or a maximal concentration of 1 mg/ml of normal saline. Initial rate was 50 cc/hr for the first hour; if no toxicity was seen, dose rate was able to be escalated to a maximum of 200 cc/hr.

Toxicity (as indicated by the clinician) ranged from “none”, to “fever” to “moderate” (two patients) to “severe” (one patient); all patients completed the therapy treatment. Peripheral Blood Lymphocytes were analyzed to determine, *inter alia*, the impact of C2B8 on T-cells and B-cells. Consistently for all patients, Peripheral Blood B Lymphocytes were depleted after infusion with C2B8 and such depletion was maintained for in excess of two weeks.

One patient (receiving 100 mg/m² of C2B8) evidenced a Partial Response to the C2B8 treatment (reduction of greater than 50% in the sum of the products of the perpendicular diameters of all measurable indicator lesions lasting greater than four weeks, during which no new lesions may appear and no existing lesions may enlarge); at least one other patient (receiving 500 mg/m²) evidenced a Minor Response to the C2B8 treatment (reduction of less than 50% but at least 25% in the sum of the products of the two longest perpendicular diameters of all measurable indicator lesions). For presentational efficiency, results of the PBLs are set forth in FIG. 14A; data for the patient evidencing a PR is set forth in FIG. 14B. In FIG. 14, the following are applicable: ■=Lymphocytes; □=CD3+ cells (T cells); ▲=CD20+ cells; ●=CD19+ cells; ⊕=Kappa; △=lambda; and ◆=C2B8. As evidenced, the B cell markers CD20 and CD19, Kappa and Lambda, were depleted for a period in excess of two weeks; while there was a slight, initial reduction in T-cell counts, these returned to an approximate base-line level in a relatively rapid time-frame.

ii. Phase I/II Clinical Trial of C2B8: Multiple Dose Therapy Study

Patients having histologically confirmed B cell lymphoma with measurable progressive disease are eligible for this study which is separated into two parts: in Phase I, consisting of a dose escalation to characterize dose limiting toxicities and determination of biologically active tolerated dose level, groups of three patients will receive weekly i.v.

US 7,381,560 B2

29

infusions of C2B8 for a total of four (4) separate infusions. Cumulative dose at each of the three levels will be as follows: 500 mg/m² (125 mg/m²/infusion); 1000 mg/m² (250 mg/m²/infusion); 1500 mg/m² (375 mg/m²/infusion). A biologically active tolerated dose is defined, and will be determined, as the lowest dose with both tolerable toxicity and adequate activity); in Phase II, additional patients will receive the biologically active tolerated dose with an emphasis on determining the activity of the four doses of C2B8.

IV. Combination Therapy: C2B8 and Y2B8

A combination therapeutic approach using C2B8 and Y2B8 was investigated in a mouse xenographic model (nu/nu mice, female, approximately 10 weeks old) utilizing a B cell lymphoblastic tumor (Ramos tumor cells). For comparative purposes, additional mice were also treated with C2B8 and Y2B8.

Ramos tumor cells (ATCC, CRL 1596) were maintained in culture using RPMI-1640 supplemented with 10% fetal calf serum and glutamine at 37° C. and 5% CO₂. Tumors were initiated in nine female nude mice approximately 7-10 weeks old by subcutaneous injection of 1.7×10⁶ Ramos cells in a volume of 0.10 ml (HBSS) using a 1 cc syringe fitted with 25 g needle. All animals were manipulated in a laminar flow hood and all cages, bedding, food and water were autoclaved. Tumor cells were passaged by excising tumors and passing these through a 40 mesh screen; cells were washed twice with 1× HBSS (50 ml) by centrifugation (1300RPM), resuspended in 1× HBSS to 10×10⁶ cells/ml, and frozen at -70° C. until used.

For the experimental conditions, cells from several frozen lots were thawed, pelleted by centrifugation (1300RPM) and washed twice with 1× HBSS. Cells were then resuspended to approximately 2.0×10⁶ cells/ml. Approximately 9 to 12 mice were injected with 0.10 ml of the cell suspension (s.c.) using a 1 cc syringe fitted with a 25 g needle; injections were made on the animal's left side, approximately mid-region. Tumors developed in approximately two weeks. Tumors were excised and processed as described above. Study mice were injected as described above with 1.67×10⁶ cells in 0.10 ml HBSS.

Based on preliminary dosing experiments, it was determined that 200 mg of C2B8 and 100 μCi of Y2B8 would be utilized for the study. Ninety female nu/nu mice (approximately 10 weeks old) were injected with the tumor cells. Approximately ten days later, 24 mice were assigned to four study groups (six mice/group) while attempting to maintain a comparable tumor size distribution in each group (average tumor size, expressed as a product of length x width of the tumor, was approximately 80 mm²). The following groups were treated as indicated via tail-vein injections using a 100 μl Hamilton syringe fitted with a 25 g needle:

- A. Normal Saline
- B. Y2B8 (100 μCi)
- C. C2B8 (200 μg); and
- D. Y2B8 (100 μCi)+C2B8 (200 μg)

Groups tested with C2B8 were given a second C2B8 injection (200 μg/mouse) seven days after the initial injection. Tumor measurements were made every two or three days using a caliper.

Preparation of treatment materials were in accordance with the following protocols:

A Preparation of Y2B8

Yttrium-[90] chloride (6 mCi) was transformed to a polypropylene tube and adjusted to pH 4.1-4.4 using metal free 2M sodium acetate. 2B8-MX-DTPA (0.3 mg in normal saline; see above for preparation of 2B8-MX-DTPA) was

30

added and gently mixed by vortexing. After 15 min. incubation, the reaction was quenched by adding 0.05× volume 20 mM EDTA and 0.05× volume 2M sodium acetate. Radioactivity concentration was determined by diluting 5.0 μl of the reaction mixture in 2.5 ml 1× PBS containing 75 mg/ml HSA and 1 mM DTPA ("formulation buffer"); counting was accomplished by adding 10.01 μl to 20 ml of Ecolume™ scintillation cocktail. The remainder of the reactive mixture was added to 3.0 μml formulation buffer, sterile filtered and stored at 2-8° C. until used. Specific activity (14 mCi/mg at time of injection) was calculated using the radioactivity concentration and the calculated protein concentration based upon the amount of antibody added to the reaction mixture. Protein-associated radioactivity was determined using instant thin-layer chromatography. Radioincorporation was 95%. Y2B8 was diluted in formulation buffer immediately before use and sterile-filtered (final radioactivity concentration was 1.0 mCi/ml).

B. Preparation of C2B8

C2B8 was prepared as described above. C2B8 was provided as a sterile reagent in normal saline at 5.0 mg/ml. Prior to injection, the C2B8 was diluted in normal saline to 2.0 mg/ml and sterile filtered.

C. Results

Following treatment, tumor size was expressed as a product of length and width, and measurements were taken on the days indicated in FIG. 11 (Y2B8 vs. Saline); FIG. 12 (C2B8 vs. Saline); and FIG. 13 (Y2B8 +C2B8 vs. Saline). Standard error was also determined.

As indicated in FIG. 13, the combination of Y2B8 and C2B8 exhibited tumoricidal effects comparable to the effects evidenced by either Y2B8 or C2B8.

V. Alternative Therapy Strategies

Alternative therapeutic strategies recognized in view of the foregoing examples are evident. One such strategy employs the use of a therapeutic dose of C2B8 followed within about one week with a combination of either 2B8 and radiolabeled 2B8 (eg Y2B8); or 2B8, C2B8 and, eg Y2B8; or C2B8 and, eg Y2B8. An additional strategy is utilization of radiolabeled C2B8—such a strategy allows for utilization of the benefits of the immunologically active portion of C2B8 plus those benefits associated with a radiolabel. Preferred radiolabels include yttrium-90 given the larger circulating half-life of C2B8 versus the murine antibody 2B8. Because of the ability of C2B8 to deplete B-cells, and the benefits to be derived from the use of a radiolabel, a preferred alternative strategy is to treat the patient with C2B8 (either with a single dose or multiple doses) such that most, if not all, peripheral B cells have been depleted. This would then be followed with the use of radiolabeled 2B8; because of the depletion of peripheral B cells, the radiolabeled 2B8 stands an increased chance of targeting tumor cells. Iodine [131] labeled 2B8 is preferably utilized, given the types of results reported in the literature with this label (see Kaminski). An alternative preference involves the use of a radiolabeled 2B8 (or C2B8) first in an effort to increase the permeability of a tumor, followed by single or multiple treatments with C2B8; the intent of this strategy is to increase the chances of the C2B8 in getting both outside and inside the tumor mass. A further strategy involved the use of chemotherapeutic agent in combination with C2B8. These strategies include so-called "staggered" treatments, ie, treatment with chemotherapeutic agent, followed by treatment with C2B8, followed by a repetition of this protocol. Alternatively, initial treatment with a single or multiple doses of C2B8, thereafter

US 7,381,560 B2

31

followed with chemotherapeutic treatment, is viable. Preferred chemotherapeutic agents include, but are not limited to: cyclophosphamide; doxorubicin; vincristine; and prednisone. See Armitage, J. O. et al., *Cancer* 50:1695 (1982), incorporated herein by reference.

The foregoing alternative therapy strategies are not intended to be limiting, but rather are presented as being representative.

VI. Deposit Information

Anti-CD20 in TCAE 8 (transformed in *E. coli* for purposes of deposit) was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rock-

32

ville, Md., 20852, under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure ("Budapest Treaty"). The microorganism was tested by the ATCC on Nov. 9, 1992, and determined to be viable on that date. The ATCC has assigned this microorganism for the following ATCC deposit number: ATCC 69119 (anti-CD20 in TCAE 8). Hybridoma 2B8 was deposited with the ATCC on Jun. 22, 1993 under the provisions of the Budapest Treaty. The viability of the culture was determined on Jun. 25, 1993 and the ATCC has assigned this hybridoma the following ATCC deposit number: HB 11388.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 9

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

27

(2) INFORMATION FOR SEQ ID NO: 2:

se pairs

- (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
CCGCTCTAGG CCTCCAAAA AGCCTCCTCA CTACTTCTGG AATAGCTCAG AATAGCTCAG    60
AGGCCGAGGC GGCCTCGGCC TCTGCATAAA TAAAAAAAT TAGTCAGCCA TGCATGGGGC    120
GGAGAATGGG CGGAAGTGGG CGGAGTTAGG GCGGGGATGG GCGGAGTTAG GGGCGGGACT    180
ATGTTGCTG ACTAATTGAG ATGCATGCTT TGCATACTTC TGCTTCTGG GGAGCCTGGG    240
GACTTTCCAC ACCTGGTTGC TGACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT    300
GGGGAGCCTG GGGACTTTCC ACACCCTAAC TGACACACAT TCCACAGAAT TAATCCCCT    360
AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCGGC    420
GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG    480
ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA    540
TGGGTGGACT ATTTACGGTA AACTGCCAC TTGGCAGTAC ATCAAGTGTG TCATATGCCA    600
AGTACGCCCC CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATTG TGCCAGTAC    660
ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC    720
ATGGTGATGC GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA    780
```

US 7,381,560 B2

33

34

-continued

TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG	840
GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA	900
CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACGTGAACC GTCAGATCGC CTGGAGACGC	960
CATCACAGAT CTCTCACCAT GAGGGTCCCC GCTCAGCTCC TGGGGCTCCT GCTGCTCTGG	1020
CTCCAGGTG CACGATGTGA TGGTACCAAG GTGAAATCA AACGTACGGT GGCTGCACCA	1080
TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAAGTGC CTCTGTTGTG	1140
TGCCTGCTGA ATAACTTCTA TCCCAGAGAG GCCAAAGTAC AGTGGAAAGT GGATAACGCC	1200
CTCCAATCGG GTAACCTCCA GGAGAGTGTC ACAGAGCAGG ACAGCAAGGA CAGCACCTAC	1260
AGCCTCAGCA GCACCTGAC GCTGAGCAAA GCAGACTACG AGAAACACAA AGTCTACGCC	1320
TGCGAAGTCA CCCATCAGGG CCTGAGCTCG CCCGTCACAA AGAGCTTCAA CAGGGGAGAG	1380
TGTTGAATTC AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATTCTG GACAACATGC	1440
GGCCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT	1500
GTTTGCCCTT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC TGTCCCTTCC	1560
TAATAAATG AGGAAATGTC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT	1620
GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT	1680
GCGGTGGGCT CTATGGAACC AGCTGGGGCT CGACAGCTAT GCCAAGTACG CCCCCTATTG	1740
ACGTCAATGA CGGTAATGCG CCCGCTGGC ATTATGCCCA GTACATGACC TTATGGGACT	1800
TTCTACTTGG CAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT	1860
GGCAGTACAT CAATGGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC	1920
CCATTGACGT CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CAAAATGTC	1980
GTAACAACCT CGCCCATTTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA	2040
TAAGCAGAGC TGGGTACGTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCCGTCGAC	2100
ATGGGTTGGA GCCTCATCTT GCTCTTCCTT GTCGCTGTTG CTACGCGTGT CGCTAGCACC	2160
AAGGGCCCAT CGGTCTTCCC CCTGGCACCC TCCTCCAAGA GCACCTCTGG GGGCACAGCG	2220
GCCCTGGGCT GCCTGGTCAA GGACTIONC CCCGAACCGG TGACGGTGTG GTGGAACCTA	2280
GGCGCCCTGA CCAGCGGCGT GCACACCTTC CCGGCTGTCC TACAGTCTC AGGACTCTAC	2340
TCCTCAGCA GCGTGGTGAC CGTGCCCTCC AGCAGCTTGG GCACCCAGAC CTACATCTGC	2400
AACGTGAATC ACAAGCCCAG CAACACCAAG GTGGACAAGA AAGCAGAGCC CAAATCTTGT	2460
GACAAAACCT ACACATGCCC ACCGTGCCCA GCACCTGAAC TCCTGGGGGG ACCGTCAGTC	2520
TTCTCTTCC CCCCCAAACC CAAGGACACC CTCATGATCT CCCGGACCCC TGAGGTCAACA	2580
TGCGTGGTGG TGACAGTGAG CCACGAAGAC CCTGAGGTCA AGTTCAACTG GTACGTGGAC	2640
GGCGTGGAGG TGCATAATGC CAAGACAAAG CCGCGGGAGG AGCAGTACAA CAGCACGTAC	2700
CGTGTGGTCA GCGTCTCTAC CGTCTGCAC CAGGACTGGC TGAATGGCAA GGACTIONC	2760
TGCAAGGTCT CCAACAAAGC CCTCCCAGCC CCCATCGAGA AAACCATCTC CAAAGCCAAA	2820
GGGCAGCCCC GAGAACCACA GGTGTACACC CTGCCCCCAT CCCGGGATGA GCTGACCAGG	2880
AACCAGGTCA GCCTGACCTG CCTGGTCAAA GGCTTCTATC CCAGCGACAT CGCCGTGGAG	2940
TGGGAGAGCA ATGGGCAGCC GGAGAACAAC TACAAGACCA CGCTCCCGT GCTGGACTCC	3000
GACGGCTCCT TCTTCTCTA CAGCAAGCTC ACCGTGGACA AGAGCAGGTG GCAGCAGGGG	3060
AACGTCTTCT CATGCTCCGT GATGCATGAG GCTCTGCACA ACCACTACAC GCAGAAGAGC	3120

US 7,381,560 B2

35

36

-continued

CTCTCCCTGT	CTCCGGGTAA	ATGAGGATCC	GTTAACGGTT	ACCAACTACC	TAGACTGGAT	3180
TCGTGACAAC	ATGCGGCCGT	GATATCTACG	TATGATCAGC	CTCGACTGTG	CCTTCTAGTT	3240
GCCAGCCATC	TGTTGTTTGC	CCCTCCCCCG	TGCCTTCCTT	GACCTTGAA	GGTGCCACTC	3300
CCACTGTCTT	TTCCTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3360
CTATTCTGGG	GGGTGGGGTG	GGGCAGGACA	GCAAGGGGGA	GGATTGGGAA	GACAATAGCA	3420
GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	AACCAGCTGG	GGCTCGACAG	CGCTGGATCT	3480
CCCGATCCCC	AGCTTTGCTT	CTCAATTTCT	TATTTGCATA	ATGAGAAAAA	AAGGAAAATT	3540
AATTTTAAAC	CAAATTCAGT	AGTTGATTGA	GCAAATGCGT	TGCCAAAAAG	GATGCTTTAG	3600
AGACAGTGTT	CTCTGCACAG	ATAAGGACAA	ACATTATTCA	GAGGGAGTAC	CCAGAGCTGA	3660
GACTCCTAAG	CCAGTGAGTG	GCACAGCATT	CTAGGGAGAA	ATATGCTTGT	CATCACCGAA	3720
GCCTGATTCC	GTAGAGCCAC	ACCTTGGTAA	GGGCCAATCT	GCTCACACAG	GATAGAGAGG	3780
GCAGGAGCCA	GGGCAGAGCA	TATAAGGTGA	GGTAGGATCA	GTTGCTCCTC	ACATTTGCTT	3840
CTGACATAGT	TGTGTTGGGA	GCTTGGATAG	CTTGGACAGC	TCAGGGCTGC	GATTTGCGGC	3900
CAAACCTGAC	GGCAATCCTA	GCGTGAAGGC	TGGTAGGATT	TTATCCCCGC	TGCCATCATG	3960
GTTTCGACCAT	TGAACTGCAT	CGTCGCCGTG	TCCCAAATA	TGGGGATTGG	CAAGAACGGA	4020
GACCTACCCT	GGCCTCCGCT	CAGGAACGAG	TTCAAGTACT	TCCAAAGAAT	GACCACAACC	4080
TCTTCAGTGG	AAGGTAAACA	GAATCTGGTG	ATTATGGGTA	GGAAAACCTG	GTTCTCCATT	4140
CCTGAGAACA	ATCGACCTTT	AAAGGACAGA	ATTAATATAG	TTCTCAGTAG	AGAACTCAA	4200
GAACCACCAC	GAGGAGCTCA	TTTTCTTGCC	AAAAGTTTGG	ATGATGCCTT	AAGACTTATT	4260
GAACAACCGG	AATTGGAAG	TAAAGTAGAC	ATGGTTTGG	TAGTCGGAGG	CAGTTCTGTT	4320
TACCAGGAAG	CCATGAATCA	ACCAGGCCAC	CTTAGACTCT	TTGTGACAAG	GATCATGCAG	4380
GAATTTGAAA	GTGACACGTT	TTTCCAGAA	ATTGATTTGG	GAAATATAA	ACTTCTCCA	4440
GAATACCCAG	GCGTCTCTC	TGAGGTCCAG	GAGGAAAAAG	GCATCAAGTA	TAAGTTGAA	4500
GTCTACGAGA	AGAAAGACTA	ACAGGAAGAT	GCTTTCAAGT	TCTCTGCTCC	CCTCCTAAAG	4560
TCATGCATTT	TTATAAGACC	ATGGGACTTT	TGCTGGCTTT	AGATCAGCCT	CGACTGTGCC	4620
TTCTAGTTGC	CAGCCATCTG	TTGTTTGCCC	CTCCCCGTG	CCTTCCTTGA	CCCTGGAAGG	4680
TGCCACTCCC	ACTGTCCTTT	CCTAATAAAA	TGAGGAAAATT	GCATCGCATT	GTCTGAGTAG	4740
GTGTCATTCT	ATTCTGGGGG	GTGGGGTGGG	GCAGGACAGC	AAGGGGGAGG	ATTGGGAAGA	4800
CAATAGCAGG	CATGCTGGGG	ATGCGGTGGG	CTCTATGGAA	CCAGCTGGGG	CTCGAGCTAC	4860
TAGCTTTGCT	TCTCAATTTT	TTATTTGCAT	AATGAGAAAA	AAAGGAAAAT	TAATTTTAAAC	4920
ACCAATTCAG	TAGTTGATTG	AGCAAATGCG	TTGCCAAAA	GGATGCTTTA	GAGACAGTGT	4980
TCTCTGCACA	GATAAGGACA	AACATTATTC	AGAGGGAGTA	CCCAGAGCTG	AGACTCCTAA	5040
GCCAGTGAGT	GGCACAGCAT	TCTAGGGAGA	AATATGCTTG	TCATCACCGA	AGCCTGATTC	5100
CGTAGAGCCA	CACCTTGGTA	AGGGCCAATC	TGCTCACACA	GGATAGAGAG	GGCAGGAGCC	5160
AGGGCAGAGC	ATATAAGGTG	AGGTAGGATC	AGTTGCTCCT	CACATTTGCT	TCTGACATAG	5220
TTGTGTTGGG	AGCTTGGATC	GATCCTCTAT	GGTTGAACAA	GATGGATTGC	ACGCAGGTTT	5280
TCCGGCCGCT	TGGGTGGAGA	GGCTATTCGG	CTATGACTGG	GCACAACAGA	CAATCGGCTG	5340
CTCTGATGCC	GCCGTGTTCC	GGCTGTCAGC	GCAGGGGCGC	CCGGTTCTTT	TTGTCAAGAC	5400
CGACCTGTCC	GGTGCCCTGA	ATGAAGTGA	GGACGAGGCA	GCGCGGCTAT	CGTGGCTGGC	5460
CACGACGGGC	GTTCTTGGC	CAGCTGTGCT	CGACGTTGTC	ACTGAAGCGG	GAAGGGACTG	5520

US 7,381,560 B2

37

38

-continued

GCTGCTATTG GCGAAGTGC CGGGGCAGGA TCTCCTGTCA TCTCACCTTG CTCCTGCCGA 5580
GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT ACGCTTGATC CGGCTACCTG 5640
CCCATTGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA CGTACTCGGA TGGAGCCGG 5700
TCTTGTCGAT CAGGATGATC TGGACGAAGA GCATCAGGGG CTCGCGCCAG CCGAACTGTT 5760
CGCCAGGCTC AAGGCGCGCA TGCCCGACGG CGAGGATCTC GTCGTGACCC ATGGCGATGC 5820
CTGCTTGCCG AATATCATGG TGGAAAATGG CCGCTTTTCT GGATTCATCG ACTGTGGCCG 5880
GCTGGGTGTG GCGGACCGCT ATCAGGACAT AGCGTTGGCT ACCCGTGATA TTGCTGAAGA 5940
GCTTGCGCGG GAATGGGCTG ACCGCTTCCT CGTGCTTTAC GGTATCGCCG CTTCCCGATT 6000
CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG ACGAGTTCTT CTGAGCGGGA CTCTGGGGTT 6060
CGAAATGACC GACCAAGCGA CGCCCAACCT GCCATCACGA GATTCGATT CCACCCCGCG 6120
CTTCTATGAA AGGTTGGGCT TCGGAATCGT TTTCCGGGAC GCCGGCTGGA TGATCCTCCA 6180
GCGCGGGGAT CTCATGCTGG AGTTCCTCGC CCACCCCAAC TTGTTTATTG CAGCTTATAA 6240
TGTTTACAAA TAAAGCAATA GCATCACAAA TTTACAAAAT AAAGCATTTT TTCACTGCA 6300
TTCTAGTTGT GGTGTTGCCA AACTCATCAA TCTATCTTAT CATGTCTGGA TCGCGGCCGC 6360
GATCCCGTCG AGAGCTTGGC GTAATCATGG TCATAGCTGT TTCCTGTGTG AAATTGTTAT 6420
CCGCTCACAA TTCCACACAA CATACGAGCC GGAGCATAAA GTGTAAAGCC TGGGGTGCCT 6480
AATGAGTGAG CTAACTCACA TTAATGCGT TGCGCTCACT GCCCGCTTTC CAGTCGGGAA 6540
ACCTGTGCTG CCAGCTGCAT TAATGAATCG GCCAACGCGC GGGGAGAGGC GGTGTCGTA 6600
TTGGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT CGGCTGCGGC 6660
GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAATCA GGGGATAACG 6720
CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA AAGGCCGCGT 6780
TGCTGGCGTT TTTCCATAGG CTCGCCCCC CTGACGAGCA TCACAAAAAT CGACGCTCAA 6840
GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA GGCCTTTCCC CCTGGAAGCT 6900
CCCTCGTGGC CTCTCCTGTT CCGACCCTGC CGCTTACCGG ATACCTGTCC GCCTTTCTCC 6960
CTTCGGGAA GCTGGCGCTT TCTCAATGCT CACGCTGTAG GTATCTCAGT TCGGTGTAGG 7020
TCGTTGCTC CAAGCTGGGC TGTGTGCACG AACCCCGGT TCAGCCCGAC CGTGCCTCCT 7080
TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG CCACTGGCAG 7140
CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA GAGTCTTGA 7200
AGTGGTGGCC TAACTACGGC TACACTAGAA GGACAGTATT TGGTATCTGC GCTCTGCTGA 7260
AGCCAGTTAC CTTGCGAAAA AGAGTTGGTA GCTCTTGATC CGGCAACAA ACCACCGCTG 7320
GTAGCGGTGG TTTTTTGTG TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG 7380
AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAG 7440
GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA AATTAATAAT 7500
GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAACTTG GTCTGACAGT TACCAATGCT 7560
TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTTC TTCATCCATA GTTGCCTGAC 7620
TCCCGTCTGT GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTCTGCAA 7680
TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC CAGCCAGCCG 7740
GAAGGGCCGA GCGCAGAAGT GGTCTGCAA CTTTATCCGC CTCATCCAG TCTATTAAT 7800
GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTGCCA 7860

US 7,381,560 B2

39

40

-continued

TTGCTACAGG	CATCGTGGTG	TCACGCTCGT	CGTTTGGTAT	GGCTTCATTC	AGCTCCGGTT	7920
CCCAACGATC	AAGGCGAGTT	ACATGATCCC	CCATGTTGTG	CAAAAAAGCG	GTTAGCTCCT	7980
TCGGTCTCTC	GATCGTTGTC	AGAAGTAAGT	TGGCCGCAGT	GTTATCACTC	ATGGTTATGG	8040
CAGCACTGCA	TAATTCTCTT	ACTGTCTATC	CATCCGTAAG	ATGCTTTTCT	GTGACTGGTG	8100
AGTACTCAAC	CAAGTCATTC	TGAGAATAGT	GTATGCGGCG	ACCGAGTTGC	TCTTGCCCGG	8160
CGTCAATACG	GGATAATACC	GCGCCACATA	GCAGAACCTT	AAAAGTGCTC	ATCATTGGAA	8220
AACGTTCTTC	GGGGCGAAAA	CTCTCAAGGA	TCTTACCGCT	GTTGAGATCC	AGTTCGATGT	8280
AACCCACTCG	TGCACCCAAC	TGATCTTCAG	CATCTTTTAC	TTTCACCAGC	GTTTCTGGGT	8340
GAGCAAAAAC	AGGAAGGCAA	AATGCCGCAA	AAAAGGGAAT	AAGGGCGACA	CGGAAATGTT	8400
GAATACTCAT	ACTCTTCCTT	TTTCAATATT	ATTGAAGCAT	TTATCAGGGT	TATTGTCTCA	8460
TGAGCGGATA	CATATTTGAA	TGTATTTAGA	AAAATAAACA	AATAGGGGTT	CCGCGCACAT	8520
TTCCCGGAAA	AGTGCCACCT					8540

(2) INFORMATION FOR SEQ ID NO: 3:

ase pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CCGCTCTAGG	CCTCCAAAA	AGCCTCTCA	CTACTTCTGG	AATAGCTCAG	AATAGCTCAG	60
AGGCCGAGGC	GGCCTCGGC	TCTGCATAAA	TAAAAAAAT	TAGTCAGCCA	TGCATGGGGC	120
GGAGAATGGG	CGAACTGGG	CGGAGTTAGG	GGCGGGATGG	GCGGAGTTAG	GGGCGGGACT	180
ATGGTTGCTG	ACTAATTGAG	ATGCATGCTT	TGCATACTTC	TGCCTGCTGG	GGAGCCTGGG	240
GACTTTCCAC	ACCTGGTTGC	TGACTAATG	AGATGCATGC	TTTGCATACT	TCTGCCTGCT	300
GGGGAGCCTG	GGGACTTTCC	ACACCCTAAC	TGACACACAT	TCCACAGAAT	TAATCCCCCT	360
AGTTATTAAT	AGTAATCAAT	TACGGGGTCA	TTAGTTTATA	GCCATATAT	GGAGTTCCGC	420
GTTACATAAC	TTACGGTAAA	TGGCCCGCCT	GGCTGACCGC	CCAACGACCC	CCGCCCATG	480
ACGTCAATAA	TGACGTATGT	TCCCATAGTA	ACGCCAATAG	GGACTTTCCA	TTGACGTCAA	540
TGGGTGGACT	ATTTACGGTA	AACTGCCAC	TTGGCAGTAC	ATCAAGTGA	TCATATGCCA	600
AGTACGCCCC	CTATTGACGT	CAATGACGGT	AAATGGCCCG	CCTGGCATT	TGCCCAGTAC	660
ATGACCTTAT	GGGACTTTCC	TACTTGGCAG	TACATCTACG	TATTAGTCAT	CGCTATTACC	720
ATGGTGATGC	GGTTTTGGCA	GTACATCAAT	GGCGTGGAT	ACCGGTTTGA	CTCACGCGGA	780
TTTCCAAGTC	TCCACCCCAT	TGACGTCAAT	GGGAGTTTGT	TTTGGCACCA	AAATCAACGG	840
GACTTTCCAA	AATGTCGTAA	CAACTCCGCC	CCATTGACGC	AAATGGGCGG	TAGGCGTGTA	900
CGGTGGGAGG	TCTATATAAG	CAGAGCTGGG	TACGTGAACC	GTCAGATCGC	CTGGAGACGC	960
CATCACAGAT	CTCTCACTAT	GGATTTTCAG	GTGCAGATTA	TCAGCTTCTC	GCTAATCAGT	1020
GCTTCAGTCA	TAATGTCCAG	AGGACAAATT	GTTCTCTCCC	AGTCTCCAGC	AATCCTGTCT	1080
GCATCTCCAG	GGGAGAAGGT	CACAATGACT	TGCAGGGCCA	GCTCAAGTGT	AAGTTACATC	1140
CACTGGTTCC	AGCAGAAGCC	AGGATCCTCC	CCCAAACCCT	GGATTTATGC	CACATCCAAC	1200

US 7,381,560 B2

41

42

-continued

CTGGCTTCTG GAGTCCCTGT TCGCTTCAGT GGCAGTGGGT CTGGGACTTC TTACTCTCTC	1260
ACAATCAGCA GAGTGGAGGC TGAAGATGCT GCCACTTATT ACTGCCAGCA GTGGACTAGT	1320
AACCCACCCA CGTTCGGAGG GGGGACCAAG CTGGAAATCA AACGTACGGT GGCTGCACCA	1380
TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAAGTGC CTCTGTTGTG	1440
TGCCTGCTGA ATAACCTCTA TCCCAGAGAG GCCAAAGTAC AGTGAAGGT GGATAACGCC	1500
CTCCAATCGG GTAACCTCCA GGAGAGTGTC ACAGAGCAGG ACAGCAAGGA CAGCACCTAC	1560
AGCCTCAGCA GCACCTGAC GCTGAGCAAA GCAGACTACG AGAAACACAA AGTCTACGCC	1620
TGCGAAGTCA CCCATCAGGG CCTGAGCTCG CCCGTCACAA AGAGCTTCAA CAGGGGAGAG	1680
TGTTGAATTC AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATTTCGT GACAACATGC	1740
GGCCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT	1800
GTTTGCCCTT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCAC TGTCCTTTCC	1860
TAATAAAATG AGGAAATTC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT	1920
GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT	1980
GCGGTGGGCT CTATGGAACC AGCTGGGGCT CGACAGCTAT GCCAAGTACG CCCCCTATTG	2040
ACGTCAATGA CGGTAATAGG CCCGCCTGGC ATTATGCCA GTACATGACC TTATGGGACT	2100
TTCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT	2160
GGCAGTACAT CAATGGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC	2220
CCATTGACGT CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAAATGTC	2280
GTAACAACCT CGCCCCATTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA	2340
TAAGCAGAGC TGGGTACGTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCCGTCGAC	2400
ATGGGTTGGA GCCTCATCTT GCTCTTCCTT GTCGCTGTTG CTACGCGTGT CCTGTCCCAG	2460
GTACAACTGC AGCAGCCTGG GGCTGAGCTG GTGAAGCCTG GGGCCTCAGT GAAGATGTCC	2520
TGCAAGGCTT CTGGCTACAC ATTTACCAGT TACAATATGC ACTGGGTAAC ACAGACACCT	2580
GGTCGGGGCC TGGAAATGGAT TGGAGCTATT TATCCCGGAA ATGGTGATAC TTCTACAAT	2640
CAGAAGTTCA AAGGCAAGGC CACATTGACT GCAGACAAAT CCTCCAGCAC AGCCTACATG	2700
CAGCTCAGCA GCCTGACATC TGAGGACTCT GCGGTCTATT ACTGTGCAAG ATCGACTTAC	2760
TACGGCGGTG ACTGGTACTT CAATGTCTGG GGCAGGAGGA CCACGGTCAC CGTCTCTGCA	2820
GCTAGCACCA AGGGCCCATC GGTCTTCCCC CTGGCACCCCT CCTCCAAGAG CACCTCTGGG	2880
GGCACAGCGG CCCTGGGCTG CCTGGTCAAG GACTACTTCC CCGAACCGGT GACGGTGTG	2940
TGGAACTCAG GCGCCCTGAC CAGCGGCGTG CACACCTTCC CGGCTGTCTT ACAGTCTCTA	3000
GGACTCTACT CCCTCAGCAG CGTGGTGACC GTGCCCTCCA GCAGCTTGGG CACCCAGACC	3060
TACATCTGCA ACGTGAATCA CAAGCCAGC AACACCAAGG TGGACAAGAA AGCAGAGCCC	3120
AAATCTTGTG ACAAACCTCA CACATGCCA CCGTGCCAG CACCTGAACT CCTGGGGGGA	3180
CCGTCACTCT TCCTCTTCCC CCCAAAACCC AAGGACACCC TCATGATCTC CCGGACCCCT	3240
GAGGTCACAT GCGTGGTGGT GGACGTGAGC CACGAAGACC CTGAGGTCAA GTTCAACTGG	3300
TACGTGGACG GCGTGGAGGT GCATAATGCC AAGACAAAGC CGCGGGAGGA GCAGTACAAC	3360
AGCACGTACC GTGTGGTACG CGTCTCACC GTCCTGCACC AGGACTGGCT GAATGGCAAG	3420
GAGTACAAGT GCAAGGTCTC CAACAAAGCC CTCCAGCCC CCATCGAGAA AACCATCTCC	3480
AAAGCCAAAG GGCAGCCCCG AGAACCACAG GTGTACACCC TGCCCCATC CCGGGATGAG	3540
CTGACCAAGA ACCAGGTCAG CCTGACCTGC CTGGTCAAAG GCTTCTATCC CAGCGACATC	3600

US 7,381,560 B2

43

44

-continued

GCCGTGGAGT	GGGAGAGCAA	TGGGCAGCCG	GAGAACAAC	ACAAGACCAC	GCCTCCCGTG	3660
CTGGACTCCG	ACGGCTCCTT	CTTCCTCTAC	AGCAAGCTCA	CCGTGGACAA	GAGCAGGTGG	3720
CAGCAGGGGA	ACGTCTTCTC	ATGCTCCGTG	ATGCATGAGG	CTCTGCACAA	CCACTACACG	3780
CAGAAGAGCC	TCTCCCTGTC	TCCGGGTAAA	TGAGGATCCG	TTAACGGTTA	CCAACTACCT	3840
AGACTGGATT	CGTGACAACA	TGCGGCCGTG	ATATCTACGT	ATGATCAGCC	TCGACTGTGC	3900
CTTCTAGTTG	CCAGCCATCT	GTTGTTTGCC	CCTCCCCCGT	GCCTTCCTTG	ACCCTGGAAG	3960
GTGCCACTCC	CACTGTCCCT	TCCTAATAAA	ATGAGGAAAT	TGCATCGCAT	TGTCTGAGTA	4020
GGTGTCAATC	TATTCTGGGG	GGTGGGGTGG	GGCAGGACAG	CAAGGGGGAG	GATTGGGAAG	4080
ACAATAGCAG	GCATGCTGGG	GATGCGGTGG	GCTCTATGGA	ACCAGCTGGG	GCTCGACAGC	4140
GCTGGATCTC	CCGATCCCCA	GCTTTGCTTC	TCAATTTCTT	ATTTGCATAA	TGAGAAAAAA	4200
AGGAAAATTA	ATTTTAAAC	CAATTCACTA	GTTGATTGAG	CAAATGCGTT	GCCAAAAAGG	4260
ATGCTTTAGA	GACAGTGTTT	TCTGCACAGA	TAAGGACAAA	CATTATTGAG	AGGGAGTACC	4320
CAGAGCTGAG	ACTCCTAAGC	CAGTGAGTGG	CACAGCATT	TAGGGAGAAA	TATGCTTGTC	4380
ATCACCGAAG	CCTGATTCCG	TAGAGCCACA	CCTTGGTAAG	GGCCAATCTG	CTCACACAGG	4440
ATAGAGAGGG	CAGGAGCCAG	GGCAGAGCAT	ATAAGGTGAG	GTAGGATCAG	TTGCTCCTCA	4500
CATTGCTTTC	TGACATAGTT	GTGTTGGGAG	CTTGGATAGC	TTGGACAGCT	CAGGGCTGCG	4560
ATTCGCGCC	AAACTTGACG	GCAATCCTAG	CGTGAAGGCT	GGTAGGATTT	TATCCCCGCT	4620
GCCATCATGG	TTGACCATTT	GAAGTGCATC	GTCGCCGTGT	CCCCAAATAT	GGGGATTGGC	4680
AAGAACGGAG	ACCTACCCCTG	GCCTCCGCTC	AGGAACGAGT	TCAAGTACTT	CCAAAGAATG	4740
ACCACAACCT	CTTCAGTGGA	AGGTAACAG	AATCTGGTGA	TTATGGGTAG	GAAAACCTGG	4800
TTCTCCATTC	CTGAGAAGAA	TCGACCTTTA	AAGGACAGAA	TTAATATAGT	TCTCAGTAGA	4860
GAAGTCAAAG	AACCACCACG	AGGAGCTCAT	TTTCTTGCCA	AAAGTTTGGG	TGATGCCTTA	4920
AGACTTATTG	AACAACCGGA	ATTGGCAAGT	AAAGTAGACA	TGGTTTGGAT	AGTCGGAGGC	4980
AGTTCGTGTT	ACCAGGAAGC	CATGAATCAA	CCAGGCCACC	TTAGACTCTT	TGTGACAAGG	5040
ATCATGCAGG	AATTTGAAAG	TGACACGTTT	TTCCAGAAA	TTGATTTGGG	GAAATATAAA	5100
CTTCTCCAG	AATACCCAGG	CGTCTCTCT	GAGGTCCAGG	AGGAAAAAGG	CATCAAGTAT	5160
AAGTTTGAAG	TCTACGAGAA	GAAAGACTAA	CAGGAAGATG	CTTTCAAGTT	CTCTGCTCCC	5220
CTCCTAAAGC	TATGCATTTT	TATAAGACCA	TGGGACTTTT	GCTGGCTTTA	GATCAGCCTC	5280
GACTGTGCCT	TCTAGTTGCC	AGCCATCTGT	TGTTTGCCCC	TCCCCCGTGC	CTTCTTTGAC	5340
CCTGGAAGGT	GCCACTCCCA	CTGTCCTTTC	CTAATAAAAT	GAGGAAATTG	CATCGCATTG	5400
TCTGAGTAGG	TGTCATTCTA	TTCTGGGGGG	TGGGTGGGG	CAGGACAGCA	AGGGGGAGGA	5460
TTGGAAGAC	AATAGCAGGC	ATGCTGGGGA	TGCGGTGGGC	TCTATGGAAC	CAGCTGGGGC	5520
TCGAGCTACT	AGCTTTGCTT	CTCAATTTCT	TATTGTCATA	ATGAGAAAAA	AAGGAAAATT	5580
AATTTTAAAC	CCAATTCAGT	AGTTGATTGA	GCAATGCGT	TGCCAAAAAG	GATGCTTTAG	5640
AGACAGTGTT	CTCTGCACAG	ATAAGGACAA	ACATTATTCA	GAGGGAGTAC	CCAGAGCTGA	5700
GACTCCTAAG	CCAGTGAGTG	GCACAGCATT	CTAGGGAGAA	ATATGCTTGT	CATCACCGAA	5760
GCCTGATTCC	GTAGAGCCAC	ACCTTGGTAA	GGGCCAATCT	GCTCACACAG	GATAGAGAGG	5820
GCAGGAGCCA	GGCAGAGCA	TATAAGGTGA	GGTAGGATCA	GTTGCTCCTC	ACATTTGCTT	5880
CTGACATAGT	TGTGTTGGGA	GCTTGGATCG	ATCCTCTATG	GTTGAACAAG	ATGGATTGCA	5940

US 7,381,560 B2

45

46

-continued

CGCAGGTTCT	CCGGCCGCTT	GGGTGGAGAG	GCTATTCGGC	TATGACTGGG	CACAACAGAC	6000
AATCGGCTGC	TCTGATGCCG	CCGTGTTCCG	GCTGTCAGCG	CAGGGGCGCC	CGGTTCTTTT	6060
TGTCAAGACC	GACCTGTCCG	GTGCCCTGAA	TGAACTGCAG	GACGAGGCAG	CGCGGCTATC	6120
GTGGCTGGCC	ACGACGGGCG	TTCCTTGCGC	AGCTGTGCTC	GACGTTGTCA	CTGAAGCGGG	6180
AAGGGACTGG	CTGCTATTGG	GCGAAGTGCC	GGGGCAGGAT	CTCCTGTTCAT	CTCACCTTGC	6240
TCCTGCCGAG	AAAGTATCCA	TCATGGCTGA	TGCAATGCGG	CGGCTGCATA	CGCTTGATCC	6300
GGCTACCTGC	CCATTGACCC	ACCAAGCGAA	ACATCGCATC	GAGCGAGCAC	GTAAGCTGGT	6360
GGAAGCCGGT	CTTGTGATC	AGGATGATCT	GGACGAAGAG	CATCAGGGGC	TCGCGCCAGC	6420
CGAAGTGTTC	GCCAGGCTCA	AGGCGCGCAT	GCCCGACGGC	GAGGATCTCG	TCGTGACCCA	6480
TGGCGATGCC	TGCTTCCGCA	ATATCATGGT	GGAAAATGGC	CGTTTTCTG	GATTCATCGA	6540
CTGTGGCCGG	CTGGGTGTGG	CGGACCGCTA	TCAGGACATA	GCGTTGGCTA	CCCGTGATAT	6600
TGCTGAAGAG	CTTGGCGGCG	AATGGGCTGA	CCGCTTCCCT	GTGCTTTACG	GTATCGCCGC	6660
TCCCATTTCG	CAGCGCATCG	CCTTCTATCG	CCTTCTTGAC	GAGTTCTTCT	GAGCGGGACT	6720
CTGGGGTTCG	AAATGACCCA	CCAAGCGACG	CCCAACCTGC	CATCACGAGA	TTTCGATTCC	6780
ACCGCCGCCT	TCTATGAAAG	GTTGGGCTTC	GGAATCGTTT	TCCGGGACGC	CGGCTGGATG	6840
ATCCTCCAGC	GCGGGGATCT	CATGCTGGAG	TTCTTCGCCC	ACCCCAACTT	GTTTATTGCA	6900
GCTTATAATG	GTACAAATA	AAGCAATAGC	ATCACAAATT	TCACAAATA	AGCATTTTTT	6960
TCACTGCATT	CTAGTTGTGG	TTTGTCCAAA	CTCATCAATC	TATCTTATCA	TGTCTGGATC	7020
GCGGCCGCGA	TCCCGTGCAG	AGCTTGGCGT	AATCATGGTC	ATAGCTGTTT	CCTGTGTGAA	7080
ATTGTTATCC	GCTCACAATT	CCACACAACA	TACGAGCCGG	AAGCATAAAG	TGTAAAGCCT	7140
GGGGTGCCCTA	ATGAGTGAGC	TAAGTCCAT	TAATTGCGTT	GCGCTCACTG	CCCGCTTTC	7200
AGTCGGGAAA	CCTGTCGTGC	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	7260
GTTTGCATAT	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	TCGGTCGTTC	7320
GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	ACGTTTATCC	ACAGAAATCAG	7380
GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	AAGCCAGCA	AAAGCCAGG	AACCGTAAAA	7440
AGGCCGCGTT	GCTGGCGTTC	TCCCATAGGC	TCCGCCCCCC	TGACGAGCAT	CACAAAAATC	7500
GACGCTCAAG	TCAGAGGTGG	CGAAACCCGA	CAGGACTATA	AAGATACCAG	GCGTTTCCCC	7560
CTGGAAGCTC	CCTCGTGCGC	TCTCCTGTTC	CGACCTGACC	GCTTACCGGA	TACCTGTCCG	7620
CCTTCTTCCC	TTCGGGAAGC	GTGGCGCTTT	CTCAATGCTC	ACGCTGTAGG	TATCTCAGTT	7680
CGGTGTAGGT	CGTTCGCTCC	AAGCTGGGCT	GTGTGCACGA	ACCCCCGTT	CAGCCCGACC	7740
GCTGCGCCTT	ATCCGGTAAC	TATCGTCTTG	AGTCCAACCC	GGTAAGACAC	GACTTATCGC	7800
CACTGGCAGC	AGCCACTGGT	AACAGGATTA	GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	7860
AGTTCTTGAA	GTGGTGGCCT	AACTACGGCT	ACACTAGAAG	GACAGTATTT	GGTATCTGCG	7920
CTCTGCTGAA	GCCAGTTACC	TTCGGAAAAA	GAGTTGGTAG	CTCTTGATCC	GGCAACAAA	7980
CCACCGCTGG	TAGCGGTGGT	TTTTTTGTTT	GCAAGCAGCA	GATTACGCGC	AGAAAAAAG	8040
GATCTCAAGA	AGATCCTTTG	ATCTTTTCTA	CGGGGTCTGA	CGCTCAGTGG	AACGAAAACT	8100
CACGTTAAGG	GATTTTGGTC	ATGAGATTAT	CAAAAAGGAT	CTTACCTTAG	ATCCTTTTAA	8160
ATTAATAAATG	AAGTTTTTAA	TCAATCTAAA	GTATATATGA	GTAAACTTGG	TCTGACAGTT	8220
ACCAATGCTT	AATCAGTGAG	GCACCTATCT	CAGCGATCTG	TCTATTTCTG	TCATCCATAG	8280
TGCTGACT	CCCCGCTGTC	TAGATAACTA	CGATACGGGA	GGGCTTACCA	TCTGGCCCCA	8340

US 7,381,560 B2

47

48

-continued

GTGCTGCAAT GATACCGCGA GACCCACGCT CACCGGCTCC AGATTTATCA GCAATAAACC 8400
AGCCAGCCGG AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT 8460
CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT TTGCGCAACG 8520
TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG GCTTCATTCA 8580
GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC AAAAAAGCGG 8640
TTAGCTCCTT CGGTCCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGAGTG TTATCACTCA 8700
TGTTTATGGC AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTTCTG 8760
TGACTGGTGA GTACTCAACC AAGTCATTCT GAGAATAGTG TATCGGCGA CCGAGTTGCT 8820
CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA AAAGTGCTCA 8880
TCATTGAAA ACGTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG TTGAGATCCA 8940
GTTGATGTA ACCCACTCGT GCACCCAAC TATCTTCAGC ATCTTTTACT TTCACCAGCG 9000
TTTCTGGGTG AGCAAAAACA GGAAGGCAAA ATGCCGCAA AAAGGAATA AGGGCGACAC 9060
GGAAATGTTG AATACTATA CTCTTCTTTT TCAATATTA TTGAAGCATT TATCAGGGTT 9120
ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAACAA ATAGGGGTTT 9180
CGCGCACATT TCCCCGAAA GTGCCACCT 9209

(2) INFORMATION FOR SEQ ID NO: 4:
TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TCTCACCATG GATTTTCAGG TGCAGATTAT CAGCTTC 47

(2) INFORMATION FOR SEQ ID NO: 5:
CE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TACGTTTGA TTTCCAGCTT 30

(2) INFORMATION FOR SEQ ID NO: 6:
CHARACTERISTICS:
(A) LENGTH: 384 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

US 7,381,560 B2

49

50

-continued

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..384

(ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 67..384

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CAG ATT ATC AGC TTC CTG CTA ATC AGT GCT TCA	48
Met Asp Phe Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser	
-22 -20 -15 -10	
GTC ATA ATG TCC AGA GGG CAA ATT GTT CTC TCC CAG TCT CCA GCA ATC	96
Val Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile	
-5 -1 1 5 10	
CTG TCT GCA TCT CCA GGG GAG AAG GTC ACA ATG ACT TGC AGG GCC AGC	144
Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser	
15 20 25	
TCA AGT GTA AGT TAC ATC CAC TGG TTC CAG CAG AAG CCA GGA TCC TCC	192
Ser Ser Val Ser Tyr Ile His Trp Phe Gln Lys Pro Gly Ser Ser	
30 35 40	
CCC AAA CCC TGG ATT TAT GCC ACA TCC AAC CTG GCT TCT GGA GTC CCT	240
Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro	
45 50 55	
GTT CGC TTC AGT GGC AGT GGG TCT GGG ACT TCT TAC TCT CTC ACA ATC	288
Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile	
60 65 70	
AGC AGA GTG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAG TGG	336
Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp	
75 80 85 90	
ACT AGT AAC CCA CCC ACG TTC GGA GGG GGG ACC AAG CTG GAA ATC AAA	384
Thr Ser Asn Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys	
95 100 105	

(2) INFORMATION FOR SEQ ID NO: 7:
 :
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GCGTGCCT GTCCCAG

27

(2) INFORMATION FOR SEQ ID NO: 8:
 CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 3
 (D) OTHER INFORMATION: /note= "Nucleotide 3 is N wherein N is G or C."

US 7,381,560 B2

51

52

-continued

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 18
 (D) OTHER INFORMATION: /note= "Nucleotide 18 is N wherein N is A or C."
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 19
 (D) OTHER INFORMATION: /note= "Nucleotide 19 is N wherein N is A or G."
- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 25
 (D) OTHER INFORMATION: /note= "Nucleotide 25 is N wherein N is G or A."
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

erein

N is G or A."

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 420 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..420
- (ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 58..420
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATG GGT TGG AGC CTC ATC TTG CTC TTC CTT GTC GCT GTT GCT ACG CGT	48
Met Gly Trp Ser Leu Ile Leu Leu Phe Leu Val Ala Val Ala Thr Arg	
-19 -15 -10 -5	
GTC CTG TCC CAG GTA CAA CTG CAG CAG CCT GGG GCT GAG CTG GTG AAG	96
Val Leu Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys	
-1 1 5 10	
CCT GGG GCC TCA GTG AAG ATG TCC TGC AAG GCT TCT GGC TAC ACA TTT	144
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe	
15 20 25	
ACC AGT TAC AAT ATG CAC TGG GTA AAA CAG ACA CCT GGT CGG GGC CTG	192
Thr Ser Tyr Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu	
30 35 40 45	
GAA TGG ATT GGA GCT ATT TAT CCC GGA AAT GGT GAT ACT TCC TAC AAT	240
Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn	
50 55 60	
CAG AAG TTC AAA GGC AAG GCC ACA TTG ACT GCA GAC AAA TCC TCC AGC	288
Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser	
65 70 75	
ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG GAC TCT GCG GTC	336
Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val	
80 85 90	

US 7,381,560 B2

53

54

-continued

TAT TAC TGT GCA AGA TCG ACT TAC TAC GGC GGT GAC TGG TAC TTC AAT	384
Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn	
95 100 105	
GTC TGG GGC GCA GGG ACC ACG GTC ACC GTC TCT GCA	420
Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ala	
110 115 120	

What is claimed is:

1. A host cell comprising nucleic acid sequences encoding the light chain and the heavy chain of an immunologically active chimeric anti-CD20 antibody, wherein the sequence encoding the light chain comprises a nucleotide sequence encoding amino acid residues 23 to 128 of SEQ ID NO: 4, and the sequence encoding the heavy chain comprises a nucleotide sequence encoding amino acid residues 20 to 140 of SEQ ID NO: 6, wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody.

2. The host cell of claim 1 wherein the sequence encoding the light chain further comprises a nucleotide sequence encoding a human kappa light chain constant region, and the sequence encoding the heavy chain further comprises a nucleotide sequence encoding a human gamma 1 heavy chain constant region.

3. A method of making a purified antibody comprising expressing the light and heavy chains encoded by the nucleic acid sequences in the host cell of claim 1 and purifying the antibody produced by the host cell.

4. The method of claim 3 further comprising combining the purified antibody with a pharmaceutically acceptable buffer.

5. The method of claim 3 further comprising combining the purified antibody with a pharmaceutical carrier.

6. The host cell of claim 1, wherein the host cell comprises an expression vector or separate expression vectors comprising the nucleic acid sequences encoding the light chain and the heavy chain.

7. The host cell of claim 1, wherein the host cell comprises an expression plasmid or separate expression plasmids comprising the nucleic acid sequences encoding the light chain and the heavy chain.

8. The host cell of claim 1 which is a mammalian cell.

9. The host cell of claim 1 which is a Chinese Hamster Ovary (CHO) cell.

10. The host cell of claim 1 which is an SP2/0 cell.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 1 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Strike the entire sequence listing (col. 31/32, line 15, through col. 53/54, line 10) and replace it with the following

--

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 11

<210> SEQ ID NO 1

<211> LENGTH: 8540

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: vector

<220> FEATURE:

<223> OTHER INFORMATION: sense orientation

<400> SEQUENCE: 1

gacgtcgcgg	ccgctctagg	cctccaaaa	agcctcctca	ctacttctgg	aatagctcag	60
aggccgaggc	ggcctcggcc	tctgcataaa	taaaaaaat	tagtcagcca	tgcattggggc	120
ggagaatggg	cggaactggg	cggagttagg	ggcgggatgg	gaggagttag	gggcgggact	180
atggttgctg	actaattgag	atgcatgctt	tgcatacttc	tgcttgctgg	ggagcctggg	240
gactttccac	acctgggttc	tgactaattg	agatgcatgc	tttgcatact	tctgcctgct	300

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 2 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

ggggagcctg	gggactttcc	acaccctaac	tgacacacat	tccacagaat	taattcccct	360
agttattaat	agtaateaat	tacggggtca	ttagttcata	gcccataat	ggagttccgc	420
gttacataac	ttacggtaaa	tggcccgcct	ggctgaccgc	ccaacgaccc	ccgcccattg	480
acgtcaataa	tgacgtatgt	tcccatagta	acgccaatag	ggactttcca	ttgacgtcaa	540
tgggtggact	atttacggta	aaotgcccac	ttggcagtac	atcaagtgtg	tcatatgcca	600
agtaagcccc	ctattgacgt	caatgacggg	aaatggcccc	cctggcatta	tgcccagtac	660
atgacottat	gggactttcc	tacttggcag	tacatctacg	tattagtcac	cgctattacc	720
atggtgatgc	ggttttggca	gtacatcaat	gggcgtggat	agcggtttga	ctcacgggga	780
tttccaagtc	tccaccccac	tgacgtcaat	gggagtttgt	tttggcacca	aaatcaacgg	840
gactttccaa	aatgtcgtaa	caactccgcc	ccattgacgc	aaatggggcg	taggcgtgta	900
cggtgggagg	tctatataag	cagagctggg	tacgtgaacc	gtcagatcgc	ctggagacgc	960
catcacagat	ctctcaccat	gaggggtccc	gctcagctcc	tggggctcct	gctgctctgg	1020
ctcccaggtg	cacgatgtga	tggtagcaag	gtggaaatca	aacgtacggg	ggctgcacca	1080
tctgtcttca	tcttcccgc	atctgatgag	cagttgaaat	ctggaactgc	ctctgttgtg	1140
tgctgtctga	ataacttcta	tcccagagag	gccaaagtac	agtggaaggt	ggataacgcc	1200
ctccaatcgg	gtaactccca	ggagagtgtc	acagagcagg	acagcaagga	cagcacctac	1260
agcctcagca	gcaccctgac	gctgagcaaa	gcagactacg	agaaacacaa	agtctacgcc	1320
tgccaagtca	cccacaggg	cctgagctcg	cccgtcacaa	agagcttcaa	caggggagag	1380
tgttgaattc	agatccgtta	acggttacca	actacctaga	ctggattcgt	gacaacatgc	1440
ggcctgata	tctacgtatg	atcagcctcg	actgtgcctt	ctagttgcca	gccatctggt	1500
gtttgcccct	cccccgctgc	tcccttgacc	ctggaaggtg	ccactcccac	tgctcctttcc	1560
taataaaatg	aggaaattgc	atcgcattgt	ctgagtaggt	gtcattctat	tctgggggggt	1620
ggggtggggc	aggacagcaa	gggggaggat	tgggaagaca	atagcaggca	tgctggggat	1680
gagggtgggct	ctatggaaac	agctggggct	cgacagctat	gccaagtacg	ccccctattg	1740
acgtcaatga	cggtaaatgg	cccgcctggc	attatgcccc	gtacatgacc	ttatgggact	1800
ttcctaactg	gcagtacatc	tacgtattag	tcatcgtat	taccatgggtg	atgcccgtttt	1860

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 3 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

ggcagtacat	caatgggagt	ggatagcggt	ttgactcagc	gggatttcca	agtctccacc	1920
ccattgacgt	caatgggagt	ttgttttggc	accaaaatca	acgggacttt	ccaaaatgtc	1980
gtaacaactc	cgccccattg	acgcaaattg	gcggtaggcg	tgtacggtgg	gaggtctata	2040
taagcagagc	tgggtacgtc	ctcacattca	gtgatcagca	ctgaacacag	acccgtcgac	2100
atgggttggg	gcctcatctt	gctcttctct	gtcgtgtgtg	ctacgcgtgt	cgctagcacc	2160
aagggcccat	cggtcttccc	cctggcacc	tctccaaga	gcacctctgg	gggcacagcg	2220
gcctgggct	gcctgggcaa	ggactacttc	cccgaaccgg	tgacggtgtc	gtggaactca	2280
ggcgccctga	ccagggcggt	gcacaccttc	ccggctgtcc	tacagtctct	aggactctac	2340
tcctcagca	gcgtgggtgac	cgtgccctcc	agcagcttgg	gcacccagac	ctacatctgc	2400
aacgtgaatc	acaagcccag	caacaccaag	gtggacaaga	aagcagagcc	caaactctgt	2460
gacaaaactc	acacatgccc	accgtgccc	gcacctgaac	tctggggggg	accgtcagtc	2520
ttctcttcc	ccccaaaacc	caaggacacc	ctcatgatct	cccgacccc	tgaggtcaca	2580
tgcgtgggtg	tggacgtgag	ccacgaagac	cctgaggtca	agttcaactg	gtacgtggac	2640
ggcgtggagg	tgcataatgc	caagacaag	ccgcgggagg	agcagtacaa	cagcacgtac	2700
cgtgtggta	gcgtcctcac	cgctctgcac	caggactggc	tgaatggcaa	ggactacaag	2760
tgcaaggtct	ccaacaaagc	cctcccagcc	cccctcgaga	aaaccatctc	caaagccaaa	2820
gggcagcccc	gagaaccaca	ggtgtacacc	ctgccccat	cccgggatga	gctgaccagg	2880
aaccaggta	gcctgacctg	cctgggcaaa	ggcttctatc	ccagcgacat	cgccgtggag	2940
tgggagagca	atgggcagcc	ggagaacaac	tacaagacca	cgctcccgt	gctggactcc	3000
gacggctct	tcttctctta	cagcaagctc	accgtggaca	agagcaggtg	gcagcagggg	3060
aacgtctct	catgctccgt	gatgcatgag	gctctgcaca	accactacac	gcagaagagc	3120
ctctccctgt	ctccgggtaa	atgaggatcc	gttaacggtt	accaactacc	tagactggat	3180
tcgtgacaac	atcgggccgt	gatatctacg	tatgatcagc	ctcgactgtg	cttctagtt	3240
gccagccatc	tgttgtttgc	ccctcccccg	tgcttctctt	gacctggaa	ggtgccactc	3300
ccactgtct	ttcctaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	3360
ctattctggg	gggtgggggtg	gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	3420

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 4 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

ggcatgctgg	ggatgcggtg	ggctctatgg	aaccagctgg	ggctcgacag	cgctggatct	3480
ccogatcccc	agctttgctt	ctcaatttct	tatttgcata	atgagaaaaa	aaggaaaatt	3540
aattttaaca	ccaattcagt	agttgattga	gcaaatgogt	tgccaaaaag	gatgctttag	3600
agacagtggt	ctctgcacag	ataaggacaa	acattattca	gagggagtac	ccagagctga	3660
gactcctaag	ccagtgagtg	gcacagcatt	ctagggagaa	atatgcttgt	catcaccgaa	3720
gcctgattcc	gtagagccac	accttggtaa	gggccaatct	gctcacacag	gatagagagg	3780
gcaggagcca	gggcagagca	tataaggtga	ggtaggatca	gttgctcctc	acatttgctt	3840
ctgacatagt	tgtggtggga	gcttggatag	cttggacagc	tcagggtgct	gatttcgcgc	3900
caaaactgac	ggcaatccta	gcgtgaaggc	tggtaggatt	ttatccccgc	tgccatcatg	3960
gttcgaccat	tgaactgcat	cgctgcctgt	tcccaaaata	tggggattgg	caagaacgga	4020
gacctaccct	ggcctccgct	caggaacgag	tccaagtact	tccaaagaat	gaccacaacc	4080
tcttcagtgg	aaggtaaaca	gaatctggtg	attatgggta	ggaaaacctg	gttctccatt	4140
cctgagaaca	atcgaccttt	aaaggacaga	attaatatag	ttctcagtag	agaactcaaa	4200
gaaccaccac	gaggagctca	ttttcttgcc	aaaagtttgg	atgatgcctt	aagacttatt	4260
gaacaaccgg	aattggcaag	taaagtagac	atggtttggg	tagtcggagg	cagttctgtt	4320
taccaggaag	ccatgaatca	accaggccac	cttagactct	ttgtgacaag	gatcatgcag	4380
gaatttgaaa	gtgacacgtt	tttcccagaa	attgatttgg	ggaaatataa	acttctccca	4440
gaatacccag	gggtcctctc	tgaggtccag	gaggaaaaag	gcatacaagta	taagtttgaa	4500
gtctacgaga	agaaagacta	acaggaagat	gctttcaagt	tctctgctcc	cctcctaag	4560
tcatgcattt	ttataagacc	atgggacttt	tgctggcttt	agatcagcct	cgactgtgcc	4620
ttctagttgc	cagccatctg	ttgtttgccc	ctccccctgt	ccttccttga	ccctggaagg	4680
tgccactccc	actgtccttt	cctaataaaa	tgaggaaatt	gcatcgcatt	gtctgagtag	4740
gtgtcattct	attctggggg	gtgggtggg	gcaggacagc	aagggggagg	attgggaaga	4800
caatagcagg	catgctgggg	atgcggtggg	ctctatggaa	ccagctgggg	ctcgagctac	4860
tagctttget	tctcaatttc	ttatttgcac	aatgagaaaa	aaaggaaaat	taattttaac	4920
accaattcag	tagttgattg	agcaaatgcg	ttgcaaaaaa	ggatgcttta	gagacagtgt	4980

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 5 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

tctctgcaca	gataaggaca	aacattatct	agagggagta	cccagagctg	agactcctaa	5040
gccagtgagt	ggcacagcat	tctagggaga	aatatgcttg	tcataccga	agcctgattc	5100
cgtagageca	caccttggtg	agggccaatc	tgctcacaca	ggatagagag	ggcaggagcc	5160
agggcagagc	atataaggtg	aggtaggatc	agttgctcct	cacatttgct	tctgacatag	5220
ttgtggtggg	agcttggatc	gatcctctat	ggttgaacaa	gatggattgc	acgcaggttc	5280
tccggccgct	tgggtggaga	ggctattcgg	ctatgactgg	gcacaacaga	caatcggctg	5340
ctctgatgcc	gocgtgttcc	ggctgtcagc	gcagggggcg	ccggttcttt	ttgtcaagac	5400
cgacctgtcc	ggtgccctga	atgaactgca	ggacgaggca	gcgcggctat	cgtggctggc	5460
cacgacgggc	gttcttgcg	cagctgtgct	cgacgttgct	actgaagcgg	gaagggactg	5520
gctgctattg	ggcgaagtgc	cggggcagga	tctcctgtca	tctcaccttg	ctcctgccga	5580
gaaagtatcc	atcatggctg	atgcaatgcg	gocgctgcat	acgcttgatc	cggctacctg	5640
cccattcgac	caccaagcga	aacatcgcct	cgagccagca	cgtactcgga	tggaaagccg	5700
tcttgtcgat	caggatgatc	tggacgaaga	gcatacaggg	ctcgcgccag	ccgaactggt	5760
cgccaggctc	aaggcgcgca	tgcccagcgg	cgaggatctc	gtcgtgacct	atggcgatgc	5820
ctgcttgccg	aatatcatgg	tggaaaatgg	cgccttttct	ggattcactc	actgtggccg	5880
gctgggtgtg	gaggaaccgt	atcaggacat	agcgttggtc	accogtgata	ttgctgaaga	5940
gcttggcggc	gaatgggctg	accgcttctc	cgtgctttac	ggtatcgccg	ctcccgatte	6000
gcagcgcctc	gccttctatc	gccttcttga	cgagttcttc	tgagcgggac	tctggggttc	6060
gaaatgaccg	accaagcgcg	gcccacctcg	ccatacagag	atttcgatte	caccgcccgc	6120
ttctatgaaa	ggttgggctt	cggaatcgtt	ttccgggacg	ccggctggat	gatcctccag	6180
cgccggggatc	tcatgctgga	gttctctgcc	caccccaact	tgtttattgc	agcttataat	6240
ggttacaaat	aaagcaatag	catcacaaat	ttcacaaata	aagcattttt	ttcactgcat	6300
tctagttgtg	gtttgtccaa	actcatcaat	ctatcttata	atgtctggat	cgcggccgcg	6360
atcccgtcga	gagcttggcg	taatcatggt	catagctggt	tcctgtgtga	aattgttata	6420
cgctcacaat	tccacacaac	atacgagccg	gaagcataaa	gtgtaaagcc	tgggggtgct	6480
aatgagtgag	ctaactcaca	ttaattgcgt	tgcgctcact	gcccgccttc	cagtcgggaa	6540

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 6 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

acctgtcgtg	ccagctgcat	taatgaatcg	gccaacgcgc	ggggagaggc	ggtttgcgta	6600
ftgggocctc	ttocgcttcc	tcgctcactg	actcgcctgcg	ctcggctcgtt	cggtcgcggc	6660
gagcgggtatc	agctcactca	aaggcggtaa	tacggttatc	cacagaatca	ggggataacg	6720
caggaaagaa	catgtgagca	aaaggccagc	aaaaggccag	gaaccgtaaa	aaggccgcgt	6780
tgctggcggt	tttccatagg	ctccgcccc	ctgacgagca	tcacaaaaat	cgacgctcaa	6840
gtcagaggtg	gogaaaacccg	acaggactat	aaagatacca	ggcgtttccc	cctggaagct	6900
ccctcgtgog	ctctcctggt	ccgaccctgc	cgcttaccgg	atacctgtcc	gcctttctcc	6960
cttcgggaag	cgtggcgctt	tctcaatgct	cacgcctgtag	gstatctcagt	tcgggtgtagg	7020
tcgttcgctc	caagctggggc	tgtgtgcaoc	aacccccgct	tcageccgac	cgctgcgcct	7080
tatccggtaa	ctatcgtctt	gagtocaaoc	cggtaaagaca	cgacttatcg	ccactggcag	7140
cagccactgg	taacaggatt	agcagagcga	ggtatgtagg	cggtgctaca	gagttcttga	7200
agtgggtggc	taactacggc	tacactagaa	ggacagttat	tggtatctgc	gctctgctga	7260
agccagttac	cttcggaaaa	agagttggta	gctcttgatc	cggaacaaa	accaccgctg	7320
gtagcgggtg	tttttttgtt	tgcaagcagc	agattacgcg	cagaaaaaaaa	ggatctcaag	7380
aagatccttt	gatcttttct	acgggggtctg	acgctcagtg	gaacgaaaa	tcacgttaag	7440
ggattttgg	catgagatta	tcaaaaagga	tcttcacctc	gatcctttta	aattaaaaat	7500
gaagttttaa	atcaatctaa	agtatatatg	agtaaacttg	gtctgacagt	taccaatgct	7560
taatcagtga	ggcacctatc	tcagcgatct	gtctatttctg	ttcatccata	gttgcctgac	7620
tcccgcgtct	gtagataact	acgatacggg	aggccttacc	atctggcccc	agtgcctgcaa	7680
tgataccgcg	agacccacgc	tcacccgctc	cagatttatc	agcaataaac	cagccagccg	7740
gaagggccga	gcgcagaagt	ggtcctgcaa	ctttatccgc	ctccatccag	tctattaatt	7800
gttgccggga	agctagagta	agtagttcgc	cagttaatag	tttgcccaac	gttggtgcca	7860
ttgetacagg	catcgtgggtg	tcacgctcgt	cgtttggtat	ggcttcatte	agctccgggt	7920
cccaacgatc	aaggcgagtt	acatgatccc	ccatgttctg	caaaaaagcg	gtagctcct	7980
tcggctcctc	gategttctc	agaagtaagt	tggccgcagt	ggtatcactc	atgggtatgg	8040
cagcactgca	taattctctt	actgtcatgc	catccgtaag	atgcttttct	gtgactgggtg	8100

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 7 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

```
agtactcaac caagtcattc tgagaatagt gtatgcggcg accgagttgc tcttgcccgg 8160
cgtcaatacg ggataatacc gcgccacata gcagaacttt aaaagtgctc atcattggaa 8220
aacgttcttc ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt 8280
aaccactcg tgcacccaac tgatcttcag catcttttac tttcaccagc gtttctgggt 8340
gagcaaaaac aggaaggcaa aatgccgcaa aaaaggggat aagggcgaca cggaaatggt 8400
gaatactcat actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca 8460
tgagcggata catatctgaa tgtatttaga aaaataaaca aatagggggt ccgcgccat 8520
ttccccgaaa agtgccacct 8540
```

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 8 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 2
 <211> LENGTH: 9209
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence

<220> FEATURE:
 <223> OTHER INFORMATION: vector with chimeric antibody sequence

<220> FEATURE:
 <223> OTHER INFORMATION: sense orientation

<400> SEQUENCE: 2

gacgtcgcgg	ccgctctagg	cctccaaaaa	agcctcctca	ctacttctgg	aatagctcag	50
aggccgaggc	ggcctcggcc	tctgcataaa	taaaaaaaat	tagtcagcca	tgcatggggc	120
ggagaatggg	cgyaactggg	cgagtttagg	ggcgggatgg	gcgagtttag	gggcgggact	180
atggttgctg	actaattgag	atgcatgctt	tgcatacttc	tgcttgctgg	ggagcctggg	240
gactttccac	aectggttgc	tgactaattg	agatgcatgc	tttgcatact	tctgcctgct	300
ggggagcctg	gggactttcc	acaccetaac	tgacacacat	tccacagaat	taattcccct	360
agttattaat	agtaatcaat	tacgggggtca	ttagttcata	gcccatatat	ggagttccgc	420
gttacataac	ttacggtaaa	tggcccgcct	ggctgaccgc	ccaacgacc	ccgcccattg	480
acgtcaataa	tgacgtatgt	tcccatagta	acgccaatag	ggactttcca	ttgacgtcaa	540
tgggtggact	atttacggta	aactgcccac	ttggcagtac	atcaagtgta	tcatatgcc	600
agtacgcccc	ctattgacgt	caatgacggg	aaatggccc	cctggcatta	tgcccagtac	660
atgaccttat	gggactttcc	tacttggcag	tacatctacg	tattagtc	cgctattacc	720
atggtgatgc	ggttttggca	gtacatcaat	gggcgtggat	accggtttga	ctcacgcgga	780
tttccaagtc	tccaccccat	tgacgtcaat	gggagtttgt	tttggcacca	aaatcaacgg	840

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 9 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

gactttccaa	aatgtcgtaa	caactccgcc	ccattgacgc	aatggggcgg	taggcgtgta	900
cggtagggagg	tctatataag	cagagctggg	tacgtgaacc	gtcagatcgc	ctggagacgc	960
catcacagat	ctctcactat	ggatthttcag	gtgcagatta	tcagcttcct	gctaatacag	1020
gottcagtea	taatgtccag	aggacaaaatt	gttctctccc	agtctccagc	aatcctgtct	1080
gcattctccag	gggagaagg	cacaatgact	tgcagggcca	gctcaagtgt	aagttacatc	1140
cactgggttcc	agcagaagcc	aggatcctcc	cccaaaccct	ggatttatgc	cacatccaac	1200
ctggcttctg	gagtcctgt	tcgcttcagt	ggcagtggggt	ctgggacttc	ttactctctc	1260
acaatcagca	gagtgaggcc	tgaagatgct	gccacttatt	actgccagca	gtggactagt	1320
aaccaccaca	cgttcggagg	ggggaccaag	ctggaaatca	aacgtacggg	ggctgcacca	1380
tctgtcttca	tcttcccgcc	atctgatgag	cagttgaaat	ctggaactgc	ctctgtttgt	1440
tgctctctga	ataacttcta	tcccagagag	gccaaagtac	agtggaagg	ggataacgcc	1500
ctccaatcgg	gtaactccca	ggagagtgtc	acagagcagg	acagcaagga	cagcacctac	1560
agcctcagca	gcaccctgac	gctgagcaaa	gcagactacg	agaaacacaa	agtctacgcc	1620
tgcaagtca	cccatcaggg	cctgagctcg	cccgtcacia	agagcttcaa	caggggagag	1680
tggtgaatc	agatccgtta	aeggttacca	actacctaga	ctggattcgt	gacaacatgc	1740
ggcctgata	tctacgtatg	atcagcctcg	actgtgcctt	ctagttgcca	gccatctgtt	1800
gtttgcccc	cccccgtagc	ttccttgacc	ctggaagggt	ccactcccac	tgctccttcc	1860
taataaaatg	aggaaaattgc	atcgcattgt	ctgagtaggt	gtcattctat	tctgggggggt	1920
ggggtggggc	aggacagcaa	gggggaggat	tgggaagaca	atagcaggca	tgctggggat	1980
gcggtgggct	ctatggaacc	agctggggct	cgacagctat	gccaagtacg	ccccctattg	2040
acgtcaatga	cggtaaatgg	cccgcctggc	attatgcccc	gtacatgacc	ttatgggact	2100
ttcctacttg	gcagtacatc	tacgtattag	tcatcgctat	taccatgggtg	atgcggtttt	2160
ggcagtagat	caatggggcgt	ggatagcggg	ttgactcacg	gggatttcca	agtctccacc	2220
ccattgacgt	caatggggagt	ttgttttggc	accaaaatca	acgggacttt	ccaaaatgtc	2280
gtaucaactc	cgccccattg	acgcaaatgg	gcggtaggcg	tgtacgggtg	gaggtctata	2340
taagcagagc	tgggtacgtc	ctcacattca	gtgatcagca	ctgaacacag	accctctcac	2400

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 10 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

atggggttggg	gcctcatcct	gctcttcctt	gtcgcgtgtg	ctacgcgtgt	cctgtcccag	2460
gtacaactgc	agcagcctgg	ggctgagctg	gtgaagcctg	gggcctcagt	gaagatgtcc	2520
tgcaaggctt	ctggctacac	atltaccagt	tacaatatgc	actgggtaaa	acagacacct	2580
ggtcggggcc	tggaatggat	tggagctatt	tatcccggaa	atggtgatac	ttcctacaat	2640
cagaagttca	aaggcaaggc	cacattgact	gcagacaaat	cctccagcac	agcctacatg	2700
cagctcagca	gcctgacatc	tgaggactct	gcggctctatt	actgtgcaag	atcgacttac	2760
tacggcggtg	actggtactt	caatgtctgg	ggcgcagggg	ccacgggtcac	cgtctctgca	2820
gctagcacca	agggcccatc	ggtcttcccc	ctggcacctt	cctccaagag	cacctctggg	2880
ggcacagcgg	ccctgggctg	cctgggtcaag	gactacttcc	ccgaaccggg	gacgggtgtc	2940
tggaaactcag	gcgccctgac	cagcggcgtg	cacaccttcc	cggctgtcct	acagtcctca	3000
ggactctact	ccctcagcag	cgtgggtgacc	gtgccctcca	gcagcttggg	caccagacc	3060
tacatctgca	acgtgaatca	caagcccagc	aacaccaagg	tggacaagaa	agcagagccc	3120
aaatcttgtg	acaaaactca	caatgccc	ccgtgccag	caactgaact	cctgggggga	3180
ccgtcagctt	tcctcttccc	cccaaaaccc	aaggacaccc	tcctgatctc	ccggacccct	3240
gaggtcacat	gcgtgggtgg	ggacgtgagc	cacgaagacc	ctgaggtcaa	gttcaactgg	3300
tacgtggacg	gcgtggaggt	gcataatgcc	aagacaaagc	cgcgggagga	gcagtacaac	3360
agcactgacc	gtgtgggtcag	cgtcctcacc	gtcctgcacc	aggactggct	gaatggcaag	3420
gagtacaagt	gcaaggtctc	caacaaagcc	ctcccagccc	ccatcgagaa	aacctctcc	3480
aaagccaaag	ggcagccccg	agaaccacag	gtgtacaccc	tgccccatc	ccgggatgag	3540
ctgaaccaaga	accaggtcag	cctgacctgc	ctgggtcaaag	gcttctatcc	cagcgacatc	3600
gccgtggagt	gggagagcaa	tgggcagccg	gagaacaact	acaagaccac	gcctcccctg	3660
ctggactcctg	acggctcctt	cttctctctac	agcaagctca	ccgtggacaa	gagcaggtgg	3720
cagcagggga	acgtcttctc	atgctccgtg	atgcatgagg	ctctgcacaa	ccactacaag	3780
cagaagagcc	tctccctgtc	tccgggtaaa	tgaggatccg	ttaacggtta	ccaactacct	3840
agactggatt	cgtgacaaca	tgccggcctg	atatctactg	atgatcagcc	tcgactgtgc	3900
cttctagttg	ccagccatct	gttgtttggc	cctccccctg	gccttctctg	accctggaag	3960

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 11 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

gtgccactcc	cactgtcctt	tcctaataaa	atgaggaaat	tgcatcgcct	tgtctgagta	4020
gggtgcattc	tattctgggg	gggggggtgg	ggcaggacag	caagggggag	gattgggaaag	4080
acaatagcag	gcctgctggg	gatgctgggt	gctctatgga	accagctggg	gctcgacagc	4140
gctggatctc	ccgatcccca	gctttgcttc	tcaatttctt	atttgcataa	tgagaaaaaa	4200
aggaaaatta	attttaacac	caattcagta	gttgattgag	caaatgcggt	gcaaaaaagg	4260
atgctttaga	gacagtgttc	tctgcacaga	taaggacaaa	cattattcag	agggagtacc	4320
cagagctgag	actcctaagc	cagtgcagtg	cacagcattc	tagggagaaa	tatgcttctc	4380
atcaccgaag	cctgattccg	tagagccaca	ccttggttaag	ggccaatctg	ctcacacagg	4440
atagagagg	caggagccag	ggcagagcat	ataaggtgag	gtaggatcag	ttgctcctca	4500
catttgcttc	tgacatagtt	gtgttgggag	cttggatagc	ttggacagct	cagggctgcg	4560
atctcgcgcc	aaacttgacg	gcaatcctag	cgtgaaggct	gtaggattt	tatccccgct	4620
gccatcatgg	ttogaccatt	gaactgcctc	gtcgcctgtt	cccaaaatat	ggggattggc	4680
aagaacggag	acctaaccctg	gcctccgctc	aggaacgagt	tcaagtactt	ccaagaatg	4740
accacaacct	cttcagtgga	aggtaaacag	aatctggtga	ttatgggtag	gaaaacctgg	4800
ttctccattc	ctgagaagaa	tgcaccttta	aaggacagaa	ttaatatagt	tctcagtaga	4860
gaactcaaag	aaccaccacg	aggagctcat	tttcttgcca	aaagtttggg	tgatgcctta	4920
agacttattg	aacaaccgga	attggcaagt	aaagtagaca	tggtttggat	agtcggaggc	4980
agttctgttt	accaggaagc	catgaatcaa	ccagggcacc	ttagactctt	tgtagacaagg	5040
atcatgcagg	aatttgaaag	tgacacgttt	ttcccagaaa	ttgatttggg	gaaatataaa	5100
cttctcccag	aatacccagg	cgtcctctct	gaggtccagg	aggaaaaagg	catcaagtat	5160
aagtttgaag	tctacgagaa	gaaagactaa	caggaagatg	ctttcaagtt	ctctgctccc	5220
ctcctaaagc	tatgcatttt	tataagacca	tgggactttt	gctggcttta	gatcagcctc	5280
gactgtgcct	tctagttgoc	agccatctgt	tgtttgcccc	tccccctgtc	cttccttgac	5340
cctggaaggt	gccactccca	ctgtcctttc	ctaataaaat	gaggaaattg	catcgcattg	5400
tctgagtagg	tgtcattcta	ttctgggggg	tgggggtggg	caggacagca	agggggagga	5460
ttgggaagac	aatagcaggc	atgctggggg	tgcggtgggc	tctatggaac	cagctggggc	5520

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 12 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

tegagetact	agctttgctt	ctcaatttct	tatttgcata	atgagaaaaa	aaggaaaatt	5580
aattttaaca	coaattcagt	agttgattga	gcaaatgcgt	tgccaaaaag	gatgctttag	5640
agacagtgtt	ctctgcacag	ataaggacaa	acattattca	gagggagtac	ccagagctga	5700
gactcctaag	ccagtgagtg	gcacagcatt	ctagggagaa	atatgcttgt	catcaccgaa	5760
gectgattcc	gtagagccac	accttggtaa	gggccaatct	gctcacacag	gatagagagg	5820
gcaggagcca	gggcagagca	tataaggtga	ggtaggatca	gttgctcttc	acatttgctt	5880
ctgacatagt	tgtgttggga	gcttggatcg	atcctctatg	gttgaacaag	atggattgca	5940
cgcaggttct	ccyggcgtct	gggtggagag	gctattcggc	tatgactggg	cacaacagac	6000
aatcggctgc	tctgatgcog	ccgtgttccg	gctgtcagcg	cagggggcgc	cggttctttt	6060
tgtcaagacc	gaoctgtccg	gtgcctgaa	tgaactycag	gacgaggcag	cgcggtatc	6120
gtggctggcc	acgacgggcg	ttccttgccg	agctgtgctc	gacgttgtca	ctgaagcggg	6180
aagggactgg	ctgctattgg	gcgaagtgcc	ggggcaggat	ctcctgtcat	ctcaccttgc	6240
tcttgccgag	aaagtatcca	tcattggctga	tgcaatgcgg	cggtctgata	cgcttgatcc	6300
ggctacctgc	ccattcgacc	accaagcgaa	acatcgcac	gagcgagcac	gtactcggat	6360
ggaagccggt	cttgtcgatc	aggatgatct	ggacgaagag	catcaggggc	tcgcccagc	6420
cgaactgttc	gccaggctca	aggcgcgcat	gcccgaocgg	gaggatctcg	tcgtgaccca	6480
tggcgatgcc	tgcttgccga	atatcatggt	ggaaaatggc	cgctttctcg	gattcatcga	6540
ctgtggccgg	ctgggtgtgg	cggacocgta	tcaggacata	gcgttggcta	cccgtgatat	6600
tgctgaagag	cttgccggcg	aatgggctga	ccgcttcttc	gtgctttacg	gtatcgccgc	6660
tcccgattcg	cagcgcacog	ccttctatcg	ccttcttgac	gagttcttct	gagcgggact	6720
ctggggttcg	aaatgaccga	ccaagcgacg	cccaacctgc	catcaocgaga	tttcgattcc	6780
accgcccgcct	tctatgaaag	gttgggcttc	ggaatcgttt	tccgggacgc	cggtcggatg	6840
atcctccagc	gcggggatct	catgctygag	ttcttcgccc	accccaactt	gtttattgca	6900
gcttataatg	gttacaataa	aagcaatagc	atcacaat	tcacaaataa	agcatttttt	6960
tcactgcatt	ctagtgtggt	tttgtccaaa	ctcatcaatc	tatcttatca	tgtctggatc	7020
gcggccgcga	tcccgtcgag	agcttggcgt	aatcatggtc	atagctgttt	cctgtgtgaa	7080

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 13 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

attggtatcc	gctcacaatt	ccacacaaca	tacgagccgg	aagcataaag	tgtaaagcct	7140
ggggtgccta	atgagtgagc	taactcacat	taattgctgt	gcctcactg	cccgccttcc	7200
agtcgggaaa	cctgtcgtgc	cagctgcatt	aatgaatcgg	ccaacgcgcg	gggagaggcg	7260
gtttgcgtat	tgggcctctc	tccgcttccct	cgctcactga	ctcgcctgcg	tcggtcgttc	7320
ggctgcggcg	agcggtatca	gctcactcaa	aggcggtaat	acggttatcc	acagaatcag	7380
gggataacgc	aggaaagaac	atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	7440
aggccgcggt	gctggcgttt	ttccataggc	tccgcccccc	tgacgagcat	cacaaaaatc	7500
gacgctcaag	tcagaggtgg	cgaaacccga	caggactata	aagataccag	gcgtttcccc	7550
ctggaagctc	cctcgtgcgc	tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	7620
cecttctccc	ttcgggaagc	gtggcgcttt	ctcaatgctc	acgctgtagg	tatctcagtt	7680
cgggtgtagt	cgttogctcc	aagctgggct	gtgtgcacga	acccccggt	cagcccgacc	7740
gctgcgcctt	atccggtaac	tatcgtcttg	agtccaaccc	ggtaaagcac	gacttatcgc	7800
cactggcagc	agccactggt	aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	7860
agttcttgaa	gtggtggcct	aactacggct	acactagaag	gacagtattt	ggtatctgcg	7920
ctctgctgaa	gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaaaaaa	7980
ccaccgctgg	tagcgggtgg	ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	8040
gatctcaaga	agatcctttg	atcttttcta	cggggctctga	cgctcagtgg	aacgaaaact	8100
cacgttaagg	gattttggtc	atgagattat	caaaaaggat	cttcacctag	atccttttaa	8160
attaaaaatg	aagttttaaa	tcaatctaaa	gtatatatga	gtaaacttgg	tctgacagtt	8220
accaatgctt	aatcagtgag	gcacctatct	cagcgatctg	tctatttctg	tcctccatag	8280
ttgcctgact	cccgcctcgt	tagataacta	cgatacggga	gggcttacca	tctggcccca	8340
gtgctgcaat	gataccgcga	gacccacgct	caccggctcc	agatttatca	gcaataaacc	8400
agccagccgg	aagggccgag	cgcagaagtg	gtcctgcaac	tttatccgcc	tccatccagt	8460
ctattaatg	ttgccgggaa	gctagagtaa	gtagttcgcc	agttaatagt	ttgcgcaacg	8520
ttgttgccat	tgctacaggc	atcgtggtgt	cacgctcgtc	gtttggtatg	gcttcattca	8580
gctccggttc	ccaacgatca	aggcgagtta	catgatcccc	catgttgtgc	aaaaaagcgg	8640

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 14 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

ttagctcctt	cggtcctcgg	atcgttggtca	gaagtaagtt	ggccgcagtg	ttatcactca	8700
tggttatggc	agcactgcat	aattctctta	ctgtcatgcc	atccgtaaga	tgcttttctg	8760
tgactggtga	gtactcaacc	aagtcattct	gagaatagtg	tatgcggcga	ccgagttgct	8820
cttgcccggc	gtcaatacgg	gataataccg	cgccacatag	cagaacttta	aaagtgtca	8880
tcattggaaa	acgttcttcg	gggcgaaaac	tctcaaggat	cttaccgctg	ttgagatcca	8940
gttcgatgta	accactcgt	gcacccaact	gatcttcagc	atcttttact	ttcaccagcg	9000
tttctgggtg	agcaaaaaaca	ggaaggcaaa	atgccgcaaa	aaaggaata	agggcgacac	9060
ggaaatggtg	aatactcata	ctcttccttt	ttcaatatta	ttgaagcatt	tatcagggtt	9120
attgtctcat	gagcggatac	atatttgaat	gtatttagaa	aaataaacia	ataggggttc	9180
cgcgcacatt	tccccgaaa	gtgccacct				9209

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 15 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 3
 <211> LENGTH: 384
 <212> TYPE: DNA
 <213> ORGANISM: *Mus musculus*

<220> FEATURE:
 <223> OTHER INFORMATION: sense orientation

<400> SEQUENCE: 3

atggattttc aggtgcagat tadcagcttc ctgctaataca gtgcttcagt cataatgtcc	60
agagggcaaa ttgtttctctc ccagctctcca gcaatcctgt ctgcatctcc aggggagaag	120
gtcacaatga cttgcagggc cagcctgtct gcatctccag gggagaaggt cacaatgact	180
tgcagggcca gcccacaacc ctggatttat gccacatcca acctggcttc tggagtccct	240
gttcgcttca gtggcagtggt gtctgggact tcttactctc tcacaatcag cagagtggag	300
gctgaagatg ctgccactta ttactgccag cagtggacta gtaaccacc cacgttcgga	360
ggggggacca agctggaaat caaa	384

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 16 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 4
 <211> LENGTH: 128
 <212> TYPE: PRT
 <213> ORGANISM: *Mus musculus*

<400> SEQUENCE: 4

Met	Asp	Phe	Gln	Val	Gln	Ile	Ile	Ser	Phe	Leu	Leu	Ile	Ser	Ala	Ser
1				5					10					15	
Val	Ile	Met	Ser	Arg	Gly	Gln	Ile	Val	Leu	Ser	Gln	Ser	Pro	Ala	Ile
			20					25					30		
Leu	Ser	Ala	Ser	Pro	Gly	Glu	Lys	Val	Thr	Met	Thr	Cys	Arg	Ala	Ser
		35					40					45			
Ser	Ser	Val	Ser	Tyr	Ile	His	Trp	Phe	Gln	Gln	Lys	Pro	Gly	Ser	Ser
		50				55					60				
Pro	Lys	Pro	Trp	Ile	Tyr	Ala	Thr	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro
65					70					75				80	
Val	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	Ile
				85					90					95	
Ser	Arg	Val	Glu	Ala	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp
			100					105					110		
Thr	Ser	Asn	Pro	Pro	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys
			115				120					125			

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 17 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 5
<211> LENGTH: 420
<212> TYPE: DNA
<213> ORGANISM: *Mus musculus*

<220> FEATURE:
<223> OTHER INFORMATION: sense orientation

<400> SEQUENCE: 5
atgggttggg gccatcatt gctcttcctt gtcgctgttg ctacgcgtgt cctgtcccag 60
gtacaactgc agcagcctgg ggctgagctg gtgaagcctg gggcctcagt gaagatgtcc 120
tgcaaggctt ctggctacac atttaccagt tacaatatgc actgggtaaa acagacacct 180
ggtcggggcc tggaatggat tggagctatt tatcccggaa atggtgatac ttcctacaat 240
cagaagtcca aaggcaagge cacattgact gcagacaaat cctccagcac agcctacatg 300
cagctcagca gcttgacatc tgaggactct gcggtctatt actgtgcaag atcgacttac 360
tacggcggtg actggtactt caatgtctgg ggcgcagggg ccacggtcac cgtctctgca 420

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
 APPLICATION NO. : 09/911692
 DATED : June 3, 2008
 INVENTOR(S) : D. R. Anderson et al.

Page 18 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 6
 <211> LENGTH: 140
 <212> TYPE: PRT
 <213> ORGANISM: *Mus musculus*

<400> SEQUENCE: 6

Met	Gly	Trp	Ser	Leu	Ile	Leu	Leu	Phe	Leu	Val	Ala	Val	Ala	Thr	Arg
1			5						10					15	
Val	Leu	Ser	Gln	Val	Gln	Leu	Gln	Gln	Pro	Gly	Ala	Glu	Leu	Val	Lys
			20				25						30		
Pro	Gly	Ala	Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe
		35					40					45			
Thr	Ser	Tyr	Asn	Met	His	Trp	Val	Lys	Gln	Thr	Pro	Gly	Arg	Gly	Leu
		50				55					60				
Glu	Trp	Ile	Gly	Ala	Ile	Tyr	Pro	Gly	Asn	Gly	Asp	Thr	Ser	Tyr	Asn
65					70					75					80
Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Lys	Ser	Ser	Ser
			85						90					95	
Thr	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val
			100					105						110	
Tyr	Tyr	Cys	Ala	Arg	Ser	Thr	Tyr	Tyr	Gly	Gly	Asp	Trp	Tyr	Phe	Asn
		115					120					125			
Val	Trp	Gly	Ala	Gly	Thr	Thr	Val	Thr	Val	Ser	Ala				
		130				135					140				

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 19 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 7
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

<220> FEATURE:
<223> OTHER INFORMATION: impaired Kozak sequence and restriction enzyme site

<220> FEATURE:
<223> OTHER INFORMATION: sense orientation

<400> SEQUENCE: 7
gggagcttgg atcgatcctc tatggtt

27

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 20 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 8
<211> LENGTH: 47
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<220> FEATURE:
<223> OTHER INFORMATION: sense orientation

<400> SEQUENCE: 8
atcacagatc tctcaccatg gattttcagg tgcagattat cagcttc

47

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 21 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 9
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<220> FEATURE:
<223> OTHER INFORMATION: antisense orientation

<400> SEQUENCE: 9
tgcagcatcc gtacgttga tttccagctt

30

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 22 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 10
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<220> FEATURE:
<223> OTHER INFORMATION: sense orientation

<400> SEQUENCE: 10
gcggctccca cgcgtgtcct gtcccag

27

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 23 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<210> SEQ ID NO 11
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<220> FEATURE:
<223> OTHER INFORMATION: antisense orientation

<220> FEATURE:
<221> misc_feature
<222> LOCATION: (1)..(29)
<223> OTHER INFORMATION: s is g or c

<220> FEATURE:
<221> misc_feature
<222> LOCATION: (1)..(29)
<223> OTHER INFORMATION: m is a or c

<220> FEATURE:
<221> misc_feature
<222> LOCATION: (1)..(29)
<223> OTHER INFORMATION: r is g or a

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,381,560 B2
APPLICATION NO. : 09/911692
DATED : June 3, 2008
INVENTOR(S) : D. R. Anderson et al.

Page 24 of 24

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<400> SEQUENCE: 11
ggstgtttg ctagctgmrq agacrgtga .

29 --

Signed and Sealed this

Second Day of September, 2008



JON W. DUDAS
Director of the United States Patent and Trademark Office